{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.12366"}, {"@name": "filename", "#text": "17980_arquivo1213_1.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "i\n\n \n\n \n\n \n\n \n\nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nCENTRO DE CI\u00caNCIAS DA SA\u00daDE \n\nDEPARTAMENTO DE CI\u00caNCIAS FARMAC\u00caUTICAS \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM CI\u00caNCIAS FARMAC\u00caUTICAS \n\nTESE DE DOUTORADO \n\n \n\n \n\n \n\n \n\n \n\n \n\nDDeesseennvvoollvviimmeennttoo  ee  ccaarraacctteerriizzaa\u00e7\u00e7\u00e3\u00e3oo  ddee  mmiiccrrooeessffeerraass  ccoonntteennddoo              \n\nttrraannss--ddeessiiddrrooccrroottoonniinnaa  ee  ccoommpplleexxoo  ddee  iinncclluuss\u00e3\u00e3oo  ddee                                                      \n\nttrraannss--ddeessiiddrrooccrroottoonniinnaa  ccoomm  22--hhiiddrrooxxiipprrooppiill--??--cciiccllooddeexxttrriinnaa \n\n \n \n\n \n\n \n\nWALDENICE DE ALENCAR MORAIS \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nRECIFE/2010 \n\n\n\n ii\n \n \n\n \n \n\n \n\nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nCENTRO DE CI\u00caNCIAS DA SA\u00daDE \n\nDEPARTAMENTO DE CI\u00caNCIAS FARMAC\u00caUTICAS \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM CI\u00caNCIAS FARMAC\u00caUTICAS \n\n \n\n \n\n \n\nDDeesseennvvoollvviimmeennttoo  ee  ccaarraacctteerriizzaa\u00e7\u00e7\u00e3\u00e3oo  ddee  mmiiccrrooeessffeerraass  ccoonntteennddoo              \n\nttrraannss--ddeessiiddrrooccrroottoonniinnaa  ee  ccoommpplleexxoo  ddee  iinncclluuss\u00e3\u00e3oo  ddee                                                      \n\nttrraannss--ddeessiiddrrooccrroottoonniinnaa  ccoomm  22--hhiiddrrooxxiipprrooppiill--??--cciiccllooddeexxttrriinnaa \n\n \n\n \n\n  \n \n\n \n\n \n\n \n\n \n\n \n\n \n \n\nProfa. Dra. Nereide Stela Santos Magalh\u00e3es \nORIENTADORA \n\n \nProfa. Dra. Maria Aparecida M. Maciel \n\nCO-ORIENTADORA   \n \n\nWaldenice de Alencar Morais \nDOUTORANDA \n\n \n\n \n\nRECIFE/2010 \n\nTese de doutorado submetida ao Programa \nde P\u00f3s-gradua\u00e7\u00e3o do Departamento de \nCi\u00eancias Farmac\u00eauticas do Centro de \nCi\u00eancias da Sa\u00fade da Universidade Federal \nde Pernambuco, em cumprimento \u00e0s \nexig\u00eancias para obten\u00e7\u00e3o do grau de \nDoutor em Ci\u00eancias Farmac\u00eauticas. \n\u00c1rea de concentra\u00e7\u00e3o: Produ\u00e7\u00e3o e Controle \nde Qualidade de Medicamentos. \n\n\n\n iii\n \n \n\n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nMorais, Waldenice de Alencar  \n\n \n\nDesenvolvimento e caracteriza\u00e7\u00e3o de microesferas\ncontendo trans-desidrocrotonina e complexo de\ninclus\u00e3o de trans-desidrocrotonina com\n2-hidroxipropil-?-ciclodextrina / Waldenice de Alencar\nMorais.  \u2013  Recife : O Autor, 2010.  \n\n133 folhas; il., graf., fig., tab.  \n \n\n \n\n     Tese (doutorado) \u2013 Universidade Federal de \nPernambuco. CCS. Ci\u00eancias Farmac\u00eauticas, 2010. \n\n \n\n  \n Inclui bibliografia. \n \n\n \n\n 1. Sistemas de libera\u00e7\u00e3o de f\u00e1rmacos. 2. \nMicroesferas. 3. Complexo de inclus\u00e3o de f\u00e1rmaco \ncom ciclodextrina.  4. trans-Desidrocrotonina.   5. \nAn\u00e1lise fatorial I. T\u00edtulo. \n\n \n\n         \n      615.014 CDU (2.ed.) UFPE  \n      615.58 CDD (22.ed.) CCS-05/2010   \n\n\n\n iv\n \n \n\n \n \n\n \n \n\n \n\niii\n\n\n\n v\n \n \n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \nA meus pais: \u00e0 minha ador\u00e1vel m\u00e3e, meu exemplo de \n\ncoragem e perseveran\u00e7a, e \u00e0 mem\u00f3ria do meu querido pai, \n\nmeu exemplo eterno de integridade e honestidade. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\niv\n\n\n\n vi\n \n \n\n \n \n\nAGRADECIMENTOS \n\n \nDirijo o meu mais sincero agradecimento... \n\n \n\nPrimeiramente a Deus por toda f\u00e9, coragem e perseveran\u00e7a; \n\n \n\n\u00c0 minha fam\u00edlia pelo amor, compreens\u00e3o e apoio em todos os momentos felizes e dif\u00edceis e que \n\nsempre me motivaram em meus objetivos....especialmente \u00e0 mem\u00f3ria do meu pai; \n\n \n\n\u00c0 Prof\u00aa Dr\u00aa Nereide Stela Santos Magalh\u00e3es pela orienta\u00e7\u00e3o, paci\u00eancia e confian\u00e7a que me \n\nacolheu em seu laborat\u00f3rio de pesquisa, contribuindo para o meu crescimento acad\u00eamico e \n\ncient\u00edfico; \n\n \n\n\u00c0 Prof\u00aa Dr\u00aa Maria Aparecida Medeiros Maciel pela co-orienta\u00e7\u00e3o, dedica\u00e7\u00e3o e confian\u00e7a em meu \n\ntrabalho para desenvolver novos sistemas terap\u00eauticos com o diterpeno bioativo                \n\ntrans-desidrocrotonina (t-DCTN); \n\n \n\nAos alunos de inicia\u00e7\u00e3o cient\u00edfica Gineide Concei\u00e7\u00e3o dos Anjos, Luan Silveira Alves de Moura, \n\nC\u00e1ssia Carvalho de Almeida, Gilvani Gomes de Carvalho e Aline Maria Sales Solano pelo esfor\u00e7o \n\nna extra\u00e7\u00e3o e reisolamento da t-DCTN no Laborat\u00f3rio de Produtos Naturais da UFRN sob \n\norienta\u00e7\u00e3o da Prof\u00aa Dr\u00aa Maria Aparecida Medeiros Maciel; \n\n \n\n\u00c0 Prof\u00aa Dr\u00aa. Beate Seageser Santos, \u00e0 Prof\u00aa Dr\u00aa Noemia Pereira da Silva Santos e ao Prof. Dr. \n\nAnt\u00f4nio Rodolfo de Faria  pela disponibilidade e contribui\u00e7\u00e3o para a avalia\u00e7\u00e3o deste trabalho no \n\nExame de Qualifica\u00e7\u00e3o de Tese; \n\n \n\nAo Prof. Dr. Ben\u00edcio de Barros Neto, ao Prof. Dr. Jos\u00e9 Luiz C. Fonseca, \u00e0 Prof\u00aa Dr\u00aa Noemia \n\nPereira da Silva Santos, \u00e0 Prof\u00aa Dr\u00aa Maria Nelly Caetano Pisciottano e \u00e0 Prof\u00aa Dr\u00aa. Beate Seageser \n\nSantos pela disponibilidade e contribui\u00e7\u00e3o para a avalia\u00e7\u00e3o desta tese de doutorado; \n\n \n\nA todos os colegas e amigos do Grupo de Pesquisa de Sistemas de Libera\u00e7\u00e3o Controlada (SLC), \n\nque me receberam com toda solidariedade, aten\u00e7\u00e3o e carinho; \n\nv\n\n\n\n vii\n \n \n\n \n \nAo Profo Dr\u00ba. Ben\u00edcio Barros Neto pela disponibiliza\u00e7\u00e3o do software Statistic vers\u00e3o 6.0, \u00e0 Profa \n\nDra Maria Fernanda Pimental e ao doutorando Pabyton Gadelha pela contribui\u00e7\u00e3o no estudo de \n\nan\u00e1lise fatorial; \n\n  \n\n\u00c0s alunas de inicia\u00e7\u00e3o cient\u00edfica Rosana Silva Batista, Dina Melissa Amaya Silva e Rebeca \n\nCavalcanti Silveira pelo esfor\u00e7o, dedica\u00e7\u00e3o e compreens\u00e3o pelo desenvolvimento deste trabalho;  \n\n \n\n\u00c0s doutorandas Milena Sales Ferraz, Mariane Cajub\u00e1 de Brito Lira e Elis\u00e2ngela Afonso de Moura \n\nMendon\u00e7a pelas discuss\u00f5es cient\u00edficas e companheirismo; \n\n \n\nAos mestrandos Taciana Lima Salviano Lapenda e Hywre Cesar de Brito Pinto pela colabora\u00e7\u00e3o; \n\n \n\nA todos os amigos e colegas do Laborat\u00f3rio de Bioqu\u00edmica do LIKA-UFPE pela saud\u00e1vel \n\nconviv\u00eancia em laborat\u00f3rio; \n\n \n\n\u00c0 minha grande amiga Mariana Paola Cabrera pela amizade e companheirismo; \n\n \n\nAo Laborat\u00f3rio de Imunopatologia Keizo-Asami (LIKA) e ao Centro de Tecnologias Estrat\u00e9gicas \n\ndo Nordeste (CETENE-PE) pelo suporte dado a este trabalho; \n\n \n\nAo Minist\u00e9rio de Ci\u00eancia e Tecnologia (MCT), ao Conselho Nacional de Desenvolvimento \n\nCient\u00edfico e Tecnol\u00f3gico (CNPq) e \u00e0 Pr\u00f3-Reitoria de Pesquisa da Universidade Federal de \n\nPernambuco (PROPESQ-UFPE) pelo suporte financeiro durante o curso deste trabalho. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nvi\n\n\n\n viii\n \n \n\n \n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\u201c....estejais seguros que Deus n\u00e3o nos imp\u00f4s uma tarefa \n\nacima de nossas for\u00e7as, e que n\u00e3o vos abandonou sozinhos na Terra, \n\nsem amigos e sem sustenta\u00e7\u00e3o.\u201d \n\n \n\n \nS\u00e3o Lu\u00eds, Santo Agostinho \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nvii\n\n\n\n ix\n \n \n\n \n \n\nSUM\u00c1RIO \n\n \nLISTA DE ABREVIATURAS............................................................................................. x \n\nLISTA DE FIGURAS........................................................................................................... xi \n\nLISTA DE TABELAS........................................................................................................... xii \n\nRESUMO............................................................................................................................... xiii \n\nABSTRACT........................................................................................................................... xiv \n\n1 INTRODU\u00c7\u00c3O......................................................................................................... 16 \n2 REVIS\u00c3O DE LITERATURA................................................................................ 20 \n\n2.1 Nanotecnologia farmac\u00eautica - Sistemas de libera\u00e7\u00e3o de f\u00e1rmacos.............. 20 \n2.2 Sistemas particulados polim\u00e9ricos.................................................................... 23 \n\n2.2.1 Pol\u00edmeros utilizados na prepara\u00e7\u00e3o de sistemas particulados.............. 25 \n\n             2.3 Micropart\u00edculas.................................................................................................. 27 \n\n                   2.3.1 M\u00e9todos de prepara\u00e7\u00e3o de micropart\u00edculas........................................... 29 \n\n                   2.3.2 M\u00e9todos de caracteriza\u00e7\u00e3o de micropart\u00edculas...................................... 32 \n\n             2.4 Cin\u00e9tica de libera\u00e7\u00e3o.......................................................................................... 36 \n\n             2.5 An\u00e1lise fatorial................................................................................................... 39 \n\n             2.6 Ciclodextrinas..................................................................................................... 40 \n\n                    2.6.1 Complexos de inclus\u00e3o de f\u00e1rmacos com ciclodextrinas...................... 44 \n\n             2.7 trans-Desidrocrotonina (t-DCTN)..................................................................... 47 \n\n3 OBJETIVOS...................................................................................................................... 52 \n\nARTIGO  \n\nPhysicochemical and release characteristics of t-dehydrocrotonin and  \n\nt-DCTN:hydroxypropyl-?-cyclodextrin inclusion complex into PCL and PLGA \n\nmicroparticles........................................................................................................................ \n\n \n\n \n \n\n \n\n54 \n\n4 CONCLUS\u00d5ES.................................................................................................................. 98 \n\n5 PERSPECTIVAS............................................................................................................... 101 \n\n6 REFER\u00caNCIAS BIBLIOGR\u00c1FICAS ............................................................................ 103 \n\n  \n\n  \n\n  \n\nviii\n\n\n\n x\n \n \n\n \n \nANEXOS  \n\nANEXO A \n\nARTIGO I \u2013 Abstract \n\nEncapsulation and release characteristics of DCTN/PLGA microspheres. Journal of \n\nMicroencapsulation. Published...............................................................................................\n\n \n\n \n\n \n\n129 \n\nANEXO B \n\nARTIGO II \u2013 Abstract \n\nValidation of UV spectrophotometric method for the determination of \n\ndehydrocrotonin and application in inclusion complexes with hydroxypropyl-?-\n\ncyclodextrin.  \n\nA ser submetido....................................................................................................................... \n\n \n\n \n \n \n \n \n131 \n\nANEXO C \n\nCONCURSO P\u00daBLICO \n\nAprova\u00e7\u00e3o em Concurso P\u00fablico para o Cargo de Professor Adjunto no \n\nDepartamento de Farm\u00e1cia na \u00e1rea de Farmacot\u00e9cnica na Universidade Federal do \n\nRio Grande do Norte. DOU, se\u00e7\u00e3o 2, 31 de dezembro de 2009........................................... \n\n \n\n \n\n \n\n \n\n133 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\niv\n\n\n\n xi\n \n \n\n \n \n\nLISTA DE ABREVIATURAS  \n\n \nBCS \u2013 Sistema de classifica\u00e7\u00e3o biofarmac\u00eautica \nBET - Brunauer-Emmette-Teller  \nBJH- Barret- Joyner-Halenda  \nCD \u2013 Ciclodextrina \nCI50 - Concentra\u00e7\u00e3o do f\u00e1rmaco que inibe 50% do crescimento celular \nCLAE \u2013 Cromatografia l\u00edquida de alta efici\u00eancia \nDE50 \u2013 Dose terap\u00eautica efetiva para 50% dos animais \nDL50 \u2013 Dose letal para 50% dos animais \nDNA \u2013 \u00c1cido desoxiribonucl\u00e9ico \nDSC \u2013 Calorimetria explorat\u00f3ria diferencial  \ndv - di\u00e2metro volum\u00e9trico m\u00e9dio \nFDA \u2013 Food and drug administration \nGPC- Cromatografia de permea\u00e7\u00e3o em gel  \nHP?CD \u2013 2-Hidroxipropil-?-ciclodextrina \ni.p. \u2013 Via intraperitoneal \ni.v. \u2013 Via intravenosa \nIR - Espectroscopia na regi\u00e3o do infravermelho \nLog P \u2013 Coeficiente de parti\u00e7\u00e3o \nMET \u2013 Microscopia eletr\u00f4nica de transmiss\u00e3o \nMEV \u2013 Microscopia eletr\u00f4nica de varredura \nPCL \u2013 Policaprolactona \nPEG \u2013 Polietilenoglicol \nPGA \u2013 Pol\u00edmero de \u00e1cido glic\u00f3lico \npH \u2013 Potencial hidrogeni\u00f4nico \nPHBHV - Poli (hidroxibutirato-co-hidroxivalerato)  \npKa \u2013 Logaritmo negativo da constante de ioniza\u00e7\u00e3o \nPLA \u2013 Pol\u00edmero de \u00e1cido l\u00e1ctico \nPLA-PEG \u2013 Copol\u00edmero de PLA com PEG \nPLGA \u2013 Copol\u00edmero de \u00e1cido l\u00e1ctico e glic\u00f3lico \nPVA \u2013 \u00c1lcool polivin\u00edlico \nRMN \u2013 Resson\u00e2ncia magn\u00e9tica nuclear \nRNA - \u00c1cido ribonucl\u00e9ico \ns.c. \u2013 Via subcut\u00e2nea \nSIDA \u2013 S\u00edndrome da imunodefici\u00eancia adquirida \nt1/2 \u2013  Tempo de meia-via \nt-DCTN \u2013 trans-Desidrocrotonina \nTGA \u2013 An\u00e1lise termogravim\u00e9trica \nUV-Vis \u2013 Espectrofotometria na regi\u00e3o do ultravioleta-vis\u00edvel \nv.o. \u2013 Via oral  \nXRD \u2013 Difra\u00e7\u00e3o de raios-X \n?CD \u2013 ?-Ciclodextrina \n?CD \u2013 ?-Ciclodextrina \n?CD \u2013 ?-Ciclodextrina \n\nx\n\n\n\n xii\n \n \n\n \n \n\nLISTA DE FIGURAS \n\n                                             \nINTRODU\u00c7\u00c3O E REVIS\u00c3O DE LITERATURA \n\n \n\nFigura 1 - Compara\u00e7\u00e3o do perfil farmacocin\u00e9tico de formas farmac\u00eauticas convencionais e \n\nde sistemas de libera\u00e7\u00e3o controlada (adaptado de \n\nhttp://www.qmc.ufsc.br/qmcweb/exemplar15.html).................................................................\n\n \n\n \n\n21 \n\nFigura 2 - Representa\u00e7\u00e3o esquem\u00e1tica da classifica\u00e7\u00e3o de nanopart\u00edculas e micropart\u00edculas: \n\nnanoesfera e microesfera (sistema matricial) (A); nanoc\u00e1psula e microc\u00e1psula (sistema \n\nreservat\u00f3rio) (B) (http://www.nanoparticles.org/links/Nanosphere.jpg)...................................\n\n \n\n \n\n24 \n\nFigura 3 - M\u00e9todo de prepara\u00e7\u00e3o de micropart\u00edculas por emulsifica\u00e7\u00e3o (o/a) e evapora\u00e7\u00e3o \n\ndo solvente: (1) solubiliza\u00e7\u00e3o dos componentes na fase oleosa org\u00e2nica, (2) mistura da fase \n\norg\u00e2nica com a fase cont\u00ednua contendo emulsificante sob agita\u00e7\u00e3o (3) evapora\u00e7\u00e3o do \n\nsolvente (4) separa\u00e7\u00e3o das micropart\u00edculas (adaptado de LI et al., 2008)................................. \n\n \n\n \n\n \n\n31 \n\nFigura 4 - Estrutura qu\u00edmica de uma ciclodextrina (A) e desenho esquem\u00e1tico ilustrando a \n\ncavidade hidrof\u00f3bica, a posi\u00e7\u00e3o das hidroxilas prim\u00e1rias e secund\u00e1rias e suas dimens\u00f5es: \n\naltura (H), di\u00e2metro interno (DI) e di\u00e2metro externo (DE) (adaptado de BREWSTER; \n\nLOFTSSON, 2007)...........................................................................................................\n\n \n\n \n\n \n\n41 \n\nFigura 5 - Estruturas moleculares das ciclodextrinas naturais (adaptado de SONG et., \n\n2009).......................................................................................................................................... \n\n \n\n42 \n\nFigura 6 - Esquema da associa\u00e7\u00e3o entre ciclodextrina hidratada (CD) e mol\u00e9cula h\u00f3spede \n\n(G): (acima) complexos de inclus\u00e3o 1:1 e (abaixo) complexos de inclus\u00e3o 2:1 \n\nciclodextrina:f\u00e1rmaco (SONG et al., 2009)............................................................................... \n\n \n\n \n\n46 \n\nFigura 7 - Estrutura qu\u00edmica da trans-desidrocrotonina (t-DCTN)......................................... 48 \n\nxi\n\n\n\n xiii\n \n \n\n \n \n\nLISTA DE TABELAS \n\n \nINTRODU\u00c7\u00c3O E REVIS\u00c3O DE LITERATURA \n\n \n\nTabela 1 - Exemplos de sistemas de libera\u00e7\u00e3o de f\u00e1rmacos......................................................\n\n \n\n22 \n\nTabela 2 - Propriedades f\u00edsico-qu\u00edmicas das ciclodextrinas (CONNORS, 1997).................... 43 \n\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n\n \n\n \n\n \n\n \n\n \n \n \n \n\n \n\nxii\n\n\n\n xiv\n \n \n\n \n \n\nRESUMO \n\nMicroesferas s\u00e3o sistemas polim\u00e9ricos de libera\u00e7\u00e3o controlada capazes de aumentar a \nbiodisponibilidade e diminuir a toxicidade de uma variedade de f\u00e1rmacos. Complexos de inclus\u00e3o \nde f\u00e1rmacos com ciclodextrinas podem modificar as caracter\u00edsticas f\u00edsico-qu\u00edmicas e de cin\u00e9tica \nde libera\u00e7\u00e3o de microesferas. A trans-desidrocrotonina (t-DCTN) \u00e9 um princ\u00edpio ativo extra\u00eddo do \nCroton cajucara Benth com v\u00e1rias atividades farmacol\u00f3gicas, tais como a hipoglicemiante. \nEntretanto, a sua baixa solubilidade em \u00e1gua e hepatotoxicidade restrigem a sua aplica\u00e7\u00e3o \nterap\u00eautica. O objetivo deste estudo foi avaliar a influ\u00eancia da presen\u00e7a de t-DCTN e complexo de \ninclus\u00e3o de t-DCTN com hidroxipropil-?-ciclodetrina (t-DCTN:HP?CD) em microesferas de \npolicaprolactona (PCL) e poli\u00e1cido l\u00e1ctico e glic\u00f3lico (PLGA) em suas propriedades              \nf\u00edsico-qu\u00edmicas e de cin\u00e9tica de libera\u00e7\u00e3o. Tr\u00eas diferentes sistemas de microesferas contendo         \nt-DCTN, t-DCTN:HP?CD ou de t-DCTN:HP?CD e t-DCTN coencapsuladas foram preparados \npelo m\u00e9todo de emuls\u00e3o m\u00faltipla (a/o/a) segido de evapora\u00e7\u00e3o do solvente. O polietilenoglicol \n(PEG) e o \u00e1lcool polivinilico (PVA) foram usados como estabilizantes das emuls\u00f5es simples e \nm\u00faltipla, respectivamente. Inicialmente, foram realizados estudos de pr\u00e9-formula\u00e7\u00e3o com \nmicroesferas de PCL (sem f\u00e1rmaco) utilisando an\u00e1lise fatorial fracion\u00e1ria 24?1, variando-se as \nconcentra\u00e7\u00f5es de PEG e PVA, e os volumes das fases aquosas interna e externa. Com isso, foi \ninvestigada a influ\u00eancia dos par\u00e2metros no tamanho de part\u00edculas (dv) e polidispers\u00e3o (span) das \nmicroesferas de PCL. A an\u00e1lise fatorial mostrou ser uma excelente ferramenta para a otimiza\u00e7\u00e3o \nde micropart\u00edculas de PCL. A varia\u00e7\u00e3o dos volumes das fases aquosas interna e externa das \nemuls\u00f5es afetaram consideravelmente o dv e o span dos sistemas. O dv das micropart\u00edculas de PCL \nvariou de 6,68 to 28,41 ?m e o span de 1,16 to 4,76 com a varia\u00e7\u00e3o dos fatores. Considerando as \nformula\u00e7\u00f5es mais est\u00e1veis, microesferas de PCL e PLGA contendo t-DCTN ou t-DCTN:HP?CD \nforam preparadas para avaliar a influ\u00eancia da natureza do pol\u00edmero. A t-DCTN foi encapsulada \ncom \u00eaxito nas microesferas de PCL e PLGA com uma quantidade de f\u00e1rmaco encapsulada de 4% \ne 6% na raz\u00e3o de 1:10 de f\u00e1rmaco:pol\u00edmero, respectivamente. As microesferas contendo               \nt-DCTN:HP?CD apresentaram uma superf\u00edcie lisa, e uma diminui\u00e7\u00e3o da quantidade de f\u00e1rmaco \nencapsulada, do tamanho de part\u00edcula e dos par\u00e2metros de porosidade, em rela\u00e7\u00e3o \u00e0quelas \ncontendo somente t-DCTN. A coencapsula\u00e7\u00e3o de t-DCTN:HP?CD com t-DCTN na raz\u00e3o 1:5 de \nf\u00e1rmaco:pol\u00edmero aumentou a quantidade de f\u00e1rmaco encapsulada para 14% em microesferas de \nPLGA, com tamanho de part\u00edculas (dv=9,59 \u00b5m) e polidispers\u00e3o (span=1,57) satisfat\u00f3rios. No que \nse refere a cin\u00e9tica de libera\u00e7\u00e3o in vitro, os perfis apresentaram uma boa correla\u00e7\u00e3o com o modelo \nfickiano, indicando que a difus\u00e3o est\u00e1 envolvida no mecanismo de libera\u00e7\u00e3o. O complexo de \ninclus\u00e3o t-DCTN:HP?CD modificou as propriedades de libera\u00e7\u00e3o das microesferas, produzindo \nmenores velocidades de difus\u00e3o k2 de 0,105 (PCL) e k2 de 0,107 (PLGA), quando comparadas aos \nsistemas contendo t-DCTN, k2 de 0,289 (PCL) e k2 de 0,395 (PLGA), respectivamente. A \ncoencapsula\u00e7\u00e3o tamb\u00e9m reduziu o efeito burst (1,5%) e a velocidade de difus\u00e3o (k2=0,079). Os \nresultados sugerem uma menor afinidade da t-DCTN pela matriz de PCL em rela\u00e7\u00e3o ao PLGA, \ndevido \u00e0 menor quantidade de f\u00e1rmaco encapsulada, maior modifica\u00e7\u00e3o do potencial zeta, bem \ncomo, maior efeito burst e cin\u00e9tica de libera\u00e7\u00e3o mais r\u00e1pida. Portanto, a microencapsula\u00e7\u00e3o de t-\nDCTN e complexo de inclus\u00e3o t-DCTN:HP?CD em pol\u00edmeros biodegrad\u00e1veis pode ser uma \nalternativa terap\u00eautica inovadora na avalia\u00e7\u00e3o da atividade hipoglicemiante da t-DCTN. \n\n \nPalavras-Chave: Sistemas de libera\u00e7\u00e3o de f\u00e1rmacos, microesferas, complexo de inclus\u00e3o de \nf\u00e1rmaco com ciclodextrina, trans-desidrocrotonina, an\u00e1lise fatorial. \n \n \n\nxiii\n\n\n\n xv\n \n \n\n \n \n\nABSTRACT \n\nMicrospheres are drug delivery polymeric systems able to enhance the bioavailability and to \nreduce the toxicity of a variety of drugs. The inclusion complexes of drugs with cyclodextrins may \nmodify the physicochemical and release characteristics of microspheres. The                \ntrans-dehydrocrotonin (t-DCTN) is a drug extracted of the Croton cajucara Benth that presents \nseveral pharmacological activities, such as hypoglycemic. However, its lower water solubility and \nhepatotoxicity limit its therapeutic application. The purpose of this study was to evaluate the \ninfluence of the presence of t-DCTN and t-DCTN:hydroxypropyl-?-cyclodextrin inclusion \ncomplex (t-DCTN:HP?CD) in polycaprolactone (PCL) and poly (lactic-co-glycolic)-acid (PLGA) \nmicroparticles on their physicochemical and release properties.  Three different microparticle \nsystems were prepared by double W/O/W emulsion-solvent evaporation method with t-DCTN,       \nt-DCTN:HP?CD or co-encapsulation of t-DCTN:HP?CD and t-DCTN. The polyethylene glycol \n(PEG) and polyvinylalcohol (PVA) were used as stabilizing of the simple and double emulsion, \nrespectively. Initially, pre-formulation studies of the preparation of unloaded PCL microparticles \nwere performed using 24?1 fractional factorial design varying PEG and PVA concentration, and \naqueous phase volume of the simple and double emulsions. Then, the influence of the formulation \nfeatures on the particle size and polydispersity (span) of unloaded PCL microspheres was thus \nevaluated using the factorial design. Factorial design showed to be an excellent tool to optimize \nPCL microparticles. The variation of the inner and outer aqueous phase volumes of emulsions \nconsiderably affected the size and the span of the resultant systems. The size of unloaded PCL \nmicroparticles varied from 6.68 to 28.41 ?m and the span changed from 1.16 to 4.76 with the \nvarying of the factors. Considering the most stables unloaded microparticle formulations, t-DCTN \nand t-DCTN:HP?CD-loaded PCL and PLGA microparticles were prepared to evaluate the \ninfluence of polymer nature. The t-DCTN was successfully encapsulated into PCL and PLGA \nmicroparticles with loading drug of 4% and 6% (w/w) at 1:10 drug/polymer ratio, respectively. \nThe t-DCTN:HP?CD-loaded microspheres presented a smooth surface and a decreasing of the \nloading, particle size and porosity parameters in relation to t-DCTN-loaded systems. The co-\nencapsulation of t-DCTN:HP?CD inclusion complex with t-DCTN at 1:5 drug/polymer ratio \nincreased the drug loading to 14% (w/w) in PLGA microspheres with satisfactory particle size \n(dv=9.59 \u00b5m) and polidispersity (span=1.57). The good agreement between kinetics profiles and \nfickian model indicated that the diffusion is involved on release mechanism. The t-DCTN:HP?CD \ninclusion complex modified the release properties with smaller diffusion rates, for PCL            \n(k2=0.105) and PLGA (k2=0.107), in comparison with microparticles containing only t-DCTN, \nk2=0.289 (PCL) and k2=0.395 (PLGA), respectively. The co-encapsulation also reduced burst \neffect (almost 1.5%) and diffusion rate (k2=0.079). The results suggest a smaller affinity of            \nt-DCTN by PCL matrix in relation to PLGA due its lower encapsulation, higher modification of \nthe zeta potential, higher effect burst and faster release. Then, the microencapsulation of t-DCTN \nand t-DCTN:HP?CD inclusion complex into biodegradable polymers may be an inovate \ntherapeutical alternative to evaluate the hypoglycemic effect of t-DCTN. \n\n \n\n \n\n \nKeywords: Drug delivery systems, microspheres, drug inclusion complex with cyclodextrin, \ntrans-dehydrocrotonin, factorial design. \n\nxiv\n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n15\n\n \n\n \n \n \n \n \n \n \n\n \n\n \n\n \n\n \n\n \n \n \n \n \n \n \n\nINTRODU\u00c7\u00c3O \nREVIS\u00c3O DE LITERATURA  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n16\n\n1 INTRODU\u00c7\u00c3O \n \n\n Os sistemas de libera\u00e7\u00e3o controlada de f\u00e1rmacos permitem o aumento da efic\u00e1cia \n\nterap\u00eautica atrav\u00e9s da modifica\u00e7\u00e3o da cin\u00e9tica de libera\u00e7\u00e3o do princ\u00edpio ativo, bem como, pelo \n\nseu direcionamento ao s\u00edtio de a\u00e7\u00e3o, oferecendo v\u00e1rias vantagens em rela\u00e7\u00e3o \u00e0s formas \n\nfarmac\u00eauticas convencionais, tais como aumento da biodisponibilidade, libera\u00e7\u00e3o prolongada, \n\nmanunten\u00e7\u00e3o da concentra\u00e7\u00e3o plasm\u00e1tica do f\u00e1rmaco constante dentro da faixa terap\u00eautica, \n\nminimiza\u00e7\u00e3o de efeitos t\u00f3xicos e subterap\u00eauticos, diminui\u00e7\u00e3o da freq\u00fc\u00eancia de administra\u00e7\u00e3o \n\nda dose e melhoria da ades\u00e3o do paciente \u00e0 terap\u00eautica (BRANNON-PEPPAS, 1995; \n\nFREIBERG; ZHU, 2004; GARBAYO et al., 2008; MAO et al., 2008). \n\n Dentre os sistemas de libera\u00e7\u00e3o controlada, as micropart\u00edculas polim\u00e9ricas merecem \n\ndestaque, tendo em vista a estabilidade f\u00edsico-qu\u00edmica e biol\u00f3gica, sendo utilizadas para a \n\nencapsula\u00e7\u00e3o de diferentes subst\u00e2ncias, como pept\u00eddeos, prote\u00ednas, DNA/RNA e f\u00e1rmacos \n\n(GARBAYO et al., 2008; WISCHKE; SCHWENDEMAN, 2008), destinadas principalmente \n\npara a via oral de administra\u00e7\u00e3o. Al\u00e9m disso, esses sistemas de libera\u00e7\u00e3o s\u00e3o utilizados na \n\nprepara\u00e7\u00e3o de produtos farmac\u00eauticos presentes no mercado (como Lupron\u00ae, Depot\u00ae, \n\nZoladex\u00ae, Decapeptyl\u00ae, Eligard\u00ae, Enantone\u00ae, Trenantone\u00ae, Nutropin Depot\u00ae, e Profact\u00ae) \n\n(HANS; LOWMAN, 2002; WISCHKE; SCHWENDEMAN, 2008). Pol\u00edmeros \n\nbiocompat\u00edveis e biodegrad\u00e1veis s\u00e3o comumente empregados no desenvolvimento de \n\nmicropart\u00edculas, tais como os poli\u00e9steres poli-?-caprolactona (PCL), poli\u00e1cido l\u00e1ctico (PLA), \n\npoli\u00e1cido glic\u00f3lico (PGA) e seus copol\u00edmeros (PLGA) (SANTOS-MAGALH\u00c3ES et al., \n\n2000; LECAROZ et al., 2006; FERN\u00c1NDEZ-CARBALLIDO et al., 2008). \n\nAs micropart\u00edculas biodegrad\u00e1veis podem ser preparadas por diferentes t\u00e9cnicas, como \n\na t\u00e9cnica de emulsifica\u00e7\u00e3o com evapora\u00e7\u00e3o do solvente \u00e9 bastante utilizada (BILATI et al., \n\n2005; GARBAYO et al., 2008; ZHANG et al., 2008). V\u00e1rios fatores na t\u00e9cnica de prepara\u00e7\u00e3o \n\npodem influenciar as caracter\u00edsticas f\u00edsico-qu\u00edmicas dos sistemas desenvolvidos (DILLEN et \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n17\n\nal., 2004). A an\u00e1lise fatorial pode ser utilizada para a avalia\u00e7\u00e3o dos efeitos das vari\u00e1veis de \n\nformula\u00e7\u00e3o e suas intera\u00e7\u00f5es nas propriedades estudadas com uma abordagem estat\u00edstica, \n\nsendo bastante \u00fatil como uma estrat\u00e9gia para a otimiza\u00e7\u00e3o de formula\u00e7\u00f5es farmac\u00eauticas \n\n(DERAKHSHANDEH et al., 2007). \n\n A trans-desidrocrotonina (t-DCTN) \u00e9 a subst\u00e2ncia majorit\u00e1ria de natureza \n\nclerod\u00e2nica isolado das cascas do caule da esp\u00e9cie vegetal nativa da regi\u00e3o amaz\u00f4nica \n\nbrasileira Croton cajucara Benth (popularmente conhecida como sacaca) (AGNER et al., \n\n1999). A t-DCTN apresenta v\u00e1rias atividades farmacol\u00f3gicas comprovadas e correlacionadas \n\nao uso popular da sacaca, dentre elas, hipoglic\u00eamica (FARIAS et al., 1997; SILVA et al., \n\n2001a), hipolipid\u00eamica (FARIAS et al., 1996; SILVA et al., 2001a; 2001b; 2001c; \n\nBIGHETTI et al., 2004), antigenot\u00f3xica (AGNER et al., 1999; 2001), antiulcerog\u00eanica \n\n(HIRUMA-LIMA et al., 1999; MELO et al., 2003; RODR\u00cdGUEZ et al., 2004), \n\nantiinflamat\u00f3ria e antinociceptiva (CARVALHO et al., 1996), antitumoral (GRYNBERG et \n\nal., 1999; MELO et al., 2004), antiestrog\u00eanica (LUNA-COSTA et al., 1999) e cardiovascular \n\n(SILVA et al., 2005). Entretanto, a baixa solubilidade aquosa (36,6 \u00b1 3,16 \u00b5g/mL a 37\u00baC) \n\n(MORAIS et al., 2008) e a hepatotoxicidade (MACIEL et al., 2002a; 2002b) da t-DCTN s\u00e3o \n\nfatores limitantes da sua aplica\u00e7\u00e3o terap\u00eautica (CORR\u00caA et al., 2005).  \n\n Em estudo pr\u00e9vio foi demonstrado que a encapsula\u00e7\u00e3o da t-DCTN em sistemas de \n\nlibera\u00e7\u00e3o controlada do tipo microesferas de PLGA melhorou o seu efeito hipoglicemiante em \n\nratos normoglic\u00eamicos, reduzindo os n\u00edveis de glicose em 26,8%, enquanto foi obtida uma \n\nredu\u00e7\u00e3o de 14,3% para a t-DCTN em suspens\u00e3o. As microesferas de PLGA contendo t-DCTN \n\nforam obtidas pelo m\u00e9todo de emuls\u00e3o m\u00faltipla a/o/a com evapora\u00e7\u00e3o do solvente e \n\napresentaram uma forma esf\u00e9rica e superf\u00edcie lisa em an\u00e1lise de microscopia eletr\u00f4nica de \n\nvarredura. Al\u00e9m disso, as microesferas demonstraram uma efici\u00eancia de encapsula\u00e7\u00e3o de \n\n85,5%, e duas popula\u00e7\u00f5es de tamanho de part\u00edcula importantes (3,2 ?m e 7,6 ?m). No que se \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n18\n\nrefere \u00e0 cin\u00e9tica de libera\u00e7\u00e3o in vitro, foi observado um efeito burst de 19,4% nas primeiras    \n\n2 h, uma etapa de libera\u00e7\u00e3o lenta e gradual com dura\u00e7\u00e3o de 12 h (com uma constante de \n\ndifusibilidade k2=0,086) e, uma libera\u00e7\u00e3o m\u00e1xima de 55,6% em 57 h (MORAIS et al., 2008). \n\n As propriedades f\u00edsicas, qu\u00edmicas e biol\u00f3gicas dos princ\u00edpios ativos podem ser \n\nmodificadas pela forma\u00e7\u00e3o de complexos de inclus\u00e3o com ciclodextrinas, podendo ser \n\nobservados o aumento da solubilidade aquosa e da estabilidade, bem como a diminui\u00e7\u00e3o da \n\ntoxicidade dos f\u00e1rmacos associados (MARTIN DEL VALLE, 2004; BREWSTER; \n\nLOFTSSON, 2007; SCHWINGEL et al., 2008). Esse mecanismo de complexa\u00e7\u00e3o molecular \u00e9 \n\nposs\u00edvel porque as ciclodextrinas s\u00e3o oligossacar\u00eddeos c\u00edclicos constitu\u00eddos de uma superf\u00edcie \n\nhidrof\u00edlica e uma cavidade hidrof\u00f3bica, a qual permite o alojamento de f\u00e1rmacos de baixa \n\npolaridade em seu interior (DUCH\u00caNE et al., 1999; LOFTSSON; DUCH\u00caNE, 2007). \n\nComplexos de inclus\u00e3o de f\u00e1rmacos com ciclodextrinas v\u00eam sendo incorporados em sistemas \n\nde libera\u00e7\u00e3o controlada, como microesferas, a fim de melhorar a efici\u00eancia de encapsula\u00e7\u00e3o e \n\nmodular a cin\u00e9tica de libera\u00e7\u00e3o dos dispositivos terap\u00eauticos (DUCH\u00caNE et al., 1999).   \n\n A ?-ciclodextrina \u00e9 uma das ciclodextrinas (CD) naturais mais utilizadas em \u00e2mbito \n\nfarmac\u00eautico devido a sua habilidade de complexa\u00e7\u00e3o com diferentes f\u00e1rmacos e seu baixo \n\ncusto (LOFTSSON; DUCH\u00caNE, 2007). Complexo de inclus\u00e3o de t-DCTN com                  \n\n?-ciclodextrina reduziu a citotoxicidade deste composto bioativo em hepat\u00f3citos de ratos e \n\nfibrobastos V79 (CORR\u00caA et al., 2005). Derivados quimicamente modificados da                 \n\n?-ciclodextrina, como a 2-hidroxipropil-?-ciclodextrina (HP?CD), v\u00eam sendo bastante \n\nutilizados devido ao aumento da solubilidade aquosa e a diminui\u00e7\u00e3o das restri\u00e7\u00f5es \n\ntoxicol\u00f3gicas relacionadas \u00e0 ?-ciclodextrina (DE ARA\u00daJO et al., 2008).   \n\n Nesse contexto, este estudo pretende conciliar as vantagens da nanotecnologia \n\nfarmac\u00eautica, juntamente com os fundamentos da forma\u00e7\u00e3o de complexos de inclus\u00e3o de \n\nf\u00e1rmacos com ciclodextrinas. A an\u00e1lise fatorial foi utilizada como estrat\u00e9gia para otimiza\u00e7\u00e3o \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n19\n\ndos sistemas de libera\u00e7\u00e3o controlada. Essa proposta de trabalho foi desenvolvida com a \n\nobten\u00e7\u00e3o e caracteriza\u00e7\u00e3o de microesferas inovadoras dos pol\u00edmeros biodegrad\u00e1veis PCL e \n\nPLGA contendo o bioativo t-DCTN e o complexo de inclus\u00e3o de t-DCTN com HP?CD. Com \n\nisso, foi avaliada a influ\u00eancia do complexo de inclus\u00e3o nas propriedades f\u00edsico-qu\u00edmicas e de \n\nlibera\u00e7\u00e3o usando diferentes matrizes polim\u00e9ricas. Desta forma, o presente trabalho viabiliza a \n\namplia\u00e7\u00e3o dos estudos com o diterpeno clerod\u00e2nico t-DCTN com uma abordagem \n\nnanotecnol\u00f3gica, os quais podem contribuir como uma alternativa em potencial no avan\u00e7o da \n\nutiliza\u00e7\u00e3o deste princ\u00edpio ativo na terap\u00eautica. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n20\n\n2 REVIS\u00c3O DE LITERATURA \n\n \n\n2.1 Nanotecnologia Farmac\u00eautica - Sistemas de libera\u00e7\u00e3o de f\u00e1rmacos  \n\n O termo nanotecnologia foi utilizado pela primeira vez por Norio Taniguchi em 1974 \n\npara definir a t\u00e9cnica de produ\u00e7\u00e3o na ordem de 1 nan\u00f4metro (SAHOO et al., 2007). De uma \n\nforma geral, a nanotecnologia representa a ci\u00eancia e engenharia que est\u00e1 envolvida com o \n\ndesenvolvimento, caracteriza\u00e7\u00e3o e aplica\u00e7\u00e3o de materiais e dipositivos funcionalizados na \n\nescala nanom\u00e9trica (a bilion\u00e9sima parte do metro) (EMERICH et al., 2003; SAHOO et al., \n\n2007).  \n\nAs primeiras aplica\u00e7\u00f5es pr\u00e1ticas da nanotecnologia contemplaram diversas \u00e1reas, \n\ncomo comunica\u00e7\u00f5es, engenharia, f\u00edsica, qu\u00edmica, biologia, rob\u00f3tica e medicina. O uso da \n\nnanotecnologia nas ci\u00eancias m\u00e9dicas oferece novas oportunidades terap\u00eauticas contribuindo \n\npara o avan\u00e7o da sa\u00fade humana com a descoberta ou aprimoramento de tratamentos para uma \n\nvariedade de doen\u00e7as e melhoria da qualidade de vida do paciente (SAHOO et al., 2007; \n\nSINGH; LILLARD, 2009).  \n\nNesse contexto, a nanotecnologia farmac\u00eautica \u00e9 respons\u00e1vel pelo delineamento de \n\nnovos dispositivos de libera\u00e7\u00e3o de f\u00e1rmacos na escala nano e microm\u00e9trica com uma \n\nabordagem multidisciplinar. Essa tecnologia de libera\u00e7\u00e3o de f\u00e1rmacos atua obtendo sistemas \n\nterap\u00eauticos mais eficientes atrav\u00e9s do direcionamento do princ\u00edpio ativo ao s\u00edtio de a\u00e7\u00e3o \n\n(c\u00e9lula, tecido ou \u00f3rg\u00e3o) ou pelo controle de sua cin\u00e9tica de libera\u00e7\u00e3o (STAMATIALIS et al., \n\n2008).  \n\nOs sistemas desenvolvidos por essa sofisticada tecnologia s\u00e3o dispositivos que liberam \n\no princ\u00edpio ativo de uma forma controlada, mantendo uma concentra\u00e7\u00e3o apropriada no local \n\nde a\u00e7\u00e3o por um maior per\u00edodo de tempo. Com isso, exerce um papel fundamental na \n\notimiza\u00e7\u00e3o da terapia medicamentosa, j\u00e1 que possibilita que os princ\u00edpios ativos tornem-se \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n21\n\nmais seletivos em termos de concentra\u00e7\u00e3o no s\u00edtio de a\u00e7\u00e3o, minimizando efeitos colaterais e \n\naumentando a dura\u00e7\u00e3o da atividade biol\u00f3gica (KUMAR et al., 2001; STAMATIALIS et al., \n\n2008). Essa estrat\u00e9gia nanotecnol\u00f3gica \u00e9 bastante \u00fatil para reintroduzir no mercado \n\nfarmac\u00eautico f\u00e1rmacos de elevada pot\u00eancia farmacol\u00f3gica que apresentam uma baixa \n\nbiodisponibilidade ou elevada toxicidade, bem como para diminuir o custo e o tempo \n\nassociados \u00e0 obten\u00e7\u00e3o de uma nova mol\u00e9cula bioativa por s\u00edntese qu\u00edmica (FENG et al., \n\n2004). \n\n As vantagens dos sistemas de libera\u00e7\u00e3o controlada em rela\u00e7\u00e3o \u00e0s formas \n\nfarmac\u00eauticas convencionais est\u00e3o relacionadas a in\u00fameros fatores (Fig. 1), tais como, \n\nprote\u00e7\u00e3o do princ\u00edpio ativo contra oxida\u00e7\u00e3o, umidade e varia\u00e7\u00e3o de pH que podem diminuir \n\nos n\u00edveis plasm\u00e1ticos do f\u00e1rmaco; direcionamento a alvos espec\u00edficos do organismo humano \n\ncom o uso de mol\u00e9culas sinalizadoras como anticorpos, pept\u00eddeos e polissacar\u00eddeos; aumento \n\nda biodisponibilidade; redu\u00e7\u00e3o do n\u00famero de doses e da quantidade do f\u00e1rmaco administrado; \n\nlibera\u00e7\u00e3o sustentada e prolongada; diminui\u00e7\u00e3o das flutua\u00e7\u00f5es sangu\u00edneas da concentra\u00e7\u00e3o do \n\nprinc\u00edpio ativo; manuten\u00e7\u00e3o da concentra\u00e7\u00e3o terap\u00eautica constante; minimiza\u00e7\u00e3o de efeitos \n\nt\u00f3xicos e subterap\u00eauticos; maior ades\u00e3o do paciente \u00e0 terapia medicamentosa e redu\u00e7\u00e3o dos \n\ncustos na sa\u00fade (BRANNON-PEPPAS, 1995; PETITTI et al., 2008).  \n\n \n\nFigura 1 - Compara\u00e7\u00e3o do perfil farmacocin\u00e9tico de formas farmac\u00eauticas convencionais e de \n\nsistemas de libera\u00e7\u00e3o controlada (adaptado de \n\nhttp://www.qmc.ufsc.br/qmcweb/exemplar15.html). \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n22\n\n \n\nTabela 1 - Exemplos de sistemas de libera\u00e7\u00e3o de agentes terap\u00eauticos. \n\nSistema Descri\u00e7\u00e3o F\u00e1rmaco Indica\u00e7\u00e3o \n\nterap\u00eautica \nMicropart\u00edculas Part\u00edculas polim\u00e9ricas s\u00f3lidas \n\ncom tamanho de 1-1000 \u00b5m      \n\n(YANG; ALEXANDRIDIS, \n\n2000) \n\nIndometacina  \n\n(POLETTO et al., 2007) \n\n \n\nDexametasona  \n\n(BALMAYOR et al., \n\n2009) \n\n \n\n \nOsteoartrite \n\n \n\n \n\nNanopart\u00edculas Part\u00edculas polim\u00e9ricas coloidais \n\ncom tamanho de 10-1000 nm     \n\n(SOPPIMATH et al., 2001) \n\nRisperidona \n\n(MUTHU et al., 2009) \n\n \n\nFosfato de betametasona \n\n(ISHIHARA et al., 2009) \n\nEsquizofrenia \n\n \n\n \n\nRinite al\u00e9rgica \n\nLipossomas Ves\u00edculas esf\u00e9ricas baseadas em \n\nbicamadas lip\u00eddicas \n\n (TORCHILIN et al., 2005) \n\nVacina DNA \n\n(KHATRI et al., 2008) \n\n \n\nTerapia g\u00eanica \n\nNanopart\u00edculas \n\nlip\u00eddicas \n\ns\u00f3lidas \n\nPart\u00edculas submicr\u00f4nicas \n\nbaseadas em monocamadas \n\nlip\u00eddicas s\u00f3lidas \u00e0 temperatura \n\nambiente ou corp\u00f3rea \n\n(FARAJI; WIPF, 2009) \n\nTretino\u00edna \n\n(SHAH et al., 2007) \n\n \n\nPaclitaxel \n\n(YUAN et al., 2007) \n\nAcne \n\n \n\n \n\nCarcinoma de \n\nov\u00e1rio \nPolimerssomas Ves\u00edculas esf\u00e9ricas baseadas em \n\nbicamadas de pol\u00edmeros \n\n(SINGH; LILLARD, 2009) \n\nDoxorubicina  \n\n(AHMED et al., 2006) \n\nLeucemias \n\nlinfobl\u00e1stica \n\naguda e \n\nmielobl\u00e1stica \n\nDendr\u00edmeros Macromol\u00e9culas com estrutura \n\nsim\u00e9trica baseadas em pol\u00edmeros \n\n(FARAJI; WIPF, 2009) \n\nDoxorubicina \n\n(LEE et al., 2006) \n\n \n\nC\u00e2ncer de \n\nbexiga \n\n \n\n \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n23\n\nNesse contexto, podem ser produzidos diferentes dispositivos, tais quais as \n\nmicropart\u00edculas, nanopart\u00edculas, lipossomas, nanopart\u00edculas lip\u00eddicas s\u00f3lidas, polimerssomas, \n\ndendr\u00edmeros, contendo f\u00e1rmacos de aplica\u00e7\u00f5es terap\u00eauticas diversas (Tab. 1), produzindo \n\ndiferentes perfis de libera\u00e7\u00e3o de acorco com o sistema e a via de administra\u00e7\u00e3o utilizados \n\n(PETITTI et al., 2008). \n\n \n\n2.2 Sistemas particulados polim\u00e9ricos  \n\nOs sistemas particulados s\u00e3o dispositivos polim\u00e9ricos de libera\u00e7\u00e3o controlada de \n\nf\u00e1rmacos com tamanho variando da escala nanom\u00e9trica (nanopart\u00edculas) a microm\u00e9trica \n\n(micropart\u00edculas) capazes de incorporar diferentes agentes terap\u00eauticos (Tab. 1) desde \n\nf\u00e1rmacos de baixo peso molecular a macromol\u00e9culas (BARAT et al., 2008). \n\nEsses sistemas podem ser classificados de acordo com a sua composi\u00e7\u00e3o e organiza\u00e7\u00e3o \n\nestrutural em nanoesferas/microesferas e nanoc\u00e1psulas/microc\u00e1psulas (Fig. 2) (BERKLAND \n\net al., 2001; MANDAL et al., 2001; SINGH et al., 2001; PETITTI et al., 2008).  As \n\nnanoesferas e as microesferas s\u00e3o sistemas matriciais ou monol\u00edticos em que o f\u00e1rmaco \n\nencontra-se disperso e/ou solubilizado na matriz polim\u00e9rica, n\u00e3o sendo poss\u00edvel identificar um \n\nn\u00facleo diferenciado (LIMAYEM et al., 2004). Por outro lado, as nanoc\u00e1psulas e \n\nmicroc\u00e1psulas s\u00e3o sistemas reservat\u00f3rios nos quais o f\u00e1rmaco encontra-se contido em um \n\nn\u00facleo central (de natureza oleosa ou aquosa) com um revestimento polim\u00e9rico disposto ao \n\nredor deste n\u00facleo que atua como um filme protetor (SOPPIMATH et al., 2001). \n\nDurante as \u00faltimas d\u00e9cadas, os sistemas particulados polim\u00e9ricos v\u00eam sendo \n\napontados como uma importante alternativa em v\u00e1rias aplica\u00e7\u00f5es, dentre elas, repara\u00e7\u00e3o \n\n\u00f3ssea, engenharia de tecidos, desenvolvimento e aplica\u00e7\u00f5es biom\u00e9dicas, tais como libera\u00e7\u00e3o \n\nde vacinas, v\u00e1rios tratamentos para o c\u00e2ncer, SIDA, tuberculose e outras doen\u00e7as, \n\napresentando perspectivas futuras promissoras (BARAT et al., 2008). Al\u00e9m disso, a \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n24\n\nencapsula\u00e7\u00e3o do f\u00e1rmaco na matriz polim\u00e9rica o protege da desativa\u00e7\u00e3o durante o processo de \n\nlibera\u00e7\u00e3o e garante que a concentra\u00e7\u00e3o liberada seja suficiente para atingir o s\u00edtio de a\u00e7\u00e3o (NG \n\net al., 2009).  \n\n \n\nFigura 2. Representa\u00e7\u00e3o esquem\u00e1tica da classifica\u00e7\u00e3o de nanopart\u00edculas e micropart\u00edculas: \n\nnanoesfera e microesfera (sistema matricial) (A); nanoc\u00e1psula e microc\u00e1psula (sistema \n\nreservat\u00f3rio) (B) (http://www.nanoparticles.org/links/Nanosphere.jpg).  \n\n \n\nOs sistemas particulados polim\u00e9ricos merecem destaque como dispositivos de \n\nlibera\u00e7\u00e3o de f\u00e1rmacos devido \u00e0 catacter\u00edsticas, tais como, boa estabilidade f\u00edsico-qu\u00edmica e \n\nbiol\u00f3gica, encapsula\u00e7\u00e3o de uma variedade de f\u00e1rmacos de diversas aplica\u00e7\u00f5es \n\n(antiinflamat\u00f3rios, antibi\u00f3ticos, antif\u00fangicos, antituberculost\u00e1ticos, anticancer\u00edgenos, \n\nanest\u00e9sicos, antipsic\u00f3ticos) e versatilidade de vias de administra\u00e7\u00e3o (oral, intramuscular, \n\nsubcut\u00e2nea, bioadesiva, injet\u00e1vel, pulmonar) (HANS; LOWMAN, 2002; BARAT et al., 2008; \n\nBALMAYOR et al., 2009; KLOSE et al., 2009; SINGH; LILLARD, 2009). Outro fator que \n\ndespertou grande interesse no desenvolvimento destes sistemas foi a sua comercializa\u00e7\u00e3o em \n\nimportantes produtos farmac\u00eauticos aplicados a terap\u00eautica, muitos deles ainda presentes no \n\nmercado (como Lupron\u00ae Depot\u00ae, Zoladex\u00ae, Decapeptyl\u00ae, Eligard\u00ae, Enantone\u00ae, Trenantone\u00ae, \n\nNutropin Depot\u00ae, e Profact\u00ae) (WISCHKE; SCHWENDEMAN, 2008). \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n25\n\n2.2.1 Pol\u00edmeros utilizados na prepara\u00e7\u00e3o de sistemas particulados \n\nUma das principais raz\u00f5es do processamento de pol\u00edmeros na \u00e1rea farmac\u00eautica \u00e9 a \n\nprepara\u00e7\u00e3o de carreadores de f\u00e1rmacos (REVERCHON et al., 2009). Nas \u00faltimas d\u00e9cadas, \u00e9 \n\nobservada \u00eanfase na utiliza\u00e7\u00e3o de pol\u00edmeros biodegrad\u00e1veis para o desenvolvimento de \n\nsistemas de libera\u00e7\u00e3o controlada. Esse fato est\u00e1 associado \u00e0 capacidade destes dispositivos \n\nliberarem o f\u00e1rmaco durante certo per\u00edodo de tempo e, subsequentemente, serem \n\nmetabolizados pelo organismo humano sem a necessidade de remo\u00e7\u00e3o cir\u00fargica, obtendo a \n\ndura\u00e7\u00e3o desejada do tratamento farmacol\u00f3gico (BALMAYOR et al., 2009; KLOSE et al., \n\n2009).  \n\nNa obten\u00e7\u00e3o de nanopart\u00edculas e micropart\u00edculas podem ser utilizados tanto pol\u00edmeros \n\nnaturais quanto sint\u00e9ticos (BRANNON-PEPPAS, 1995). Dentre os pol\u00edmeros naturais mais \n\nempregados est\u00e3o albumina, col\u00e1geno, alginato, \u00e1cido hialur\u00f4nico e quitosana que oferecem \n\nnumerosas vantagens quando usados como carreadores de libera\u00e7\u00e3o de f\u00e1rmacos \n\n(BALMAYOR et al., 2009). No entanto, problemas associados \u00e0 pureza, \u00e0 necessidade de \n\nmodifica\u00e7\u00e3o qu\u00edmica ou mesmo \u00e0 incompatibilidade com outros constituintes da formula\u00e7\u00e3o, \n\njustificam o uso difundido de pol\u00edmeros sint\u00e9ticos biodegrad\u00e1veis como mat\u00e9rias-primas \n\ndestes sistemas de libera\u00e7\u00e3o (HANS; LOWMAN, 2002).   \n\nOs pol\u00edmeros sint\u00e9ticos comumente utilizados s\u00e3o poliamidas, \u00e1cidos poliamino, \n\npoli\u00e9steres, poliorto\u00e9steres, poliuretanos e poliacrilamidas (JAIN, 2000). Os poli\u00e9steres \n\nalif\u00e1ticos com liga\u00e7\u00f5es hidroliz\u00e1veis s\u00e3o pol\u00edmeros atrativos para controlar o perfil de \n\nlibera\u00e7\u00e3o em micropart\u00edculas e nanopart\u00edculas. Os poli\u00e9steres como poli-?-caprolactona \n\n(PCL), poli\u00e1cido l\u00e1ctico (PLA), poli\u00e1cido glic\u00f3lico (PGA) e seus copol\u00edmeros poli(DL-\n\nl\u00e1ctico-co-glic\u00f3lico \u00e1cido) (PLGA) s\u00e3o frequentemente usados na obten\u00e7\u00e3o de sistemas de \n\nlibera\u00e7\u00e3o de f\u00e1rmacos em virtude das suas propriedades de biocompatibilidade e \n\nbiodegrada\u00e7\u00e3o (WANG et al., 2009), al\u00e9m da seguran\u00e7a do uso em humanos, j\u00e1 sendo \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n26\n\npol\u00edmeros oficialmente regulamentados para uso interno pela ag\u00eancia de vigil\u00e2ncia sanit\u00e1ria \n\namericana, a Food and Drug Administration (FDA) (SANTOS-MAGALH\u00c3ES et al., 2000;  \n\nSOPPIMATH et al., 2001; LECAROZ et al., 2006; FERN\u00c1NDEZ-CARBALLIDO et al., \n\n2008; GARBAYO et al., 2008).  \n\nV\u00e1rios estudos utilizam o PLGA na prepara\u00e7\u00e3o de sistemas particulados de libera\u00e7\u00e3o \n\ncontrolada devido a fatores como a sua longa hist\u00f3ria de estudos de biocompatibilidade e \n\nbiodegrada\u00e7\u00e3o, versatilidade de suas propriedades de libera\u00e7\u00e3o associada \u00e0 modifica\u00e7\u00e3o de \n\nsua composi\u00e7\u00e3o (raz\u00e3o de \u00e1cido l\u00e1ctico/glic\u00f3lico), peso molecular e estrutura qu\u00edmica, \n\npodendo obter meia-vida in vivo com ampla faixa de varia\u00e7\u00e3o (de 3 meses a 1 ano em m\u00e9dia), \n\ncin\u00e9tica de biodegrada\u00e7\u00e3o previs\u00edvel, baixas imunogenicidade e toxicidade, boas propriedades \n\nmec\u00e2nicas e ao uso de t\u00e9cnicas de prepara\u00e7\u00e3o bem documentadas (BARAT et al., 2008; \n\nMUTHU et al., 2009). O PLGA j\u00e1 foi usado na prepara\u00e7\u00e3o de comprimidos orais, \n\nnanopart\u00edculas inal\u00e1veis ou intravenosas e micropart\u00edculas para formula\u00e7\u00f5es subcut\u00e2neas de \n\ndep\u00f3sito (GASPARINI et al, 2008). Entretanto, a forma\u00e7\u00e3o de subprodutos \u00e1cidos da \n\ndegrada\u00e7\u00e3o do PLGA pode ocasionar resposta inflamat\u00f3ria e limitar o uso deste pol\u00edmero em \n\nalguns casos como em aplica\u00e7\u00f5es envolvendo a engenharia de tecidos (LINHART et al., \n\n2001; HO et al., 2008; WANG et al., 2009). \n\n  O PCL \u00e9 outro pol\u00edmero sint\u00e9tico bastante utilizado na produ\u00e7\u00e3o de sistemas \n\nparticulados devido a sua alta permeabilidade a muitos f\u00e1rmacos e biocompatibilidade em \n\nmeio fisol\u00f3gico, al\u00e9m de outras vantagens em rela\u00e7\u00e3o a outros pol\u00edmeros (como o PLA), \n\ndentre elas, ser mais est\u00e1vel em condi\u00e7\u00f5es ambientes, apresentar uma biodegrada\u00e7\u00e3o mais \n\nlenta e ser menos oneroso podendo ser utilizado em grandes quantidades (OH et al., 2006; \n\nLUCIANI et al., 2008; WANG et al., 2009). \n\n \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n27\n\n2.3 Micropart\u00edculas \n\nA t\u00e9cnica de microencapsula\u00e7\u00e3o foi utilizada inicialmente com o objetivo de proteger \n\nvitaminas do processo de oxida\u00e7\u00e3o h\u00e1 aproximadamente 70 anos (TAYLOR, 1938). Algumas \n\nd\u00e9cadas depois o PLA e seus copol\u00edmeros (PLGA) foram avaliados como pol\u00edmeros \n\nbiocompat\u00edveis e biodegrad\u00e1veis para sistemas de libera\u00e7\u00e3o de f\u00e1rmacos (KULKARNI et al., \n\n1971; IGNATIUS; CLEAS, 1996; ANDERSON; SHIVE, 1997; WISCHKE; \n\nSCHWENDEMAN, 2008). A microencapsula\u00e7\u00e3o moderna de subst\u00e2ncias bioativas continua \n\na ser uma importante \u00e1rea de estudo e esfor\u00e7os s\u00e3o concentrados no sentido de aperfei\u00e7oar \n\nprotocolos de formula\u00e7\u00e3o (NG et al., 2009).  \n\nA encapsula\u00e7\u00e3o de princ\u00edpios ativos em sistemas de libera\u00e7\u00e3o em escala microm\u00e9trica, \n\ncomo em micropart\u00edculas de PLGA, pode ser utilizada como uma estrat\u00e9gia para driblar ou \n\nfavorecer mecanismos celulares e fisol\u00f3gicos a fim de melhorar a efici\u00eancia terap\u00eautica \n\n(SOPPIMATH et al., 2001; FREIBERG; ZHU, 2004). Como por exemplo, micropart\u00edculas \n\nporosas de tamanho entre 10-15 \u00b5m v\u00eam demonstrando uma deposi\u00e7\u00e3o pulmonar mais efetiva \n\ne um aumento no tempo de resid\u00eancia no tecido pulmonar devido ao seu maior di\u00e2metro e \n\ndiminui\u00e7\u00e3o da captura fagot\u00edcita alveolar em rela\u00e7\u00e3o \u00e0s part\u00edculas de menor tamanho (1-5 \u00b5m) \n\n(ARNOLD et al., 2007). Hirota e colaboradores (2007) observaram este efeito em \n\nmicropart\u00edculas de PLGA com tamanho de 10 \u00b5m contendo rifampicina. Outro exemplo \u00e9 a \n\nfaixa de tamanho de part\u00edcula adequada para o transporte atrav\u00e9s da barreira gastrointestinal, \n\nfato este importante quando o f\u00e1rmaco encapsulado destina-se a via oral de administra\u00e7\u00e3o. \n\nApesar de n\u00e3o estar totalmente elucidado, estudos demonstram que part\u00edculas com at\u00e9 10 \u00b5m \n\nn\u00e3o apresentam grandes dificuldades para atravessar o epit\u00e9lio gastrointestinal (GAUMET et \n\nal., 2007).  \n\nPrinc\u00edpios ativos das mais diversas classes terap\u00eauticas v\u00eam sendo incorporados em \n\nmicropart\u00edculas como antibi\u00f3ticos, anticancer\u00edgenos, antituberculost\u00e1ticos, antif\u00fangicos, \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n28\n\nantiinflamat\u00f3rios, analg\u00e9sicos, antireum\u00e1ticos, antimal\u00e1ricos, antivirais; bem como, enzimas, \n\nhorm\u00f4nios, ester\u00f3ides, pept\u00eddeos, prote\u00ednas, anticorpos, vacinas, RNA, dentre outros \n\n(SANTOYO et al., 2002; FREITAS et al., 2005; HIROTA et al., 2007;  FERN\u00c1NDEZ-\n\nCARBALLIDO et al., 2008; MURATA et al., 2008; SUN et al., 2008; BARCIA et al., 2009).  \n\nNas \u00faltimas d\u00e9cadas, micropart\u00edculas polim\u00e9ricas s\u00e3o extensivamente estudadas como \n\nsistemas de libera\u00e7\u00e3o de f\u00e1rmacos e utilizadas em prepara\u00e7\u00f5es farmac\u00eauticas comerciais \n\n(DEADMAN et al., 2007), devido a in\u00fameras vantagens, tais como, modula\u00e7\u00e3o da cin\u00e9tica de \n\nlibera\u00e7\u00e3o e da efici\u00eancia de encapsula\u00e7\u00e3o associadas ao tamanho do dispositivo, versatilidade \n\ndas propriedades de tamanho e porosidade, possibilidade de encapsula\u00e7\u00e3o de subst\u00e2ncias \n\nhidrof\u00edlicas e hidrof\u00f3bicas, facilidade de prepara\u00e7\u00e3o, melhoria da estabilidade e da \n\nbiodisponibilidade oral de f\u00e1rmacos e prote\u00ednas, aumento da permeabilidade e/ou estabilidade \n\nde subst\u00e2ncias atrav\u00e9s do trato gastrointestinal e diversidade de vias de administra\u00e7\u00e3o (VASIR \n\net al., 2003; WANG et al., 2009). \n\nIto e colaboradores (2008) obtiveram microesferas de PLGA contendo dextrana (usada \n\ncomo modelo de f\u00e1rmaco hidrof\u00edlico) de diferentes tamanhos (variando de 2,4-10,6 \u00b5m) e \n\nefici\u00eancias de encapsula\u00e7\u00e3o (2,4\u201363,8%). Enquanto que, Balmayor e colaboradores (2009) \n\nprepararam microesferas de PCL contendo o f\u00e1rmaco hidrof\u00f3bico dexametasona para sua \n\naplica\u00e7\u00e3o em sistemas de libera\u00e7\u00e3o de f\u00e1rmacos e engenharia de tecidos. Nesse contexto, \n\nKlose e colaboradores (2009) prepararam microesferas de PLGA com fenofibrato para a \n\nlibera\u00e7\u00e3o controlada local em sistema nervoso central e obteve redu\u00e7\u00e3o de problemas \n\nassociados \u00e0 isquemia em ratos Wistar.  \n\nMicropart\u00edculas de PLGA contendo nanopart\u00edculas polim\u00e9ricas com caracter\u00edsticas de \n\nporosidade e de di\u00e2metro aerodi\u00e2mico adequadas para a libera\u00e7\u00e3o controlada via pulmonar do \n\nantibi\u00f3tico ciprofloxacino foram desenvolvidas por Arnold e colaboradores (2007). Outro \n\nestudo desenvolvido por Hirota e colaboradores (2007) demonstrou o aumento da efici\u00eancia \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n29\n\nda atividade antituberculost\u00e1tica da rifampicina em 20 vezes quando este f\u00e1rmaco foi \n\nencapsulado em microesferas de PLGA em rela\u00e7\u00e3o a sua forma em solu\u00e7\u00e3o em estudo \n\ndesenvolvido  \n\n \n\n2.3.1 M\u00e9todos de prepara\u00e7\u00e3o de micropart\u00edculas  \n\nAs caracter\u00edsticas dos sistemas de libera\u00e7\u00e3o dependem, dentre outros fatores, do \n\nm\u00e9todo de prepara\u00e7\u00e3o (DILLEN et al., 2004). Investiga\u00e7\u00f5es experimentais com diferentes \n\nm\u00e9todos de prepara\u00e7\u00e3o, condi\u00e7\u00f5es de processo e materiais s\u00e3o realizadas para identificar a \n\ninflu\u00eancia de diferentes par\u00e2metros na encapsula\u00e7\u00e3o do f\u00e1rmaco, morfologia das \n\nmicropart\u00edculas, e consequentemente na cin\u00e9tica de libera\u00e7\u00e3o (PETITTI et al., 2008). \n\nV\u00e1rios fatores s\u00e3o levados em considera\u00e7\u00e3o no momento da escolha do m\u00e9todo de \n\nprepara\u00e7\u00e3o: propriedades f\u00edsico-qu\u00edmicas do f\u00e1rmaco (peso molecular, solubilidade, pKa, \n\ncoeficiente de parti\u00e7\u00e3o octanol/\u00e1gua \u2013 log P, estabilidade) e do pol\u00edmero (peso molecular, \n\ncomposi\u00e7\u00e3o qu\u00edmica, hidrofobicidade); farmacocin\u00e9tica do f\u00e1rmaco; o tipo de micropart\u00edcula \n\ndesejada (microesferas ou microc\u00e1psula); rendimento do processo; efici\u00eancia de \n\nencapsula\u00e7\u00e3o, dentre outros (FREITAS et al., 2005; WANG et al., 2009).  \n\nA propriedade do f\u00e1rmaco mais importante a ser avaliada para o estudo inicial da \n\nmicroencapsula\u00e7\u00e3o \u00e9 a sua solubilidade em \u00e1gua, em solventes org\u00e2nicos e em cosolventes. \n\nFatores que afetam a solubilidade aquosa tais como o pH e a presen\u00e7a de aditivos tamb\u00e9m \n\ndevem ser considerados. Estima-se que mais de 40% das mol\u00e9culas microencapsuladas s\u00e3o \n\nhidrof\u00f3bicas. O termo \u201cf\u00e1rmacos hidrof\u00f3bicos\u201d descreve um grupo heterog\u00eaneo de mol\u00e9culas \n\nque exibem baixa solubilidade aquosa, mas que s\u00e3o comumente sol\u00faveis em v\u00e1rios solventes \n\norg\u00e2nicos. Os termos ligeiramente sol\u00favel (1\u201310 mg/mL), fracamente sol\u00favel (0,1\u20131 mg/mL), \n\ne praticamente insol\u00favel (<0,1 mg/mL) s\u00e3o empregados  para classificar estas subst\u00e2ncias \n\n(WISCHKE; SCHWENDEMAN, 2008). \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n30\n\nOs m\u00e9todos usados na prepara\u00e7\u00e3o de micropart\u00edculas geralmente envolvem princ\u00edpios \n\nde evapora\u00e7\u00e3o e/ou difus\u00e3o do solvente, coacerva\u00e7\u00e3o, spray-drying, uso de fluidos sob \n\ncondi\u00e7\u00f5es supercr\u00edticas sem res\u00edduos de solventes t\u00f3xicos, etc (ITO et al., 2009). Os m\u00e9todos \n\nde emulsifica\u00e7\u00e3o com evapora\u00e7\u00e3o do solvente costumam ser bastante utilizados e envolvem a \n\nforma\u00e7\u00e3o de emuls\u00f5es com fases aquosas e oleosas org\u00e2nicas com a retirada do solvente \n\norg\u00e2nico ao final do processo. O pol\u00edmero e o f\u00e1rmaco s\u00e3o solubilizados nas fases apropriadas \n\ne estas s\u00e3o emulsificadas em uma fase cont\u00ednua (aquosa ou oleosa) contendo um emulsificante \n\nadequado com um baixo poder de solubiliza\u00e7\u00e3o do f\u00e1rmaco. No caso de fases cont\u00ednuas \n\naquosas, o \u00e1lcool polivin\u00edlico (PVA) \u00e9 o emulsificante mais usado. Ao final do processo, os \n\nsolventes vol\u00e1teis podem ser removidos por evapora\u00e7\u00e3o ou por extra\u00e7\u00e3o da fase externa \n\n(WISCHKE; SCHWENDEMAN, 2008). \n\nAs emuls\u00f5es formadas nestes m\u00e9todos podem ser do tipo simples como de \u00f3leo-em-\n\n\u00e1gua (o/a) (Fig. 3), \u00f3leo-em-\u00f3leo (o/o) ou m\u00faltiplas como \u00e1gua-em-\u00f3leo-em-\u00e1gua (a/o/a). O \n\nm\u00e9todo o/o pode ser eficaz para mol\u00e9culas que apresentam uma solubilidade aquosa razo\u00e1vel \n\n(como a hidrocortisona com 280 \u00b5g/mL), minimizando as perdas para a fase cont\u00ednua aquosa, \n\nque pode ser evidenciada com o uso da t\u00e9cnica o/a. Modifica\u00e7\u00f5es destes m\u00e9todos como o de \n\ns\u00f3lido-em-\u00f3leo-\u00e1gua (s/o/a) podem ser \u00fateis quando o f\u00e1rmaco n\u00e3o pode ser solubilizado em \n\num solvente ou mistura de solventes, ou ainda, quando a perda do f\u00e1rmaco para a fase \n\ncont\u00ednua n\u00e3o pode ser evitada com o uso de cosolventes. Como exemplo, podemos citar o \n\nlevonorgestrel (WANG et al., 2005) e o  ?-estradiol (BIRNBAUM et al., 2000; MOGI et al., \n\n2000) que j\u00e1 foram encapsulados usando a t\u00e9cnica s/o/a. Para outras mol\u00e9culas hidrof\u00f3bicas \n\noutras t\u00e9cnicas como s/o/o, o/o/o e s/a/o/a foram adequadas (HERRERO-VANELL et al., \n\n2000; JANORIA; MITRA, 2007; WISCHKE; SCHWENDEMAN, 2008). \n\nAs t\u00e9cnicas com evapora\u00e7\u00e3o do solvente apresentam v\u00e1rias vantagens, tais como: \n\ncontrole da cin\u00e9tica de libera\u00e7\u00e3o e do tamanho de part\u00edcula (produzindo amostras \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n31\n\nmonodispersas), possibilidade do uso de pol\u00edmeros insol\u00faveis em \u00e1gua, excelentes efici\u00eancias \n\nde encapsula\u00e7\u00e3o para f\u00e1rmacos hidrof\u00f3bicos (como exemplo: cisplatina, lidoca\u00edna, naltrexone \n\ne progesterona) e hidrof\u00edlicos (insulina, prote\u00ednas, pept\u00eddeos e vacinas), e a possibilidade de \n\ntransposi\u00e7\u00e3o para a escala industrial (t\u00e9cnica j\u00e1 utilizada em ind\u00fastrias farmac\u00eauticas) (LI et \n\nal., 2008). \n\nMicropart\u00edculas de SPCL, uma combina\u00e7\u00e3o polim\u00e9rica \u201cblend\u201d de PCL com amido, \n\ncontendo dexametasona, foram preparadas usando t\u00e9cnica de emuls\u00e3o com evapora\u00e7\u00e3o do \n\nsolvente, formando part\u00edculas de forma esf\u00e9rica com diferentes tamanhos (variando de           \n\n5 a 900 \u00b5m), morfologias de superf\u00edcie e efici\u00eancias de encapsula\u00e7\u00e3o acima de 93% \n\n(BALMAYOR et al., 2009). Zhang e colaboradores (2008) mostraram que o tamanho de \n\nmicroesferas de PLGA contendo bupivaca\u00edna foi controlado pela velocidade de agita\u00e7\u00e3o e \n\nconcentra\u00e7\u00e3o do pol\u00edmero usando o m\u00e9todo de emuls\u00e3o o/a com evapora\u00e7\u00e3o do solvente. \n\nEnquanto que Sun e colaboradores (2008) usando a mesma t\u00e9cnica obteve microesferas de \n\nPLGA contendo contraceptivos hormonais com controle da cin\u00e9tica de libera\u00e7\u00e3o durante        \n\n1 m\u00eas demonstrada em ensaios in vitro e in vivo. \n\n \n\n \n\n \n\n \n\n \n\nFigura 3 - M\u00e9todo de prepara\u00e7\u00e3o de micropart\u00edculas por emulsifica\u00e7\u00e3o (o/a) e evapora\u00e7\u00e3o do \n\nsolvente: (1) solubiliza\u00e7\u00e3o dos componentes na fase oleosa org\u00e2nica, (2) mistura da fase \n\norg\u00e2nica com a fase cont\u00ednua contendo emulsificante sob agita\u00e7\u00e3o (3) evapora\u00e7\u00e3o do solvente \n\n(4) separa\u00e7\u00e3o das micropart\u00edculas (adaptado de LI et al., 2008). \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n32\n\nOutros m\u00e9todos empregados na prepara\u00e7\u00e3o de micropart\u00edculas de PLA e PLGA \n\nincluem a forma\u00e7\u00e3o in situ, saltint-out (separa\u00e7\u00e3o de fases), t\u00e9cnicas de fus\u00e3o e m\u00e9todos \n\nusando fluidos supercr\u00edticos (normalmente o CO2) (WHITAKER et al., 2005). \n\nComercialmente encontram-se dispon\u00edveis f\u00e1rmacos encapsulados em micropart\u00edculas \n\npolim\u00e9ricas biodegrad\u00e1veis, com o uso destas t\u00e9cnicas, tais como, Vivitrol\u00ae (naltrexone via \n\no/a extra\u00e7\u00e3o do solvente), Consta\u00ae (risperidona via o/a extra\u00e7\u00e3o do solvente) e Arestin\u00ae \n\n(cloridrato de minociclina via s/o coacerva\u00e7\u00e3o) (WISCHKE; SCHWENDEMAN, 2008). \n\n \n\n2.3.2 M\u00e9todos de caracteriza\u00e7\u00e3o de micropart\u00edculas  \n\nCaracteriza\u00e7\u00f5es f\u00edsico-qu\u00edmicas e ensaios de cin\u00e9tica de libera\u00e7\u00e3o in vitro das \n\nmicropart\u00edculas polim\u00e9ricas contendo os princ\u00edpios ativos s\u00e3o fatores imprescind\u00edveis no \n\nestudo de otimiza\u00e7\u00e3o de formula\u00e7\u00f5es farmac\u00eauticas. Os par\u00e2metros f\u00edsico-qu\u00edmicos utilizados \n\npara a caracteriza\u00e7\u00e3o de micropart\u00edculas s\u00e3o aspectos microsc\u00f3picos, tamanho m\u00e9dio e \n\ndistribui\u00e7\u00e3o de tamanho de part\u00edcula, efici\u00eancia de encapsula\u00e7\u00e3o, carga de superf\u00edcie, \n\nporosidade e intera\u00e7\u00f5es entre os componentes da formula\u00e7\u00e3o (MAGENHEIM; BENITA, \n\n1991; SANTOS-MAGALH\u00c3ES et al., 2000; BALMAYOR et al., 2009). \n\nA an\u00e1lise microsc\u00f3pica de micropart\u00edculas pode ser realizada atrav\u00e9s de t\u00e9cnicas de \n\nmicroscopia \u00f3ptica, microscopia eletr\u00f4nica de varredura (MEV) e microscopia eletr\u00f4nica de \n\ntransmiss\u00e3o (MET) (SANTOS et al., 2006; SCHAFFAZICK et al., 2006). A aplica\u00e7\u00e3o destas \n\nt\u00e9cnicas permite avaliar a forma geom\u00e9trica, caracter\u00edsticas de superf\u00edcie (lisa ou porosa) e do \n\ninterior do dispositivo, distribui\u00e7\u00e3o de tamanho de part\u00edcula, a presen\u00e7a de agregados e \n\ncristais do f\u00e1rmaco, distribui\u00e7\u00e3o do f\u00e1rmaco na matriz polim\u00e9rica, al\u00e9m de diferenciar o tipo \n\nde micropart\u00edcula obtida (microesfera ou microc\u00e1psula) (MOSQUEIRA et al., 2000; WANG \n\net al., 2009). Micropart\u00edculas de PLGA contendo ovoalbumina foram caracterizadas quanto as \n\nsuas propriedades de superf\u00edcie e de distribui\u00e7\u00e3o de tamanho de part\u00edcula por MEV, e quanto \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n33\n\nas suas propriedades internas de distribui\u00e7\u00e3o de prote\u00edna e a ocorr\u00eancia de poros por MET \n\n(ZHAO; RODGERS et al., 2006). A morfologia interna e externa de micropart\u00edculas porosas \n\nde PLGA contendo oligonucleot\u00eddeo foi caracterizada usando MEV (AHMED; BODMEIER, \n\n2009). \n\nO tamanho m\u00e9dio e a distribui\u00e7\u00e3o de tamanho de part\u00edcula podem ser determinados \n\npor diferentes t\u00e9cnicas, tais como, microscopia, m\u00e9todos cromatogr\u00e1ficos, princ\u00edpio Coulter, \n\ndifra\u00e7\u00e3o a laser, espalhamento de luz din\u00e2mica (espectroscopia de correla\u00e7\u00e3o de f\u00f3ton) e \n\ntamisa\u00e7\u00e3o (WISCHKE; SCHWENDEMAN, 2008). A distribui\u00e7\u00e3o de tamanho de part\u00edcula \u00e9 \n\num importante par\u00e2metro que deve ser avaliado durante o desenvolvimento de formula\u00e7\u00f5es \n\nfarmac\u00eauticas, visto que avalia o grau de uniformidade de uma amostra. Nesse contexto, o \n\n\u00edndice span \u00e9 um par\u00e2metro que v\u00eam sendo bastante utilizado na literatura para mensurar a \n\nhomogeneidade de micropart\u00edculas (RIBEIRO-COSTA et al., 2008; MUTHU et al., 2009; \n\nITO et al., 2009). O c\u00e1lculo do span \u00e9 feito com os valores de tamanho de part\u00edcula (neste \n\ncaso representado pelo di\u00e2metro volum\u00e9trico m\u00e9dio, dv), correspondentes aos percentis de \n\n90%, 10% e 50% da distribui\u00e7\u00e3o de tamanho de part\u00edcula da seguinte maneira:                  \n\nspan = (dv (90%) \u2013 dv (10%)) / dv (50%) (RIBEIRO-COSTA et al., 2008). Valores pequenos de span \n\nsugerem amostras mais homog\u00eaneas, ou seja, apresentam gr\u00e1ficos de distribui\u00e7\u00e3o de tamanho \n\nde part\u00edcula com aspecto unimodal (monomodal). Microesferas polim\u00e9ricas com valores span \n\nde 1,1 a 3,3 obtidas por Ribeiro-Costa e colaboradores (2008) apresentaram distribui\u00e7\u00e3o de \n\ntamanho de part\u00edcula monomodal. Nesse contexto, Ito e colaboradores (2009) tamb\u00e9m \n\nobtiveram microesferas de PLGA contendo dextrana (BLD) (usada como um f\u00e1rmaco \n\nmodelo) monodispersas com valores de span de 0,37 a 1,90.  \n\nA efici\u00eancia de encapsula\u00e7\u00e3o em micropart\u00edculas, a raz\u00e3o entre a quantidade de \n\nf\u00e1rmaco encapsulado e a quantidade te\u00f3rica inicialmente adicionada, pode ser determinada \n\npela dissolu\u00e7\u00e3o do sistema polim\u00e9rico em um solvente apropriado, no qual o f\u00e1rmaco \u00e9 \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n34\n\nquantificado por t\u00e9cnicas espectrofotom\u00e9tricas (UV-Vis) ou cromatogr\u00e1ficas (CLAE) \n\n(RIBEIRO-COSTA et al., 2004; MORAIS et al., 2008; COCERO et al., 2009).  Solventes, \n\ntais como diclorometano, acetonitrila, acetona, tetrahidrofurano, dimetilsulf\u00f3xido ou          \n\n1,4-dioxano s\u00e3o comumente utilizados, dissolvendo a matriz polim\u00e9rica e o f\u00e1rmaco \n\nhidrof\u00f3bico (SAH; LEE, 2006), ou solventes como etanol e metanol que podem extrair \n\nseletivamente o f\u00e1rmaco independente da dissolu\u00e7\u00e3o do pol\u00edmero (WISCHKE; \n\nSCHWENDEMAN, 2008). \n\nO potencial zeta \u00e9 um par\u00e2metro que est\u00e1 relacionado \u00e0 carga de superf\u00edcie de \n\npart\u00edculas em suspens\u00e3o. O seu valor costuma ser bastante utilizado em estudos de \n\nestabilidade de produtos e processos de adsor\u00e7\u00e3o de superf\u00edcie. O potencial zeta corresponde \n\nao potencial el\u00e9trico entre o ambiente aquoso e uma regi\u00e3o difusa de carga \n\npredominantemente oposta \u00e0 superf\u00edcie da part\u00edcula. Este par\u00e2metro \u00e9 influenciado por \n\ncaracter\u00edsticas das part\u00edculas em suspens\u00e3o (como composi\u00e7\u00e3o qu\u00edmica e tamanho de \n\npart\u00edcula) e do meio dispersante (como pH, for\u00e7a i\u00f4nica e os tipos de \u00edons)                  \n\n(XU; CZERNUSZKA, 2008). Sua determina\u00e7\u00e3o \u00e9 realizada atrav\u00e9s de t\u00e9cnicas de \n\neletroforese. O potencial zeta pode ser utilizado para avaliar se o f\u00e1rmaco encontra-se no \n\ninterior da matriz ou adsorvido \u00e0 superf\u00edcie do sistema polim\u00e9rico (MAGENHEIM; BENITA, \n\n1991; CALVO et al., 1997; WISCHKE; SCHWENDEMAN, 2008). \n\nT\u00e9cnicas como difra\u00e7\u00e3o de raios-X (XRD), calorimetria explorat\u00f3ria diferencial \n\n(DSC), an\u00e1lise termogravim\u00e9trica (TGA), resson\u00e2ncia magn\u00e9tica nuclear (RMN), \n\nespectroscopia na regi\u00e3o do infravermelho (IR) e cromatografia de permea\u00e7\u00e3o em gel (GPC) \n\npodem evidenciar a presen\u00e7a e a distribui\u00e7\u00e3o do f\u00e1rmaco e aditivos na matriz polim\u00e9rica, bem \n\ncomo a intera\u00e7\u00e3o entre os componentes da formula\u00e7\u00e3o (FAISANT et al., 2002; COCERO et \n\nal., 2009; WANG et al., 2009). Nesse contexto, Fern\u00e1ndez-Carballido e colaboradores (2008) \n\nconfirmaram a presen\u00e7a de PEG em microesferas de PLGA pela sua caracteriza\u00e7\u00e3o atrav\u00e9s \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n35\n\ndas t\u00e9cnicas de DSC, GPC, IR e RMN. Mundargi e colaboradores (2007) avaliaram a \n\nestabilidade e o estado f\u00edsico da doxiciclina em blend de PLGA com PCL atrav\u00e9s de DSC e \n\nIR.  Enquanto que Silva-J\u00fanior e colaboradores (2009) usaram as t\u00e9cnicas de DSC, IR e \n\ndifra\u00e7\u00e3o de raios X para estudar a estabilidade f\u00edsico-qu\u00edmica, o estado f\u00edsico do f\u00e1rmaco na \n\nmatriz polim\u00e9rica e as intera\u00e7\u00f5es f\u00e1rmaco-pol\u00edmero em micropart\u00edculas de PLGA contendo \n\ntriamcinolona. \n\nA porosidade de micropart\u00edculas pode ser avaliada atrav\u00e9s de diferentes par\u00e2metros, \n\ntais como, densidade, tamanho de part\u00edcula, \u00e1rea espec\u00edfica, tamanho e volume de poros. \n\nV\u00e1rias t\u00e9cnicas foram desenvolvidas para a determina\u00e7\u00e3o quantitativa desses par\u00e2metros as \n\nquais normalmente se baseiam na determina\u00e7\u00e3o da quantidade adsorvida (e/ou dessorvida) de \n\num adsorvato (normalmente um g\u00e1s) na superf\u00edcie de um adsorvente em um sistema fechado \u00e0 \n\ntemperatura constante. A quantidade de g\u00e1s adsorvida pode ser calculada pela diminui\u00e7\u00e3o da \n\npress\u00e3o por meio da aplica\u00e7\u00e3o das leis dos gases ou pela massa de g\u00e1s adsorvida pelo s\u00f3lido \n\n(TEIXEIRA et al., 2001). A equa\u00e7\u00e3o de Brunauer-Emmette-Teller (BET) relaciona valores \n\nobtidos a partir das isotermas de adsor\u00e7\u00e3o com a \u00e1rea espec\u00edfica de um s\u00f3lido (BRUNAUER \n\net al., 1938). A distribui\u00e7\u00e3o de tamanhos ou de volumes de poro em fun\u00e7\u00e3o do di\u00e2metro de \n\nporo pode ser calculada a partir da press\u00e3o relativa na qual os poros s\u00e3o preenchidos com um \n\nl\u00edquido proveniente da condensa\u00e7\u00e3o de um g\u00e1s. O processo inverso, ou seja, a evapora\u00e7\u00e3o do \n\nl\u00edquido contido no poro, tamb\u00e9m pode ser utilizado. O m\u00e9todo de Barret, Joyner e Halenda \n\n(BJH) \u00e9 utilizado at\u00e9 hoje no c\u00e1lculo da distribui\u00e7\u00e3o dos tamanhos de poro, o qual utiliza a \n\nequa\u00e7\u00e3o de Kelvin e assume o esvaziamento progressivo dos poros cheios de l\u00edquido com o \n\ndecr\u00e9scimo da press\u00e3o (BARRET et al, 1951). Microesferas porosas com superf\u00edcie rugosa \n\nnormalmente apresentem elevada \u00e1rea de superf\u00edcie espec\u00edfica e velocidade de libera\u00e7\u00e3o \n\nrelativamente mais r\u00e1pida, conforme resultados obtidos com microesferas de PLGA contrendo \n\no pept\u00eddeo acetato de leuprolide (RAVIVARAPU et al., 2000). A porosidade de \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n36\n\nnanopart\u00edculas de PLA-PEG contendo propafenona foi avaliada usando os par\u00e2metros de \u00e1rea \n\nde superf\u00edcie espec\u00edfica e distribui\u00e7\u00e3o de tamanho de poros (SANT et al., 2005). \n\nNos ensaios de cin\u00e9tica de libera\u00e7\u00e3o in vitro, diferentes m\u00e9todos s\u00e3o empregados para \n\na avalia\u00e7\u00e3o do perfil de libera\u00e7\u00e3o do f\u00e1rmaco simulando condi\u00e7\u00f5es fisiol\u00f3gicas (tamp\u00e3o \n\nfosfato pH 7,4 a 37\u00baC). O m\u00e9todo de dissolu\u00e7\u00e3o costuma ser o utilizado para a cin\u00e9tica de \n\nlibera\u00e7\u00e3o em micropart\u00edculas (WISCHKE; SCHWENDEMAN, 2008; WANG et al., 2009). O \n\ndispositivo \u00e9 submetido a condi\u00e7\u00f5es controladas de agita\u00e7\u00e3o, pH e temperatura, e al\u00edquotas do \n\nmeio s\u00e3o retiradas em intervalos de tempos pr\u00e9-estabelecidos (com reposi\u00e7\u00e3o do meio), sendo \n\nfiltradas ou centrifugadas para a quantifica\u00e7\u00e3o do f\u00e1rmaco liberado no sobrenadante em \n\nfun\u00e7\u00e3o do tempo. Diferentemente das formas farmac\u00eauticas convencionais, os sistemas de \n\nlibera\u00e7\u00e3o controlada n\u00e3o apresentam m\u00e9todos oficiais estabelecidos nas farmacop\u00e9ias. No \n\nentanto, fundamentos de estudos de libera\u00e7\u00e3o devem ser respeitados, como a manuten\u00e7\u00e3o das \n\ncondi\u00e7\u00f5es sink (WISCHKE; SCHWENDEMAN, 2008). \n\n \n\n2.4 Cin\u00e9tica de libera\u00e7\u00e3o \n\nO perfil de libera\u00e7\u00e3o de micropart\u00edculas polim\u00e9ricas pode ser modificado por \n\npropriedades f\u00edsico-qu\u00edmicas dos f\u00e1rmacos e pol\u00edmeros utilizados (peso molecular, \n\ncristalinidade, composi\u00e7\u00e3o do copol\u00edmero, hidrofobicidade) (BRANNON-PEPPAS, 1995; \n\nHANS; LOWMAN, 2002; ZOLNIK; BURGESS, 2007; GARBAYO et al., 2008), bem como \n\ndos sistemas desenvolvidos (geometria, tamanho, porosidade, \u00e1rea superficial, efici\u00eancia de \n\nencapsula\u00e7\u00e3o, intera\u00e7\u00e3o f\u00e1rmaco-pol\u00edmero, distribui\u00e7\u00e3o do f\u00e1rmaco na matriz polim\u00e9rica) \n\n(DEADMAN et al., 2007; POLETTO et al., 2007). \n\nO controle da cin\u00e9tica de libera\u00e7\u00e3o de f\u00e1rmacos encapsulados em sistemas polim\u00e9ricos \n\nenvolve diferentes fatores como solubilidade e difus\u00e3o do f\u00e1rmaco no dispositivo, eros\u00e3o do \n\npol\u00edmero, dissolu\u00e7\u00e3o do f\u00e1rmaco no meio circundante ou ainda uma combina\u00e7\u00e3o destes \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n37\n\nprocessos (ZOLNIK; BURGESS, 2007; SINGH; LILLARD, 2009). A libera\u00e7\u00e3o do f\u00e1rmaco \n\npode ser predominantemente controlada por um desses mecanismos. Quando isto acontece o \n\nprincipal processo \u00e9 aquele respons\u00e1vel pela etapa mais r\u00e1pida da cin\u00e9tica de libera\u00e7\u00e3o, \n\npodendo variar de dispositivo para dispositivo (PETITTI et al., 2008).  Por exemplo, no caso \n\ndas microesferas, nas quais o f\u00e1rmaco est\u00e1 distribu\u00eddo na matriz polim\u00e9rica, a libera\u00e7\u00e3o do \n\nf\u00e1rmaco ocorre por difus\u00e3o e/ou eros\u00e3o. Se a difus\u00e3o \u00e9 mais r\u00e1pida quando comparada \u00e0 \n\neros\u00e3o da matriz, o mecanismo de libera\u00e7\u00e3o \u00e9 controlado principalmente pelo processo de \n\ndifus\u00e3o (SINGH; LILLARD, 2009). Microesferas formadas por PLGA de baixo peso \n\nmolecular (em torno de 5 kDa) apresentam uma libera\u00e7\u00e3o frequentemente controlada apenas \n\npelo mecanismo de difus\u00e3o, enquanto que quando o PLGA \u00e9 de elevado peso molecular (em \n\ntorno de 25 kDa) a libera\u00e7\u00e3o \u00e9 controlada pela combina\u00e7\u00e3o da difus\u00e3o do f\u00e1rmaco e eros\u00e3o do \n\npol\u00edmero (ZOLNIK; BURGESS, 2007).  \n\nO processo de eros\u00e3o do PLGA \u00e9 iniciado com a entrada de \u00e1gua no dispositivo, \n\ncausando a hidr\u00f3lise das liga\u00e7\u00f5es \u00e9ster de sua estrutura qu\u00edmica, produzindo olig\u00f4meros \n\n\u00e1cidos (SIEPMANN et al., 2005). A concentra\u00e7\u00e3o destes olig\u00f4meros no bulk do dispositivo \n\ncriam um microambiente acidificado, cujo pH pode variar de 1,5 a 6,4, fato este que favorece \n\no fen\u00f4meno de autocat\u00e1lise do PLGA. A difus\u00e3o dos subprodutos de degrada\u00e7\u00e3o \u00e1cidos no \n\nfluido bulk e das bases presentes nas proximidades do sistema de libera\u00e7\u00e3o ocorrem \n\nsimultaneamente com a difus\u00e3o do f\u00e1rmaco e a degrada\u00e7\u00e3o do pol\u00edmero. Assim, o \n\nmicroambiente do transporte do f\u00e1rmaco pode mudar significativamente durante a libera\u00e7\u00e3o \n\ndo f\u00e1rmaco. A autocat\u00e1lise exerce uma importante fun\u00e7\u00e3o na libera\u00e7\u00e3o do f\u00e1rmaco, uma vez \n\nque a degrada\u00e7\u00e3o da matriz resulta na forma\u00e7\u00e3o de canais atrav\u00e9s dos quais o f\u00e1rmaco \u00e9 \n\nliberado.  \n\nNeste contexto, a natureza do f\u00e1rmaco encapsulado (hidrof\u00edlico, hidrof\u00f3bico, \u00e1cido ou \n\nb\u00e1sico) pode afetar a cin\u00e9tica de degrada\u00e7\u00e3o do sistema e de libera\u00e7\u00e3o do princ\u00edpio ativo. Para \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n38\n\nf\u00e1rmacos sol\u00faveis em \u00e1gua, a penetra\u00e7\u00e3o da \u00e1gua na matrix polim\u00e9rica pode ser facilitada, \n\nacelerando a degrada\u00e7\u00e3o da matriz e criando uma estrutura relativamente mais porosa atrav\u00e9s \n\nda qual o f\u00e1rmaco \u00e9 mais facilmente difundido. Enquanto que para f\u00e1rmacos hidrof\u00f3bicos, \n\nesse processo de difus\u00e3o da \u00e1gua pode ser retardado, diminuindo o processo de degrada\u00e7\u00e3o do \n\npol\u00edmero (KLOSE et al., 2008). No caso de f\u00e1rmacos \u00e1cidos e b\u00e1sicos, a degrada\u00e7\u00e3o do \n\nPLGA pode ser acelerada uma vez que sua hidr\u00f3lise \u00e9 catalizada por \u00e1cidos e bases. \n\nO perfil de libera\u00e7\u00e3o t\u00edpico de f\u00e1rmacos hidrof\u00f3bicos consiste de uma etapa burst \n\ninicial seguida de uma fase lag e de uma segunda etapa burst (BERKLAND et al., 2002, \n\n2004; WANG et al., 2002; ZOLNIK et al., 2006). A primeira etapa burst resulta da libera\u00e7\u00e3o \n\nr\u00e1pida do f\u00e1rmaco associado \u00e0 superf\u00edcie. Por outro lado, a fase lag, do tempo requerido para \n\nque a degrada\u00e7\u00e3o do pol\u00edmero facilite a difus\u00e3o do f\u00e1rmaco. Enquanto que para f\u00e1rmacos \n\nhidrof\u00edlicos, a fase burst inicial n\u00e3o \u00e9 frequentemente observada uma vez que o f\u00e1rmaco \n\nassociado \u00e0 superf\u00edcie \u00e9 usualmente removido durante o processo, dependendo da \n\nhidrofilicidade e do peso molecular do f\u00e1rmaco (VOISINE et al., 2008). \n\nUma estrat\u00e9gia bastante utilizada para modificar o perfil de libera\u00e7\u00e3o de diferentes \n\nf\u00e1rmacos encapsulados em micropart\u00edculas \u00e9 a combina\u00e7\u00e3o de pol\u00edmeros com diferentes \n\ncaracter\u00edsticas formando blends. Micropart\u00edculas de PCL com poli (hidroxibutirato-co-\n\nhidroxivalerato) (PHBHV) foram preparadas para avaliar a influ\u00eancia no perfil de libera\u00e7\u00e3o \n\ndo diclofenaco e indometacina, e determinar o mecanismo de libera\u00e7\u00e3o dos f\u00e1rmacos \n\n(POLETTO et al., 2007). Micropart\u00edculas de PCL foram misturadas com uma solu\u00e7\u00e3o de \n\nPLGA contendo tetraglicol (10%) para prevenir a migra\u00e7\u00e3o das part\u00edculas e reter o volume da \n\nprepara\u00e7\u00e3o no local de aplica\u00e7\u00e3o (OH et al., 2006). Microesferas de PLGA foram combinadas \n\ncom gelatina e poli(propileno fumarato) (PPF) para melhorar as propriedades mec\u00e2nicas e \n\nprolongar a libera\u00e7\u00e3o da prote\u00edna morfogen\u00e9tica \u00f3ssea BMP-2 (KEMPEN et al., 2008). \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n39\n\nOutra forma de modificar a cin\u00e9tica de libera\u00e7\u00e3o \u00e9 pela adi\u00e7\u00e3o de excipientes \n\nhidrof\u00f3bicos ou hidrof\u00edlicos. Dentre os excipientes utilizados em micropart\u00edculas est\u00e3o o \n\npolietilenoglicol (PEG), usado normalmente para controlar a libera\u00e7\u00e3o inicial, todavia n\u00e3o \n\nest\u00e1 elucidado se o mesmo permanece dentro da matriz polim\u00e9rica durante muito tempo. O \n\nmecanismo do PEG no controle da libera\u00e7\u00e3o do f\u00e1rmaco em micropart\u00edculas n\u00e3o est\u00e1 \n\ntotalmente claro, uma vez que pode diminuir ou aumentar a taxa de libera\u00e7\u00e3o no caso \n\nmicroesferas de PLGA (FERN\u00c1NDEZ-CARBALLIDO et al., 2008). Ciclodextrinas tamb\u00e9m \n\nv\u00eam sendo usadas como excipientes farmac\u00eauticos em sistemas como emuls\u00f5es, \n\nmicroc\u00e1psulas, microesferas, nanoesferas, nanoc\u00e1psulas, lipossomas e niossomas para \n\nmodificar a sua cin\u00e9tica de libera\u00e7\u00e3o (TRICHARD et al., 2006; LOFTSSON; DUCH\u00caNE      \n\net al., 2007). \n\n \n\n2.5 An\u00e1lise Fatorial \n\nAs caracter\u00edsticas f\u00edsico-qu\u00edmicas e de libera\u00e7\u00e3o dos sistemas polim\u00e9ricos dependem, \n\npor exemplo, dos par\u00e2metros envolvidos no seu m\u00e9todo de prepara\u00e7\u00e3o. Dessa forma, para \n\ncontrolar estas caracter\u00edsticas, \u00e9 essencial estabelecer o efeito de suas vari\u00e1veis de formula\u00e7\u00e3o \n\ne de cada etapa do seu processamento (BUDHIAN et al., 2007). Nesse contexto, a an\u00e1lise \n\nfatorial representa uma ferramenta estat\u00edstica eficiente para se obter um modelo matem\u00e1tico \n\nmultifatorial adequado para o estudo dos efeitos de par\u00e2metros de formula\u00e7\u00e3o. Dessa forma, a \n\nan\u00e1lise fatorial \u00e9 bastante \u00fatil no estudo de otimiza\u00e7\u00e3o de sistemas de libera\u00e7\u00e3o de f\u00e1rmacos \n\n(DILLEN et al., 2004). \n\nDiferentemente dos experimentos tradicionais, em que a influ\u00eancia de cada par\u00e2metro \n\n\u00e9 avaliada de maneira isolada, na an\u00e1lise fatorial \u00e9 poss\u00edvel alterar diferentes vari\u00e1veis \n\nsimultaneamente, e ainda quantificar os efeitos causados pelas vari\u00e1veis independentes e a \n\nintera\u00e7\u00e3o entre elas em vari\u00e1veis respostas (como na efici\u00eancia de encapsula\u00e7\u00e3o, no tamanho \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n40\n\nde part\u00edcula, no potencial zeta, dentre outros). Al\u00e9m disso, a an\u00e1lise fatorial permite obter uma \n\nmaior quantidade de informa\u00e7\u00f5es com um menor n\u00famero de experimentos (GOHEL; AMIN, \n\n1998; DILLEN et al. 2004; DAVIES et al., 2009). Neste estudo, o n\u00famero de vari\u00e1veis \n\nindependentes e de n\u00edveis (padronizados como +1 e -1) da an\u00e1lise fatorial define o n\u00famero de \n\nexperimentos a serem realizados. Por exemplo, uma an\u00e1lise fatorial 24 significa que quatro \n\ndiferentes fatores (como concentra\u00e7\u00e3o de pol\u00edmero, f\u00e1rmaco, tensoativo da fase aquosa e \n\ntensoativo da fase oleosa) ser\u00e3o variados em dois n\u00edveis (como na concentra\u00e7\u00e3o de pol\u00edmero, \n\n20 e 50%), e a sua influ\u00eancia ser\u00e1 avaliada em um ou mais par\u00e2metros resposta (DILLEN et \n\nal. 2004; BOZQUIR; SAKA, 2005). \n\nDavies e colaboradores (2009) usaram an\u00e1lise fatorial para avaliar a influ\u00eancia da \n\nconcentra\u00e7\u00e3o de reagentes na prepara\u00e7\u00e3o de nanopart\u00edculas de s\u00edlica. Enquanto que \n\nDerakhshandeh e colaboradores (2007) avaliaram como quatro vari\u00e1veis modificam a \n\nencapsula\u00e7\u00e3o da nitrocamptotecina em nanopart\u00edculas de PLGA usando a mesma ferramenta \n\nestat\u00edstica. E, Lee e colaboradores (2009) otimizaram as condi\u00e7\u00f5es de prepara\u00e7\u00e3o de \n\nmicropart\u00edculas de pectinato de c\u00e1lcio com lipossomas e hidroxipropilmetilcelulose contendo \n\ncatequina usando an\u00e1lise fatorial. \n\n \n\n2.6 Ciclodextrinas \n\nA fermenta\u00e7\u00e3o enzim\u00e1tica de alguns carboidratos, como celulose, amido e sacarose, \n\nproduz uma mistura de monossacar\u00eddeos, dissacar\u00eddeos e oligossacar\u00eddeos, resultando em \n\ndextrinas lineares e c\u00edclicas, estas \u00fatimas tamb\u00e9m sendo conhecidas como ciclodextrinas \n\n(LOFTSSON; DUCH\u00caNE, 2007). As ciclodextrinas (CDs) s\u00e3o oligossacar\u00eddeos c\u00edclicos com \n\numa estrutura r\u00edgida formados por unidades de glicopiranose unidas por liga\u00e7\u00f5es ? (1?4). \n\nApresentam-se na forma de um cone truncado, onde os grupos OH secund\u00e1rios ligados aos \n\ncarbonos C-2 e C-3 ocupam a base de maior di\u00e2metro do tronco, as hidroxilas prim\u00e1rias \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n41\n\nligadas ao carbono C-6 localizam-se na base menor do tronco (Fig. 4) (CHALLA et al., \n\n2005).  \n\nA disposi\u00e7\u00e3o espacial dos grupamentos qu\u00edmicos nas ciclodextrinas favorece a \n\nforma\u00e7\u00e3o de uma cavidade central hidrof\u00f3bica e uma superf\u00edcie externa hidrof\u00edlica, \n\npermitindo desta forma, o processo de complexa\u00e7\u00e3o molecular. Geralmente subst\u00e2ncias \n\nqu\u00edmicas de baixa polaridade podem alojar-se no interior da cavidade das CDs formando \n\ncomplexos de inclus\u00e3o din\u00e2micos em solu\u00e7\u00e3o (BREWSTER; LOFTSSON, 2007). \n\n \n\nFigura 4 - Estrutura qu\u00edmica de uma ciclodextrina (A) e desenho esquem\u00e1tico ilustrando a \n\ncavidade hidrof\u00f3bica, a posi\u00e7\u00e3o das hidroxilas prim\u00e1rias e secund\u00e1rias e suas dimens\u00f5es: \n\naltura (H), di\u00e2metro interno (DI) e di\u00e2metro externo (DE) (adaptado de BREWSTER; \n\nLOFTSSON, 2007).  \n\n \n\nAs ciclodextrinas podem ser classificadas de acordo com o n\u00famero de res\u00edduos de \n\nglicopiranose. As ciclodextrinas naturais ?CDs, ?CDs, e  ?CDs, respectivamente (Fig. 5) \n\ncont\u00eam seis, sete e oito unidades glicos\u00eddicas (BREWSTER; LOFTSSON, 2007) e \n\napresentem diferentes propriedades de tamanho de cavidade, solubilidade, reatividade, \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n42\n\ncapacidade de complexa\u00e7\u00e3o e efeito na estabilidade qu\u00edmica das mol\u00e9culas h\u00f3spedes (Tab. 2) \n\n(CONNORS, 1997).  \n\n \n\nFigura 5 - Estruturas moleculares das ciclodextrinas naturais (adaptado de SONG et al., \n\n2009). \n\n \n\nDentre as ciclodextrinas naturais, a ?CD \u00e9 a mais utilizada por ser menos onerosa e \n\nafinidade com muitas mol\u00e9culas hidrof\u00f3bicas. No entanto, a sua menor solubilidade em \u00e1gua, \n\ncomparada \u00e0s demais ciclodextrinas naturais, limita o seu uso (Tab. 2). Esse fato se deve a \n\nliga\u00e7\u00e3o relativamente forte de suas mol\u00e9culas em estado s\u00f3lido (alta energia do cristal) \n\nassociada \u00e0 diminui\u00e7\u00e3o da habilidade de forma\u00e7\u00e3o de liga\u00e7\u00f5es de hidrog\u00eanio com a \u00e1gua (por \n\nformar liga\u00e7\u00f5es de hidrog\u00eanio intramoleculares) (LOFTSSON; DUCH\u00caNE, 2007). Complexo \n\nde inclus\u00e3o de DCTN com ?-ciclodextrina j\u00e1 foi desenvolvido e reduziu a sua citotoxicidade \n\nem hepat\u00f3citos de ratos e fibrobastos V79 (CORR\u00caA et al., 2005). \n\nA ciclodextrina glicosil transferase (CGTase), um exemplo de amilase, \u00e9 capaz de \n\nabrir a cadeia de um polissacar\u00eddeo e ligar as extremidades de cada fragmento formando \n\nciclodextrinas. O tratamento do amido com amilase do Bacillus macerans (com CGTase) \n\nproduz uma mistura de ?-ciclodextrina (60%), ?-ciclodextrina (20%) and ?-ciclodextrina \n\n(20%) juntamente com pequenas quantidades de ciclodextrinas com mais de oito res\u00edduos de \n\nglicose. Inova\u00e7\u00f5es biotecnol\u00f3gicas com diferentes tipos de enzimas CGTase tornaram \n\nposs\u00edvel a produ\u00e7\u00e3o mais espec\u00edfica e com maior grau de pureza das ?-,  ?- e                  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n43\n\n?-ciclodextrinas, permitindo o uso destas como excipientes farmac\u00eauticos (LOFTSSON; \n\nDUCH\u00caNE, 2007).  \n\n \n\nTabela 2 - Propriedades f\u00edsico-qu\u00edmicas das ciclodextrinas (CONNORS, 1997). \n\n Ciclodextrina  Propriedade \n\n? ? ? \n\nn? de unidades de glicose 6 7 8 \n\nF\u00f3rmula emp\u00edrica C36H60O30 C42H70O35 C48H80O40 \n\nPeso molecular 972,85 1134,99 1297,14 \n\nAltura da cavidade (?) 8 8 8 \n\nDi\u00e2metro da cavidade (?-aprox) ~ 5,2 ~ 6,6 ~ 8,4 \n\nSolubilidade (\u00e1gua, 25?C) mol L-1 0,1211 0,0163 0,168 \n\n \n\nV\u00e1rios derivados semi-sint\u00e9ticos de ciclodextrinas t\u00eam sido produzidos objetivando a \n\notimiza\u00e7\u00e3o da solubilidade e estabilidade de ciclodextrinas ancestrais. Evidenciou-se que a \n\nsubstitui\u00e7\u00e3o de qualquer um dos grupos hidroxilas por grupamentos hidrof\u00f3bicos resulta em \n\num aumento significativo da solubilidade aquosa. Outros tipos de modifica\u00e7\u00f5es estruturias \n\ncomo amina\u00e7\u00e3o, esterifica\u00e7\u00e3o das hidroxilas prim\u00e1rias e secund\u00e1rias podem ainda ser \n\nrealizadas (DAVIS; BREWSTER, 2004; MARTIN DEL VALLE, 2004; CALABR\u00d2 et al., \n\n2004; LOFTSSON; DUCH\u00caNE, 2007).  \n\nA 2-hidroxipropil-?-ciclodextrina (HP?CD) \u00e9 um derivado obtido pelo tratamento de \n\numa solu\u00e7\u00e3o de ?CD com propileno\u00f3xido, resultando em uma mistura de is\u00f4meros devido \u00e0 \n\nsubstitui\u00e7\u00e3o rand\u00f4mica dos grupamentos hidrox\u00edlicos. Estatisticamente h\u00e1 aproximadamente \n\n130.000 possibilidades de forma\u00e7\u00e3o de derivados de HP?CD, dentre eles, in\u00fameros is\u00f4meros \n\ngeom\u00e9tricos e \u00f3pticos podem ser produzidos quando os grupamentos hidrox\u00edlicos s\u00e3o \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n44\n\ninseridos em centros \u00f3pticos das mol\u00e9culas. Derivados menos polares (metoxilados, aminados \n\nou esterificados), completamente substitu\u00eddos apresentam uma menor solubilidade aquosa, \n\npela dr\u00e1stica redu\u00e7\u00e3o de possibilidade de forma\u00e7\u00e3o de isomeriza\u00e7\u00e3o. A habilidade dos \n\nderivados de ciclodextrina em formar complexos sol\u00faveis em \u00e1gua tamb\u00e9m \u00e9 dependente do \n\ngrau de substitui\u00e7\u00e3o da ciclodextrina que pode ser otimizado objetivando-se preservar as \n\npropriedades de solubiliza\u00e7\u00e3o. O grau de substitui\u00e7\u00e3o da HP?CD de uso farmac\u00eautico \u00e9 de \n\naproximadamente 0,65 (que significa que h\u00e1 em m\u00e9dia 0,65 de grupamentos hidroxipropil por \n\nunidade de glicose) (LOFTSSON; DUCH\u00caNE, 2007).  \n\nComparativamente, comprovou-se que a HP?CD apresenta maior solubilidade aquosa, \n\nmaior potencial de complexa\u00e7\u00e3o e menores restri\u00e7\u00f5es toxicol\u00f3gicas e biol\u00f3gicas em rela\u00e7\u00e3o \u00e0  \n\n?CD (GOULD; SCOTT, 2005; BREWSTER; LOFTSSON, 2007). Especificamente, a \n\nHP?CD \u00e9 bem tolerada no organismo humano, sendo metabolizada por bact\u00e9rias do c\u00f3lon, \n\nonde uma parte excretada na forma intacta (aproximadamente 60%) e outra parte como \n\nmetab\u00f3litos (aproximadamente 40%) ap\u00f3s a administra\u00e7\u00e3o oral (DAVIS; BREWSTER, \n\n2004). Estudos farmacocin\u00e9ticos em ratos demonstraram que HP?CD apresenta t1/2 de 20 min \n\n(i.v.), DL50 de 10 g/Kg (i.v.) e DL50 maior que 2 g/Kg (v.o.), e ainda, as doses m\u00e1ximas em \n\nprodutos do mercado s\u00e3o de 16.000 mg/dia (i.v.) e de 8.000 mg/dia (v.o.) (BREWSTER; \n\nLOFTSSON, 2007). \n\n \n\n2.6.1 Complexos de inclus\u00e3o de f\u00e1rmacos com ciclodextrinas \n\nAs ciclodextrinas s\u00e3o alvo de interesse farmac\u00eautico constante pela habilidade de \n\ninteragirem com f\u00e1rmacos hidrof\u00f3bicos melhorando a sua solubilidade aquosa. Os \n\nmecanismos envolvidos podem estar relacionados \u00e0 forma\u00e7\u00e3o de complexos de inclus\u00e3o, de \n\ncomplexos de n\u00e3o-inclus\u00e3o, de agregados e de solu\u00e7\u00f5es de f\u00e1rmacos supersaturadas est\u00e1veis \n\n(BREWSTER; LOFTSSON, 2007). Podem ser formados complexos de inclus\u00e3o m\u00faltiplos e \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n45\n\nde n\u00e3o-inclus\u00e3o de diferentes raz\u00f5es molares f\u00e1rmaco:ciclodextrina (1:1, 1:2, 1:3, 2:1) \n\n(LOFTSSON et al., 2005; BREWSTER; LOFTSSON, 2007). Diferentes m\u00e9todos s\u00e3o usados \n\nna literatura para a obten\u00e7\u00e3o de complexos de inclus\u00e3o tais como, pasta, co-evapora\u00e7\u00e3o, co-\n\nprecipita\u00e7\u00e3o, spray-dry e freeze-dry (ZINGONE; RUBESSA, 2005; DEVARAKONDA et al., \n\n2005).  \n\nNa forma\u00e7\u00e3o de um complexo de inclus\u00e3o 1:1 (mol/mol) (Fig. 6), \u00e9 necess\u00e1rio que a \n\nmol\u00e9cula h\u00f3spede (G) ou parte dela, associe-se em um equil\u00edbrio din\u00e2mico com a cavidade da \n\nciclodextrina e estabele\u00e7a liga\u00e7\u00f5es de car\u00e1ter n\u00e3o-covalente, como for\u00e7as de van der Waals, \n\nintera\u00e7\u00f5es hidrof\u00f3bicas e liga\u00e7\u00f5es de hidrog\u00eanio. Devido \u00e0 natureza destas liga\u00e7\u00f5es, o \n\ncomplexo de inclus\u00e3o f\u00e1rmaco:ciclodextrina (G:CD) est\u00e1 continuamente sendo formado e \n\ndissociado (MARTIN DEL VALLE, 2004; LOFTSSON et al., 2005). A habilidade de uma \n\nciclodextrina em formar um complexo de inclus\u00e3o com uma mol\u00e9cula h\u00f3spede depende tanto \n\nde fatores est\u00e9ricos (relacionados ao tamanho molecular), como termodin\u00e2micos \n\n(relacionados a intera\u00e7\u00f5es ciclodextrina-mol\u00e9cula h\u00f3spede-solvente) (MARTIN DEL VALLE \n\net al., 2004). \n\nMuitas propriedades do f\u00e1rmaco (f\u00edsico-qu\u00edmicas, biol\u00f3gicas e toxicol\u00f3gicas) podem \n\nser melhoradas com a forma\u00e7\u00e3o de complexos com ciclodextrinas, tais como, solubilidade, \n\ntaxa de dissolu\u00e7\u00e3o, biodisponibilidade oral de f\u00e1rmacos de Classe II e IV (conforme o Sistema \n\nde Classifica\u00e7\u00e3o Biofarmac\u00eautico BCS), efici\u00eancia de encapsula\u00e7\u00e3o e perfil de libera\u00e7\u00e3o em \n\nsistemas de libera\u00e7\u00e3o controlada, e problemas associados \u00e0 toxicidade e \u00e0 irrita\u00e7\u00e3o local \n\n(BREWSTER; LOFTSSON, 2007).  \n\nQuando as CDs s\u00e3o utilizadas como excipientes farmac\u00eauticos visando melhorar as \n\npropriedades dos f\u00e1rmacos associados, \u00e9 importante considerar a quantidade de ciclodextrina \n\nnecess\u00e1ria para proposta finalidade. Nesse sentido, s\u00e3o desej\u00e1veis pequenas quantidades de \n\nciclodextrina por quest\u00f5es de custo e de toxicologia, o que \u00e9 perfeitamente vi\u00e1vel quando a \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n46\n\nefici\u00eancia de complexa\u00e7\u00e3o \u00e9 satisfat\u00f3ria. Entretanto, existem estrat\u00e9gias para aumentar a \n\nefici\u00eancia de complexa\u00e7\u00e3o, com o aumento da solubilidade da mol\u00e9cula hospedeira no meio \n\naquoso de complexa\u00e7\u00e3o, atrav\u00e9s de processos de ioniza\u00e7\u00e3o, forma\u00e7\u00e3o de sal ou de complexos \n\nmet\u00e1licos ou pela adi\u00e7\u00e3o de co-solventes org\u00e2nicos como o etanol (DUCH\u00caNE et al., 1999; \n\nBREWSTER; LOFTSSON, 2007).  \n\n \n\nFigura 6 - Esquema da associa\u00e7\u00e3o entre ciclodextrina hidratada (CD) e mol\u00e9cula h\u00f3spede \n\n(G): (acima) complexos de inclus\u00e3o 1:1 e (abaixo) complexos de inclus\u00e3o 2:1 \n\nciclodextrina:f\u00e1rmaco (SONG et al., 2009). \n\n \n\nApesar das vantagens atribu\u00eddas a forma\u00e7\u00e3o dos complexos de inclus\u00e3o de f\u00e1rmaco \n\ncom ciclodextrinas, muitas vezes, apenas o mecanismo de complexa\u00e7\u00e3o molecular n\u00e3o \u00e9 \n\nsuficiente para promover a libera\u00e7\u00e3o controlada do agente terap\u00eautico. Com isso, a \n\nincorpora\u00e7\u00e3o de complexos de inclus\u00e3o em sistemas de libera\u00e7\u00e3o controlada poderia viabilizar \n\na obten\u00e7\u00e3o do perfil de libera\u00e7\u00e3o desejado (DE ROSA et al., 2005; FERNANDES et al., \n\n2007). \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n47\n\nA incorpora\u00e7\u00e3o de complexos de inclus\u00e3o f\u00e1rmaco:ciclodextrina em sistemas \n\npolim\u00e9ricos pode aumentar a efici\u00eancia de encapsula\u00e7\u00e3o e a biodisponibilidade oral dos \n\nprinc\u00edpios ativos associados, bem como, modular a cin\u00e9tica de libera\u00e7\u00e3o destes dispositivos \n\nterap\u00eauticos (DUCH\u00caNE et al., 1999).  Isso \u00e9 poss\u00edvel devido a natureza do complexo de \n\ninclus\u00e3o formado, produzindo de novas esp\u00e9cies com diferentes solubilidades e difusividades \n\nnas matrizes polim\u00e9ricas (DE ROSA et al., 2005),  capazes de melhorar a hidrata\u00e7\u00e3o da \n\nmatriz, promover sua eros\u00e3o (SONG et al., 1997) e modificar o perfil de libera\u00e7\u00e3o do sistema \n\npolim\u00e9rico (BIBBY et al., 2000; TRAPANI et al., 2003). \n\n \n\n2.7 trans-Desidrocrotonina (t-DCTN) \n\nA trans-desidrocrotonina (t-DCTN) (Fig. 7) \u00e9 o diterpeno clerod\u00e2nico majorit\u00e1rio \n\nisolado das cascas do caule (de \u00e1rvores com idade acima de 3 anos) do Croton cajucara Benth \n\n(Euphorbiaceae). Os demais metab\u00f3litos secund\u00e1rios, na sua grande maioria diterpenos \n\nclerodanos, tamb\u00e9m foram isolados das cascas do caule desta esp\u00e9cie. Em fun\u00e7\u00e3o dos teores \n\nde isolamento muito limitados, o \u00fanico que teve sua a\u00e7\u00e3o biol\u00f3gica extensivamente \n\ninvestigada foi a trans-crotonina (t-CTN) que comparativamente se mostrou menos eficaz do \n\nque a t-DCTN (MACIEL et al., 2000; 2002; 2006; COSTA et al., 2005). \n\nEsta esp\u00e9cie vegetal \u00e9 popularmente conhecida como sacaca e representa um recurso \n\nmedicinal de grande import\u00e2ncia na regi\u00e3o amaz\u00f4nica brasileira. No estado do Par\u00e1, as cascas \n\ndo seu caule s\u00e3o utilizadas na forma de ch\u00e1 ou c\u00e1psulas no combate a diarr\u00e9ia, mal\u00e1ria, febre, \n\nproblemas estomacais, inflama\u00e7\u00f5es do f\u00edgado, rins e ves\u00edcula. Ainda pode ser utilizda no \n\ncontrole do diabetes e de \u00edndices elevados de colesterol. As folhas s\u00e3o utilizadas para aux\u00edlio \n\nda digest\u00e3o (MACIEL et al., 2002).  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n48\n\nO\n\nO\n\nO H\n\nH\n\nO\n\n \n\nFigura 7 - Estrutura qu\u00edmica da trans-desidrocrotonina (t-DCTN). \n\n \n\nA a\u00e7\u00e3o medicinal do Croton cajucara est\u00e1 amplamente correlacionada ao clerodano   \n\nt-DCTN (MACIEL et al., 2000; 2002; 2006; 2007; COSTA et al., 2005), o qual apresenta as \n\nseguintes atividades farmacol\u00f3gicas: hipoglic\u00eamica (FARIAS et al., 1997; SILVA et al., \n\n2001a),  hipolipid\u00eamica (FARIAS et al., 1996; SILVA et al., 2001a; 2001b; 2001c; \n\nBIGHETTI et al., 2004), antigenot\u00f3xica (AGNER et al., 1999; 2001), antiulcerog\u00eanica \n\n(HIRUMA-LIMA et al., 1999; MELO et al., 2003; RODR\u00cdGUEZ et al., 2004), \n\nantiinflamat\u00f3ria e antinociceptiva (CARVALHO et al., 1996), antitumoral (GRYNBERG       \n\net al., 1999; MELO et al., 2004), antiestrog\u00eanica (LUNA-COSTA et al., 1999) e \n\ncardiovascular (SILVA et al., 2005).  A partir de modifica\u00e7\u00f5es qu\u00edmicas da mol\u00e9cula de          \n\nt-DCTN est\u00e3o sendo desenvolvidos estudos que objetivam a avalia\u00e7\u00e3o da rela\u00e7\u00e3o \n\nestrutura/atividade biol\u00f3gica (MACIEL et al., 2007; 2006; 2000; MELO et al., 2004; 2003; \n\n2001; ANAZETTI et al., 2004; 2003). \n\n Dentre as atividades farmacol\u00f3gicas da t-DCTN, a a\u00e7\u00e3o hipoglicemiante merece \n\ndestaque e j\u00e1 foi avaliada com este biotivo encapsulado em sistemas de libera\u00e7\u00e3o controlada \n\nde f\u00e1rmacos. A atividade hipoglicemiante da t-DCTN foi avaliada em ratos Wistar machos \n\nportadores de diabetes induzido por aloxano (150 mg/Kg, s.c.) e por estreptozotocina           \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n49\n\n(60 mg/Kg, i.p.). No m\u00e9todo de indu\u00e7\u00e3o por aloxano, o melhor resultado de hipoglicemia foi \n\nproduzido com a dose de 50 mg/Kg por via oral com uma diminui\u00e7\u00e3o de 53% depois de 5 h, \n\ncom efic\u00e1cia compar\u00e1vel a da glibenclamida  (2 mg/Kg, v.o.) usada como f\u00e1rmaco padr\u00e3o. \n\nEnquanto que no m\u00e9todo de indu\u00e7\u00e3o por estreptozotocina foi observada uma redu\u00e7\u00e3o de \n\nhiperglicemia de 61% depois de 72 h. O mecanismo de a\u00e7\u00e3o hipoglicemiante da t-DCTN n\u00e3o \n\nest\u00e1 totalmente elucidado (SILVA et al., 2001). Foi observada melhoria na atividade \n\nhipoglicemiante da t-DCTN na redu\u00e7\u00e3o da glicemia de animais normoglic\u00eamicos quando este \n\nf\u00e1rmaco foi incorporado em microesferas polim\u00e9ricas de PLGA (MORAIS et al., 2008).  \n\nAspectos referentes \u00e0 citotoxicidade e toxicidade da t-DCTN tamb\u00e9m devem ser \n\nconsiderados no \u00e2mbito do desenvolvimento de sistemas de libera\u00e7\u00e3o de f\u00e1rmacos. A \n\natividade citot\u00f3xica deste bioativo foi avaliada atrav\u00e9s de par\u00e2metros como varia\u00e7\u00f5es da \n\nmorfologia celular, medidas da viabilidade celular e da inibi\u00e7\u00e3o do metabolismo celular, \n\natrav\u00e9s de valores de CI50 (concentra\u00e7\u00e3o do f\u00e1rmaco que inibe 50% do crescimento celular). \n\nNesse contexto, diversas linhagens de c\u00e9lulas foram estudadas: c\u00e9lulas fibrobl\u00e1sticas \n\npulmonares de hamsters chineses (V79) (SOUZA-BRITO et al., 1998;  RODR\u00cdGUEZ et al., \n\n1999; MELO et al., 2001; FREIRE et al., 2003), hepat\u00f3citos de ratos  (RODR\u00cdGUEZ et al., \n\n1999; CORR\u00caA et al., 2005), carcinoma de Ehrlich (GRYNBERG et al., 1999; MACIEL et \n\nal., 2002; MELO et al., 2004), e c\u00e9lulas promieloc\u00edticas leuc\u00eamicas (HL60)  (GRYNBERG et \n\nal., 1999; MACIEL et al., 2002; MELO et al., 2004). \n\nO efeito citot\u00f3xico da t-DCTN em c\u00e9lulas fibrobl\u00e1sticas pulmonares de hamsters \n\nchineses (V79) mostrou uma redu\u00e7\u00e3o dose-dependente da viabilidade celular com uma CI50 \n\nde 240 mM, variando a concentra\u00e7\u00e3o de 80 a 400 ?M (SOUZA-BRITO et al., 1998); em \n\nc\u00e9lulas promieloc\u00edticas leuc\u00eamicas (HL60) produziu diferencia\u00e7\u00e3o celular e indu\u00e7\u00e3o de \n\napoptose; em c\u00e9lulas mononucleares sangu\u00edneas humanas mostrou baixa toxicidade \n\n(ANAZETTI et al, 2003; 2004); em c\u00e9lulas HL60 produziu inibi\u00e7\u00e3o de fosfatase e apoptose \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n50\n\n(CORR\u00caA et al., 2005); e em hepat\u00f3citos extra\u00eddos de ratos demonstrou toxicidade seletiva \n\nap\u00f3s tratamento subcr\u00f4nico com 8 ?M (RODR\u00cdGUEZ et al., 1999). Outro estudo observou \n\ndiminui\u00e7\u00e3o da citotoxicidade da t-DCTN em c\u00e9lulas de V79 e cultura de hepat\u00f3citos quando \n\neste princ\u00edpio ativo foi complexado com a ?-ciclodextrina (FREIRE et al., 2003). \n\nQuanto \u00e0 toxicidade da t-DCTN, estudos de toxicidade subaguda e aguda j\u00e1 foram \n\nrealizados. Nos ensaios de toxicidade subaguda, a t-DCTN foi administrada diariamente por \n\nvia oral durante 35 dias (25, 50 e 100 mg/Kg). Os resultados demonstraram uma redu\u00e7\u00e3o dos \n\nn\u00edveis de protoplasma, fosfatase alcalina e colesterol. Al\u00e9m disso, foram observadas \n\naltera\u00e7\u00f5es histopatol\u00f3gicas no f\u00edgado (tumefa\u00e7\u00e3o turva, degenera\u00e7\u00e3o microvacuolar e \n\naltera\u00e7\u00f5es nucleares) (RODR\u00cdGUEZ et al., 2004), e ainda, em doses mais elevadas, um \n\naumento significativo no peso do f\u00edgado e nos n\u00edveis da gama-glutamil transpeptidase (ratos \n\nf\u00eameas).  \n\nA toxicidade aguda da t-DCTN foi avaliada em camundongos Swiss machos ap\u00f3s 14 \n\ndias de administra\u00e7\u00e3o por via oral (nas doses de 125, 250, 500, 750 e 1000 mg/Kg), e por via \n\nintraperitoneal (nas doses de 25, 31, 62,5, 125, 250 e 500 mg/Kg). Os resultados destes \n\nensaios demonstraram uma baixa toxicidade deste princ\u00edpio ativo, com valores de DL50 de \n\n876 mg/Kg (12 h) e 47,2 mg/Kg (14 dias) para ambas as vias de administra\u00e7\u00e3o (SOUZA-\n\nBRITO et al., 1998). Estudos de toxicidade aguda realizados durante 72 h com administra\u00e7\u00e3o \n\nda t-DCTN por via oral n\u00e3o revelaram nenhum sintoma t\u00f3xico em n\u00edvel de sistema nervoso \n\ncentral, como estereotipia, ataxia, e convuls\u00e3o. A DL50 da t-DCTN foi determinada em \n\ncamundongos por via oral, sendo de 555 mg/Kg (v.o.) (CARVALHO et al., 1996). Apesar de \n\na t-DCTN apresentar uma baixa toxicidade, o uso indevido da sacaca (uso de folhas em \n\ntratamentos prolongados) vem sendo associado a casos de hepatite t\u00f3xica (aguda, cr\u00f4nica e \n\nfulminante) (MACIEL et al., 2006; 2002). \n\n \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n51\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nOOBBJJEETTIIVVOOSS  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n52\n\nOBJETIVOS \n\n \n\nObjetivo Geral \n\nObter e caracterizar sistemas de libera\u00e7\u00e3o controlada inovadores contendo o \n\nterpen\u00f3ide bioativo t-DCTN e o complexo de inclus\u00e3o t-DCTN:HP?CD em microesferas dos \n\npol\u00edmeros biodegrad\u00e1veis PCL e PLGA. \n\n \n\nObjetivos Espec\u00edficos \n\n\u2022 Avaliar a influ\u00eancia de par\u00e2metros de formula\u00e7\u00e3o atrav\u00e9s de an\u00e1lise fatorial usando a \n\nt\u00e9cnica de emuls\u00e3o m\u00faltipla com evapora\u00e7\u00e3o do solvente para a obten\u00e7\u00e3o das \n\nmicroesferas; \n\n\u2022 Otimizar formula\u00e7\u00f5es de microesferas atrav\u00e9s do uso de an\u00e1lise fatorial para a \n\nencapsula\u00e7\u00e3o da t-DCTN e do complexo de inclus\u00e3o t-DCTN:HP?CD; \n\n\u2022 Preparar microesferas de PCL e PLGA contendo t-DCTN; \n\n\u2022 Preparar microesferas de PCL e PLGA contendo complexo de inclus\u00e3o                  \n\nt-DCTN:HP?CD; \n\n\u2022 Caracterizar as microesferas f\u00edsico-quimicamente com a avalia\u00e7\u00e3o do percentual de \n\nencapsula\u00e7\u00e3o, polidispers\u00e3o (\u00edndice span), carga de superf\u00edcie (potencial zeta), an\u00e1lise \n\nmorfol\u00f3gica e porosidade; \n\n\u2022 Determinar o perfil de libera\u00e7\u00e3o in vitro das microesferas de PCL e PLGA contendo   \n\nt-DCTN e o complexo de inclus\u00e3o t-DCTN:HP?CD; \n\n\u2022 Avaliar o perfil de libera\u00e7\u00e3o in vitro das microesferas atrav\u00e9s do uso de modelo te\u00f3rico \n\nde cin\u00e9tica de libera\u00e7\u00e3o;   \n\n\u2022 Avaliar a influ\u00eancia do complexo de inclus\u00e3o t-DCTN:HP?CD nas propriedades \n\nf\u00edsico-qu\u00edmicas e de cin\u00e9tica de libera\u00e7\u00e3o das microesferas. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n53\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n  \n\n  \n\n  \n\n  \n\nAARRTTIIGGOO    \n\n  \nPPhhyyssiiccoocchheemmiiccaall  aanndd  rreelleeaassee  cchhaarraacctteerriissttiiccss  ooff                  \n\ntt--ddeehhyyddrrooccrroottoonniinn  aanndd  tt--DDCCTTNN::  \n\nhhyyddrrooxxyypprrooppyyll--??--ccyyccllooddeexxttrriinn  iinncclluussiioonn  \n\nccoommpplleexx  iinnttoo  PPCCLL  aanndd  PPLLGGAA  mmiiccrrooppaarrttiicclleess  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n54\n\nPhysicochemical and release characteristics of t-dehydrocrotonin and                   \n\nt-DCTN:hydroxypropyl-?-cyclodextrin inclusion complex into PCL and PLGA \n\nmicroparticles  \n\n \n\nWaldenice de Alencar Morais1, Rosana Silva Batista1, Maria Aparecida Medeiros Maciel2, \n\nNereide Stela Santos-Magalh\u00e3es1* \n\n \n\n1Universidade Federal de Pernambuco (UFPE), Laborat\u00f3rio de Imunopatologia Keizo-Asami \n\n(LIKA), Av. Prof. Moraes Rego, 1235 Cidade Universit\u00e1ria, Recife, PE, Brazil, 2Universidade \n\nFederal do Rio Grande do Norte (UFRN), Departamento de Qu\u00edmica, Natal, RN, Brazil \n\n \n\n \n\n* Corresponding author \n\nDra. Nereide Stela Santos Magalh\u00e3es  \n\nUniversidade Federal de Pernambuco \n\nGrupo de Sistemas de Libera\u00e7\u00e3o Controlada de Medicamentos \n\nLaborat\u00f3rio de Imunopatologia Keizo-Asami (LIKA) \n\nAv. Prof. Moraes Rego, 1235, Cidade Universit\u00e1ria. \n\n50670-901, Recife-PE, Brasil. \n\nPhone: + 55\u201381- 21012501; fax: +55\u201381- 21012508 \n\nE-mail: nssm@ufpe.br; nereide.magalhaes@pq.cnpq.br  \n\n \n\n \n\n \n\n \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n55\n\nAbstract \n\nThe purpose of this study was to evaluate the influence of the presence of t-DCTN and                \nt-DCTN:hydroxypropyl-?-cyclodextrin inclusion complex (t-DCTN:HP?CD) of \npolycaprolactone (PCL) and poly (D,L-lactic-co-glycolic)-acid (PLGA) microparticles on \ntheir physicochemical and release properties.  Three different microparticle systems were \nprepared by double W/O/W emulsion-solvent evaporation method with t-DCTN,                  \nt-DCTN:HP?CD or co-encapsulated t-DCTN:HP?CD incorporated into the aqueous phase \nand t-DCTN in the organic phase of the simple emulsion. The polyethylene glycol (PEG) and \npolyvinylalcohol (PVA) were used as stabilizing agents of the simple and double emulsion, \nrespectively. Initially, pre-formulation studies of unloaded PCL microparticles were \nperformed using 24?1 fractional factorial design varying PEG and PVA concentration, and \naqueous phase volume of the simple and double emulsions. The influence of the formulation \nfeatures on the particle size and polydispersity (span) of unloaded PCL microparticles was \nthus evaluated using the factorial design. Factorial design showed to be an excellent tool to \noptimize PCL microparticles. The variation of the inner and outer aqueous phase volumes of \nthe double emulsion considerably affected the size and the span of the resultant \nmicroparticles. The size of unloaded PCL microparticles varied from 6.68 to 28.41 ?m and \nthe span changed from 1.16 to 4.76 with the alteration of the factors. Considering the most \nstables unloaded microparticle formulations, t-DCTN and t-DCTN:HP?CD-loaded PCL and \nPLGA microparticles were prepared to evaluate the influence of the polymer type. The          \nt-DCTN was encapsulated into PCL and PLGA microparticles with loading drug of almost \n4% and 6% (w/w) at 1:10 drug/polymer ratio, respectively. The t-DCTN:HP?CD inclusion \ncomplex changed physicochemical characteristics of the microspheres, producing smaller \nparticle size, better encapsulation efficiency, loading, and porosity parameters (specific \nsurface area and pore size distribution), as well as, a smooth surface morphology in \ncomparison with t-DCTN-loaded systems. The co-encapsulation of DCTN:HP?CD inclusion \ncomplex with t-DCTN at 1:5 drug/polymer ratio increased the drug loading to almost 14% \n(w/w) in PLGA microspheres with particle size of 9.59 \u00b5m and span of 1.57. The good \nagreement between kinetic profiles and fickian model indicated that the diffusion is involved \non the release mechanism of t-DCTN. The t-DCTN:HP?CD inclusion complex modified the \nrelease properties with smaller diffusion rates, for PCL (k2= 0.105) and PLGA (k2= 0.107), in \ncomparison with microparticles containing only t-DCTN, k2=0.289 (PCL) and k2=0.395 \n(PLGA), respectively. The t-DCTN-loaded PLGA microspheres presented higher burst effect \nand faster drug release associated to formation of a porous network. The co-encapsulation of \nt-DCTN and t-DCTN:HP?CD in PLGA microspheres reduced the burst effect (almost 1.5%) \nand diffusion rate (k2=0.079). These results suggest a smaller affinity of t-DCTN by PCL \nmatrix in relation to PLGA due to its lower encapsulation, higher modification of the surface \ncharge (zeta potential), higher burst effect and faster release profiles. The physicochemical \nand release characteristics of PCL or PLGA microspheres were modified with the presence of \nfree drug and/or complexed drug. From these findings novel formulations of PCL and PLGA \nmicrospheres containing t-DCTN and t-DCTN:HP?CD inclusion complex were obtained to \nbe applied in in vivo studies. \n\n \n\n \nKeywords: Drug delivery systems, microparticles, trans-dehydrocrotonin, drug inclusion \ncomplex with cyclodextrin, factorial design. \n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n56\n\n1. Introduction \n\n \n\nThe diterpene 19-nor-clerodane trans-dehydrocrotonin (t-DCTN) is a bioactive \n\ncompound isolated of the stem bark of Croton cajucara Benth (Euphorbiaceae), which \n\npresents several pharmacological activities. Particularly the hypoglycemic effects of DCTN \n\nwere reported (Farias et al., 1997; Silva et al., 2001). Nevertheless, the lower water solubility \n\nand hepatotoxicity of this compound has been associated to the limitation of its therapeutic \n\napplication (Corr\u00eaa et al., 2005; Morais et al., 2008). A promising strategy to overcome these \n\nissues could be the encapsulation in polymeric microparticles to modulate its therapeutical \n\ndose, bioavailability and toxic effects. \n\nPolymeric microparticles have been commonly employed as attractive drug delivery \n\nsystems to overcome low oral bioavailability of certain drugs. Microparticles would offer \n\nseveral advantages as providing a controlled drug delivery within therapeutic range, allowing \n\nless frequent administrations and reducing toxic effects, thereby increasing patient compliance \n\n(Freiberg and Zhu, 2004; Wischke and Schwendeman, 2008). Biocompatible and \n\nbiodegradable polymers with safety profile for human use such as poly-?-caprolactone (PCL) \n\nand poly (D,L-lactic-co-glycolic)-acid (PLGA) are the most widely used materials in the \n\npreparation of drug delivery systems (Jain, 2000; Gander et al., 2001; Lecaroz et al., 2006; \n\nMart\u00ednez-Sancho et al., 2006; Fern\u00e1ndez-Carballido et al., 2008).  \n\nAmong the different methods described to prepare microparticles (Jiang and \n\nSchwendeman, 2001; Zhang et al., 2008), the double emulsion-solvent evaporation technique \n\n(w/o/w) is the widely accepted to encapsulate a variety of drugs (Garbayo et al., 2008; Li et \n\nal., 2008). The modification of variables on the formulation and preparation method allows \n\nthe control of the microparticle characteristics such as particle size and drug release \n\nproperties. The factorial design represents a theoretical model suitable to perform a \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n57\n\nquantitative relationship between the effects of the formulation variables individually or in \n\nassociation, providing a new approach to optimize pharmaceutical formulations (Dillen et al., \n\n2004; Derakhshandeh et al., 2007).  In the present study factorial design is proposed to as a \n\ntool in the optimization of microparticles containing t-DCTN. \n\nCyclodextrins (CDs), cyclic oligosaccharides, have broad pharmaceutical applications \n\nas solubilizing agents of lipophilic drug molecules, providing alteration of their \n\nphysicochemical and biological properties. Cyclodextrins enhance aqueous solubility of drugs \n\nand improve thereby their stability and bioavailability profiles, through the formation of non-\n\ncovalent dynamic (host\u2013guest) inclusion complexes (Del Valle, 2004; Brewster and Loftsson, \n\n2007). Cyclodextrins have been used as pharmaceutical row material in drug delivery systems \n\nsuch as microcapsules, microparticles, nanospheres, nanocapsules, liposomes and niosomes \n\n(Trichard et al., 2006; Loftsson and Duch\u00eane, 2007), modifying the loading and release \n\ncharacteristics of drugs (Duch\u00eane et al., 1999).  Recently, a growing interest has been showed \n\nin the use of ?CD derivatives, such as the 2-hydroxypropyl-?-cyclodextrin (HP?CD), due to \n\nits improved ability to form inclusion complexes, greater water solubility and less toxicity \n\nthan the parent cyclodextrins (Loftsson and Duch\u00eane, 2007).  \n\nAs reported, the inclusion of t-DCTN in ?CD carried out to control the drug release was \n\nable to reduce its cytotoxicity in rat hepatocytes and V79 fibroblasts (Corr\u00eaa et al., 2005). \n\nFurthermore, t-DCTN-loaded PLGA spherical microparticles were recently developed by our \n\nresearch time with mean diameters size of 3.2 \u00b1 0.1?m and 7.6 \u00b1 0.7 ?m, and encapsulation \n\nefficiency of 85.5 \u00b1 3.9%. The in vitro kinetic profile of DCTN from PLGA-microspheres \n\nwas initially fast (burst effect of 19.4% at 2 h), followed by a controlled release attaining a \n\nmaximum drug released of 55.6% within sixty hours. It was also demonstrated that the \n\nhypoglycemic effect of t-DCTN was improved by its encapsulation into drug delivery \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n58\n\nsystems. The t-DCTN-loaded PLGA microspheres reduced the glucose levels at 26.8% \n\ncomparated with 14.3% obtained to DCTN at normal glycemic animals (Morais et al., 2008). \n\nTaking into account all these findings, the aim of the present study was to combine the \n\nadvantages properties of the biodegradable microparticles and the concept of                  \n\ndrug-cyclodextrin inclusion complex to develop t-DCTN microparticles using fractional \n\nfactorial design. The main idea was to obtain novel PCL and PLGA microparticles containing \n\nthe free t-DCTN, DCTN:HP?CD inclusion complex and both free and complexed forms of     \n\nt-DCTN. The influence of the drug:inclusion complex on the physicochemical and release \n\ncharacteristics of microparticles was investigated using different polymeric matrices for \n\nfurther pharmacological purposes.  \n\n \n\n2. Materials and methods  \n\n \n\n2.1 Materials \n\nThe t-DCTN was extracted and purified from the stem bark of Croton cajucara Benth \n\n(Maciel et al., 2000), and its physicochemical characterization was carried out at the \n\nChemistry Laboratory of the Federal University of the Rio de Janeiro (Brazil). The             \n\npoly(D,L-lactic-co-glycolic)-acid (PLGA 50/50, inherent viscosity of 0.57 dl/g) was \n\npurchased from Birmingham Polymers (Alabama, USA) and polycaprolactone                 \n\n(PCL, MW?14,000 Da) was furnished by Sigma-Aldrich (St Louis, USA). The stabilizers \n\npolyvinyl alcohol (PVA, MW of 13,000-17,000 Da) and polyethylene glycol (PEG, MW 4,000 \n\nDa), the cryoprotectant trehalose and the 2-hydroxypropyl-?-cyclodextrin                  \n\n(HP?CD, MW?1380, degree of substitution?0.6) were obtained from Sigma-Aldrich             \n\n(St Louis, USA). Tween 80\u00ae was supplied by Labsynth (S\u00e3o Paulo, Brazil). Purified water \n\nwas obtained through Human UP 900 water purification system (Human Corporation, Korea) \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n59\n\nand used in the preparation of phosphate buffer solutions (pH 7.4). Silica-alumina was \n\nacquired from Micromeritics (Norcross, USA). All other reagents were of analytical grade. \n\n \n\n2.2 Methodology \n\n Three different microparticle systems were thus prepared with t-DCTN,                   \n\nt-DCTN:HP?CD and co-encapsulation of t-DCTN in the organic phase of the simple \n\nemulsion and t-DCTN:HP?CD in the aqueous phase of the double emulsion.  Initially,        \n\npre-formulation studies of the preparation of unloaded PCL microparticles were performed \n\nusing fractional factorial design.  \n\n \n\n2.2.1 Pre-formulation studies of microparticles using fractional factorial design \n\n The unloaded PCL microparticles were prepared using a water-in-oil-in-water (w/o/w) \n\nemulsion solvent evaporation technique. Briefly, a simple emulsion (w/o) was prepared by \n\ndissolving the PCL (225 mg) in dichloromethane (6 mL). The organic solution was emulsified \n\nwith a pH 7.4 phosphate buffer solution (1 \u2013 3 mL) containing PEG (50 \u2013 200 mg) at 8,000 \n\nrpm for 1 min (ultra-turrax T25, IKA, Germany) using an ice bath. Next, the simple emulsion \n\nwas added to the outer aqueous phase (30 \u2013 100 mL) constituted of PVA (0.5 \u2013 2%, w/v) and \n\nemulsified at 8,000 rpm for 30 s, resulting in a double emulsion (w/o/w).  This emulsion was \n\nthen maintained under agitation at 400 rpm for 2 h allow the solvent evaporation. The \n\nmicroparticles were recovered through centrifugation (Kubota KN-70 centrifuge, Japan) at \n\n3,000 rpm (1171 g) for 10 min and washed three times with distilled water to remove the \n\nexcess of emulsifiers. Finally, microparticles were dispersed within 1% (w/v) trehalose \n\naqueous solution (2 mL), frozen at \u201380\u00b0C and lyophilized (EZ-DRY, FTS System, USA) in \n\nequipment operating at 200 bars during 48 h. The storage of lyophilized microparticles was \n\nperformed at 25 \u00b1 1\u00b0C in a vacuum desiccator.  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n60\n\n The influence of the formulation parameters on the development of unloaded PCL \n\nmicroparticles prepared by multiple emulsion solvent evaporation method was carried out \n\nusing a 24?1 fractional factorial design (Barros Neto et al., 1995). The effects of four \n\nparameters of the simple (i) and multiple (ii) emulsions were evaluated as following: (i) factor \n\n1 (PEG A1=50, 125 or 200 mg) and factor 2 (inner aqueous phase volume, VA1=1, 2 or 3 mL); \n\nand (ii) factor 3 (PVA A2=0.5, 1.25 or 2%) and factor 4 (aqueous continuous phase volume, \n\nVA2=30, 65 or 100 mL). The response variables of the factorial experiment were the volume \n\nmean diameter (dv) and particle size distribution (span) of the microparticles. To provide an \n\nestimate of the pure error, the design was enlarged with a central point run in triplicate. The \n\nlow and high levels of the factors were represented by -1 and +1 coded values, respectively, \n\nand the central point by 0, as shown in Table 1. The design matrix was composed of eleven \n\nbatches of microparticles (from M1 to M11) prepared in a randomized manner. The \n\ninterpretation of the statistical model was performed by evaluating the main effects and their \n\ninteractions. The statistical analysis of the data was performed using the Statistica\u00ae software \n\n(version 6).  \n\n \n\nTable 1. Factor levels and response variables used in the fractional factorial design (24?1) on \n\nthe development of unloaded PCL microparticles.  \n\nCoding  \nFactors -1 0 +1 \n\nSimple emulsion  \n(1) PEG (mg), (PEG A1)  50 125 200 \n(2) Aqueous phase volume (mL), (VA1)  1 2 3 \n\nMultiple emulsion  \n(3) PVA (%), (PVA A2)  0.5 1.25 2 \n(4) Aqueous phase volume (mL), (VA2)  30 65 100 \n\nResponse variables \n \n\nVolume mean diameter (dv) \nParticle size distribution (span) \n\nPCL= 225 mg \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n61\n\n2.2.2 Preparation of DCTN:HP?CD inclusion complex and quantification of t-DCTN into \n\ninclusion complex \n\nInclusion complex of t-DCTN:HP?CD with a 1:1 molar ratio was prepared by           \n\nfreeze-drying technique. Appropriate amounts of drug and HP?CD were dissolved in an \n\nethanol:water solution (1:1), stirred for 48 h at 25\u00b0C, cooled by immersion in liquid-nitrogen \n\nat -80 \u00b0C and lyophilized (EZ-DRY, FTS System, US) for 48 h.  \n\nThe amount of t-DCTN in the inclusion complex was determined using a                  \n\nUV spectroscopic validated method (Lapenda et al., 2010). An amount of t-DCTN:HP?CD \n\ninclusion complex (equivalent to 1 mg of t-DCTN) was weighed and mixed with 10 mL of \n\nmethanol and acetonitrile mixture (1:10) to extract the drug. An aliquot of the sample was \n\ndiluted with acetonitrile to a drug theoretical concentration of 10 \u00b5g/mL. This procedure was \n\nperformed in triplicate. The standard curve of t-DCTN was performed at concentration \n\nvarying from 1 to 20 ?g/mL in acetonitrile. \n\n \n\n2.2.3 Preparation of t-DCTN-loaded microparticles \n\nBased on results of the factorial design, PCL or PLGA microparticles containing         \n\nt-DCTN or t-DCTN:HP?CD inclusion complex (11.3 - 22.5 mg) were prepared  using the \n\nwater-in-oil-in-water (w/o/w) emulsion/solvent evaporation technique, as previously \n\ndescribed in section 2.2.1. Three different microparticle systems were thus prepared \n\ncontaining free t-DCTN, which was dissolved in the organic phase of the simple emulsion; the \n\ninclusion complex t-DCTN:HP?CD dissolved in the aqueous phase of the simple emulsion; \n\nand the co-encapsulation of t-DCTN in the organic phase of the simple emulsion and                  \n\nt-DCTN:HP?CD in the aqueous phase of the simple emulsion. A typical formulation of \n\nmicroparticles was constituted of PCL or PLGA (225 mg) dissolved in 6 mL of \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n62\n\ndichloromethane, PEG (125 mg) dissolved in 2 mL of water to form the simple emulsion, and \n\nPVA (1.25%) dissolved in 45 mL of water as the continuous phase of the multiple emulsions. \n\n \n\n2.2.4 Characterization of microparticles  \n\n2.2.4.1 Particle size analysis  \n\nThe volume mean diameter (dv) and size distribution (span) of microparticles were \n\ndetermined trough laser diffraction technique using a particle size analyzer              \n\n(Microtrac\u00ae S3500, USA). Samples of lyophilized microparticles (10 mg) were dispersed in \n\n0.04% Tween 80\u00ae (w/v), sonicated for 10 min and analysed. The dv represents the volume \n\nmean diameter and the span was calculated by the equation: span=d(v,0.9)?d(v,0.1)/d(v,0.5), where \n\nd(v,0.9), d(v,0.5) and d(v,0.1) are the volume mean diameters determined at 90th, 50th and 10th \n\npercentile of particles, respectively.  \n\n \n\n2.2.4.2  Drug efficiency encapsulation and drug loading \n\nAccurately weighed amounts of lyophilized microparticles (5 mg) were dissolved in       \n\n25 mL of dichloromethane and methanol mixture (3:2) and sonicated for 10 min. t-DCTN was \n\ndetected at 238 nm. The amount of t-DCTN in microparticles was determined using a \n\nstandard curve of t-DCTN at concentrations ranging from 3 to 20 ?g/mL in methanol. The \n\nexperiments were carried out in triplicate. The drug content was thus used to calculate the \n\nencapsulation efficiency and drug loading. \n\nThe drug encapsulation efficiency was calculated by the relation between the experimental \n\nand theoretical t-DCTN concentrations determined in microparticles expressed as percentage. \n\nThe drug loading was calculated by the ratio between the encapsulated drug and the weight of \n\nlyophilized microparticles expressed as percentage (w/w) (Cocero et al., 2009; Ishihara et al., \n\n2009). \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n63\n\n2.2.4.3 Zeta potential measurements \n\nThe surface charge of microparticles was evaluated through electrophoretic mobility (?E ) \n\nmeasurements using a Zeta-Meter System 3.0+ (Zeta-Meter Inc., USA) at 25\u00b0C. \n\nMicroparticles were dispersed in 1 mM NaCl at 0.5% (w/v) and sonicated for 10 min and \n\nanalyzed. The results are reported as the average of ten runs and expressed by the zeta \n\npotential (?, mV) calculated from ?E by the Smoluchowski relationship: ?=(?E?)/(?0?r), where \n\n?0 is the permittivity of a vacuum, ?r the relative dielectric permittivity of the medium \n\n(dielectric constant), and ? is the viscosity of the dispersing phase.  \n\n \n\n2.2.4.3 Morphological analyses \n\nThe morphology of microparticles was evaluated by scanning electron microscopy \n\n(SEM, FEI, Quanta 200 FEG) at the Center of the Northeast Technology (CETENE, Recife, \n\nPE, Brazil). For SEM analysis, the samples were prepared from lyophilized microparticle \n\nredispersed in water. A sample was dropped on a piece of silicium wafer and dried in a \n\ndesiccator. After drying, the piece of silicium wafer was sealed with colloidal silver on stubs \n\nfor analysis on low vacuum at 10,00 kV and magnification of around 5,000 x. \n\n \n\n2.2.4.4 Porosity analysis \n\nThe porosity parameters of microparticles were evaluated through the surface gas \n\nadsorption technique. Measurements were performed using an accelerated surface area and a \n\nporosimetry system (ASAP 2420, Micrometrics, Norcross, USA) at the CETENE. Before \n\nanalysis a sample of lyophilized microparticles (100 mg) was placed in a volumetric sample \n\ntube and degassed under vacuum at 20\u00b0C for 48 h. The sample tube was then immersed in \n\nliquid nitrogen and the sample exposed to inner nitrogen under precisely controlled pressures. \n\nThe pressure at which adsorption equilibrium occurred is measured and the universal gas law \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n64\n\napplied to determine the quantity of gas adsorbed on the surface of microparticles. \n\nAdsorption/desorption isotherms at 77 K were plotted from the volume of nitrogen (vapor) \n\nadsorbed onto the surface of samples as a function of the relative pressure. Silica-alumina \n\npellets (specific surface area 215 \u00b1 6 m2/g; mean pore diameter of 11.5 nm) were used as \n\nstandard reference. The specific surface area was calculated using the Brunauer\u2013Emmett\u2013\n\nTeller (BET) method (Brunauer et al., 1938). The pore size distribution was determined by the \n\nadsorption branch of the N2 isotherm (1.7 \u2013 300 nm diameter range) using the Barret\u2013Joyner\u2013\n\nHalenda (BJH) model (Barrett et al., 1951). \n\n \n\n2.2.4.5 In vitro release kinetics  \n\nThe release kinetics of t-DCTN from microparticles was carried out using dissolution \n\ntechnique at sink conditions (Morais et al., 2008). Samples of microparticles (7 \u2013 20 mg) \n\ncontaining t-DCTN, t-DCTN:HP?CD inclusion complex or co-encapsulated free and \n\ncomplexed drug were placed into 200 mL of 0.2 M phosphate buffer (pH 7.4)  at 37 \u00b1 1 \u00b0C \n\nunder magnetic agitation. At pre-determined time intervals, samples of the release medium    \n\n(1 mL) were withdrawn and replaced with fresh medium, filtered (0.22 ?m membrane filter, \n\nMillipore\u00ae, USA) and the t-DCTN content analyzed spectrophotometrically as previously \n\ndescribed. Kinetics experiments were conducted in triplicate. The in vitro release profiles of  \n\nt-DCTN from different microparticles were plotted as the percentage of t-DCTN released as a \n\nfunction of time.  \n\n \n\n2.2.4.6 Mathematical modeling of drug release \n\nThe experimental release data were fitted by an exponential model using the \n\nequation: )1(/ 21\ntk\n\nt ekMM\n?\n\n? ?= , where tM  and  ?M  are the absolute cumulative amount of \n\ndrug released at time t and initial drug content, respectively; and  the constant 2k  is associated \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n65\n\nto the drug diffusion coefficient in the polymer matrix (Siepmann and Siepmann, 2008; Klose \n\net al., 2008). The first hours of the kinetics were fitted with the Fickian square-root-of-time \n\n(t1/2) model and the release rate determined by the slope of the linear regression. \n\n \n\n3. Results  \n \n\n3.1 Development of unloaded PCL microparticles using factorial design  \n\nThe aim of the factorial design was to obtain the adequate formulation of PCL \n\nmicroparticles for further incorporation of t-DCTN and t-DCTN:HP?CD inclusion complex. \n\nThe 24?1 fractional factorial design was carried out by evaluating the effect of variables of the \n\nemulsion/solvent evaporation technique on the size pattern of unloaded PCL microparticles.  \n\nThe factors of the simple emulsion (PEGA1 and VA1) and the multiple emulsion   \n\n(PVAA2  and VA2) markedly influenced the response variables dv and span of the microparticles \n\nas shown in Table 2. The volume mean diameter of unloaded PCL microparticles varied from \n\n6.68 to 28.41 ?m and the span from 1.56 to 4.76. Particularly, the volume mean diameter and \n\nspan of the reference formulation (M9, zero point), prepared in triplicate (M10 and M11), \n\nvaried from 19 to 23 ?m (\u00b1 0.45 \u2013 1.76 ?m) and 1.35 to 1.76, respectively.  \n\nThe main and interaction effects of factors of the factorial design of unloaded PCL \n\nmicroparticles are summarized in Table 3. The effect value indicates the magnitude of the \n\nimpact of each factor as well as their interactions. The values showed in bold represent the \n\nfactors that present statistical significance (p<0.05). The signal effect, positive (+) or negative \n\n(-), indicates as the response variable is modified as a function of the factor variation. A \n\npositive effect means that the output increases with the increasing of the variable level and a \n\nnegative effect that the output increases with decreasing the variable level (Barros Neto et al., \n\n1995).  \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n66\n\nTable 2. Size characteristics of unloaded PCL microparticles obtained by emulsion/solvent \n\nevaporation technique using 24?1 fractional factorial design. \n\n \nFactors Response variables  \n\nMicroparticles 1 \n(PEGA1) \n\n2 \n(VA1) \n\n3 \n(PVAA2) \n\n4 \n(VA2) \n\ndv \u00b1 sd (?m) span \n\nM1 +1 -1 -1 +1 28.41 \u00b1 0.32 2.02 \n\nM2 -1 -1 +1 +1 26.03 \u00b1 0.49 1.29 \n\nM3 +1 +1 +1 +1 14.10 \u00b1 1.12 1.62 \n\nM4 -1 +1 -1 +1 8.11 \u00b1 0.12 2.51 \n\nM5 -1 +1 +1 -1 13.00 \u00b1 0.59 4.76 \n\nM6 -1 -1 -1 -1 14.70 \u00b1 0.87 1.79 \n\nM7 +1 -1 +1 -1 7.82 \u00b1 0.16 3.23 \n\nM8 +1 +1 -1 -1 6.68 \u00b1 0.43 3.61 \n\nM9 \n\nM10 \n\nM11 \n\n0 \n\n0 \n\n0 \n\n0 \n\n0 \n\n0 \n\n0 \n\n0 \n\n0 \n\n0 \n\n0 \n\n0 \n\n20.76 \u00b1 1.76 \n\n18.62 \u00b1 0.45 \n\n22.90 \u00b1 1.47 \n\n1.56 \n\n1.35 \n\n1.76 \n\nPCL=225 mg. \n\n \n\nTable 3. The main and interaction effects of fractional factorial design of unloaded PCL \n\nmicroparticles. \n\nFactors Effect 1 \n\n (dv) \n\nEffect 2  \n\n(span) \n\nMean/Interaction 16.46636             2.31818 \n\n1 -1.20750 0.03250 \n\n2 -8.19750 0.85250 \n\n3 0.19250 0.43250 \n\n4 8.61250 -1.48750 \n\n1 by 2 1.61250 -1.24250 \n\n1 by 3 -7.91750 -0.44250 \n\n1 by 4 5.39250 -0.11250 \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n67\n\nThe data clearly indicate significant effects of the factors VA1 and VA2 on dv and span of \n\nPCL microparticles, with higher importance for VA2. The internal aqueous phase volume had a \n\nnegative effect (-8.19750) and the external aqueous phase volume had a positive effect \n\n(8.61250) in the particle size. It means that a decrease in the dv can be achieved with an \n\nincrease of VA1 and a decrease of VA2 of the reference formulation (M9). VA1 and VA2 present \n\npositive (0.85250) and negative (-1.48750) main effects in the span, respectively. It means \n\nthat a change in one of the significant factors of the factorial design (VA1 and VA2) carry out \n\nopposite effects on the size and span of the microparticles.  Taking into account the \n\nformulation M8 (VA1=3 mL and VA2= 30 mL) a smaller dv (6.68 \u00b1 0.43 \u00b5m) and an increased \n\nspan (3.61) were found.  \n\nThe significant interaction effects were 1 by 3 on dv (-7.91750), and 1 by 2 on span      \n\n(-1.24250) of the PCL microparticles. The results showed that the interaction of the factors  \n\nPEGA1 and PVAA2 produced a decrease in dv (7.82 \u00b5m, M7), and that interaction of the factors  \n\nPEGA1 and VA1 produced a decrease in span of microparticles. \n\nThe fractional factorial design allowed the production of PCL microparticles with \n\nsmaller size (<19 ?m) but higher span values (>1.76, except for M2 and M3) in relation to \n\nM9, because of the opposed effects caused by the factors on the response variables.  \n\nIn present study, it is desired a particle size &lt;10 \u00b5m and a span value &lt;2. That is due \n\nto the further application of t-DCTN loaded microparticles as systems to oral route that must \n\nhave adequate particle size to pass through the intestinal barrier (Gaumet et al., 2007). \n\nFurthermore, the span values around 2 are appropriate for drug delivery systems (Ribeiro-\n\nCosta et al., 2008). Based on this fact, the reference formulation (M9) was modified and a \n\nnew formulation (M12) was prepared containing PCL (225 mg) and PEG (125 mg) with a VA1 \n\nof 2 mL to form the simple emulsion, and PVA (1.25%) and VA2 of 45 mL as the continuous \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n68\n\nphase. As expected, M12 presented the smaller dv (6.45 \u00b1 0.53 \u00b5m) and a slightly higher span \n\n(2.09) than M9 (Figure 1).  \n\n \n\nFigure 1. Scatterplot of volume mean diameter and span of unloaded PCL microparticles \n\noptimized using fractional factorial design 24?1. \n\n \n\nThe variation of the inner/external aqueous phase (w1/w2) ratio had a great influence \n\non the size properties of the PCL microparticles. The smaller value of dv (6.45 ?m) was found \n\nfor w1/w2 ratio of 1/22.5 (M12). However, small dv values were also found for w1/w2 ratio \n\nvarying from 1/10 (6.68 ?m, M8) and 1/30 (7.82 ?m, M7). \n\nThe increase in particle size of PCL microparticles with the increase of the volume of \n\nthe external aqueous phase can be attributed to a decrease in the mixing efficiency associated \n\nwith larger volumes during the agitation process. A reduction in mixing efficiency probably \n\nproduced an increase in the size of the simple emulsion droplets, which would result in the \n\nformation of large microparticles. The decrease of the diameter and the increase of the \n\npolidispersity (span) of microparticles with the increase of the volume of the internal aqueous \n\nphase were possibly caused by the increase of the volume fraction of the dispersed to \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n69\n\ncontinuous phase (Li et al., 2008). Other authors have already reported this effect (Jeyanthi et \n\nal., 1997; Andr\u00e9-Abrant et al., 2001). When w/o/w double emulsion technique is used, the \n\nviscosity of the polymer phase may also be influenced by the presence of the inner water \n\nphase (Wischke and Schwendeman, 2008). A decrease of the viscosity of the dispersed phase \n\nof microspheres carried out a larger size distribution (Yang et al., 2000). \n\nIn the present study, PEG and PVA were used to stabilize the internal phase of the \n\nsimple emulsion and the continuous phase of the multiple emulsions, respectively, during \n\nmicrosphere preparation.  As previously reported, the increase of surfactant concentrations \n\nreduced the size of microspheres (Yang et al., 2001; Li et al., 2008; Luciani et al., 2008).  \n\n \n\n3.2 t-DCTN-loaded microparticles \n\nThe formulation of PCL microparticles (M12) was used to encapsulate the t-DCTN \n\nvarying the payload from 11.3 to 22.5 and the drug/polymer ratio from 1:10 to 1:20 (Table 3).   \n\n \n\nTable 3. Size properties and encapsulation efficiency of t-DCTN in PCL microparticles.  \n\nParticle size  \n      dv \u00b1 sd            span      \n       (\u00b5m) \n\n t-DCTN \n    (mg) \n\nDrug:polymer \nratio \n\n  \n\nEE \u00b1 sd \n(%) \n\nLoading \u00b1 sd \n(%, w/w) \n\n    22.5          1:10 49.28 \u00b1 1.65 2.12 49.70 \u00b1 0.21 4.06 \u00b1 0.02 \n\n    15.0          1:15 42.21 \u00b1 3.22 1.82 34.24 \u00b1 0.39 2.07 \u00b1 0.02 \n\n    11.3          1:20 25.81 \u00b1 0.12 1.39 18.06 \u00b1 0.25 0.79 \u00b1 0.01 \n\nPCL= 225 mg. \n\n \n\nThe presence of t-DCTN influenced the particle size properties of PCL microparticles. \n\nA remarkable increase of size and span of microparticles with the increment in the initial \n\namount of t-DCTN from 11.3 to 22.5 mg was found. The volume mean diameter varied from \n\n25.81 to 49.29 ?m and the span from 1.39 to 2.12. However, no significant increase of span \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n70\n\nvalues in relation to unloaded PCL microparticles (span 2.09) was found. It should be noted \n\nthat the smaller size was found at 1:20 drug/polymer ratio (25.81 \u00b5m). The presence of the \n\ndrug can increase the viscosity of the dispersed phase, and, as a result, the size of the droplets \n\nin the emulsification medium increased, which leads to an augmentation of the size of \n\nmicroparticles (Li et al., 2008; Balmayor et al., 2009). \n\nThe t-DCTN was encapsulated into PCL-based microparticles with encapsulation \n\nefficiency varying from 18.06 (11 mg t-DCTN) to 49.70% (22 mg t-DCTN) and the drug \n\nloading increased from 0.79 to 4.06%. As expected, the t-DCTN loading in microparticles \n\nwas improved with the increase of the drug amount. In fact, it is well known that the drug \n\nefficiency encapsulation generally increases with the drug/polymer ratio (Wan et al., 1992). \n\nFurther studies were carried out to investigate the influence of the polymer type on the    \n\nt-DCTN encapsulation. In this way, t-DCTN-loaded PLGA microparticles were prepared \n\nunder the same conditions as t-DCTN-loaded PCL microparticles (Table 4).  \n\n \n\nTable 4. Size properties and encapsulation efficiency of t-DCTN in PLGA microparticles.  \n\nParticle size  \n      dv \u00b1 sd            span      \n       (\u00b5m) \n\n t-DCTN \n    (mg) \n\nDrug:polymer \nratio \n\n  \n\nEE \u00b1 sd \n(%) \n\nLoading \u00b1 sd \n(%, w/w) \n\n     22.5          1:10 14.56 \u00b1 0.19 1.00  75.73 \u00b1 0.40 5.90 \u00b1 0.03 \n\n     15.0          1:15 16.31 \u00b1 0.40 1.02  62.67 \u00b1 0.13 3.34 \u00b1 0.01 \n\n     11.3          1:20 15.82 \u00b1 0.07 0.81  58.80 \u00b1 0.44 2.36 \u00b1 0.02 \n\nPLGA=225 mg. \n\n \n\nThe results showed that the mean size of PLGA microparticles were smaller         \n\n(14.56 \u2013 16.31 \u00b5m) than that of t-DCTN-loaded PCL microparticles (<25 \u00b5m). The span \n\nvalues slightly varied from 0.81 to 1.00 for t-DCTN contents varying from 11.4 to 22.5 mg.  \n\nThe encapsulation efficiency and drug loading increased from 58.80 to 75.73% and            \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n71\n\n2.36 to 5.90% (w/w), respectively. The increase of the drug/polymer ratio had influence on \n\nthe particle size of PLGA microparticles probably due to the higher affinity of t-DCTN to \n\nPLGA matrix. \n\nThe t-DCTN-loaded PLGA microparticles presented different characteristics of size \n\nand drug encapsulation.  The smaller mean diameters and narrow size range were found, \n\nwhereas the encapsulation percentages were improved in relation to t-DCTN-loaded PCL \n\nmicroparticles. That was probably due to the higher affinity of t-DCTN to the PLGA matrix, \n\nand therefore, causing an increased retention of the drug in the organic phase and improving \n\nemulsion stability during the formation of microparticles (Mao et al., 2008). \n\n \n\n3.3 t-DCTN:HP?CD-loaded microparticles  \n\n The HP?CD was chosen to prepare inclusion complex because it was expected to \n\nimprove the aqueous solubility of t-DCTN in comparison to ?CD as previously described \n\n(Corr\u00eaa et al., 2005). The incorporation of t-DCTN:HP?CD inclusion complex                  \n\n(120 mg equivalent to 22.5 mg of t-DCTN) in PLC or PLGA microparticles (1:10 \n\ndrug/polymer ratio) was carried out.   \n\nFigure 2 shows the size, span, loading and zeta potential properties of PCL and PLGA \n\nmicroparticles containing t-DCTN and t-DCTN:HP?CD inclusion complex. The \n\nencapsulation of t-DCTN or t-DCTN:HP?CD in the PCL matrix caused small differences on \n\nthe volume mean diameter and span of PCL microparticles (Figure 2a,b). The t-DCTN-loaded \n\nPCL microparticles presented dv of 49.28 \u00b1 1.65 \u00b5m and span of 2.12, while the                  \n\nt-DCTN:HP?CD-loaded PCL microparticles presented dv of 45.15 \u00b1 1.41 \u00b5m and span of \n\n1.95.  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n72\n\n \n\nFigure 2. Diameter (a), span (b), loading (c) and zeta potential (d) of the PCL and PLGA \n\nmicroparticles containing t-DCTN (white columns) or t-DCTN:HP?CD inclusion complex \n\n(black columns), and unloaded microparticles (sparse gray columns). *Statistically different       \n\n(p<0.05): t-DCTN/PCL and t-DCTN:HP?CD/PCL (I); t-DCTN/PLGA and                   \n\nt-DCTN:HP?CD/PLGA (II); t-DCTN/PCL and t-DCTN/PLGA (III); t-DCTN:HP?CD/PCL \n\nand t-DCTN:HP?CD/PLGA (IV); t-DCTN/PCL, t-DCTN:HP?CD/PCL and unloaded PCL \n\n(V); and t-DCTN/PLGA, t-DCTN:HP?CD/PLGA and unloaded PLGA (VI). \n\n \n\nIn the PLGA matrix, significant decrease in particle size and increase in span values \n\nwere found in the presence of t-DCTN:HP?CD (dv=7.11 ?m and span=1.89) in comparison \n\nwith t-DCTN (dv=14.56 ?m and span=1.00) (Figure 2a,b). This can be probably due to the \n\ncryoprotectant effect of HP?CD, which has already been described in the literature at \n\npolymeric systems as nanocapsules. Cryoprotectants are usually added to the formulation to \n\nprotect the drug delivery systems during freezing and desiccation steps in order to convert \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n73\n\nsolutions of labile materials into solids of sufficient stability for distribution and storage. \n\n(Abdelwahed et al., 2006). \n\nThe drug loading was decreased from 4.06 to 2.70% and from 5.90 to 4.84% when       \n\nt-DCTN:HP?CD inclusion complex was incorporated in PCL and PLGA matrices, \n\nrespectively (Figure 2c). This may be explained by the fact that the droplets of the internal \n\naqueous phase containing the soluble inclusioncomplex t-DCTN:HP?CD can diffuse to the \n\nexternal aqueous phase more easily during the formation of microparticles                  \n\n(Trapani et al., 2003). It was somewhat surprising to observe that PCL microparticles with \n\nlarger size presented smaller loading compared to PLGA microparticles for both t-DCTN and \n\nt-DCTN:HP?CD inclusion complex (Figure 2c). This shows that the encapsulation of drugs in \n\nmicroparticles is affected by different factors besides particle size, including drug/polymer \n\ninteractions and emulsion stability during the preparation process of microspheres               \n\n(De Rosa et al., 2002; Trapani et al., 2003).  \n\nThe zeta potential of PCL-based microparticles was changed with the incorporation of    \n\nt-DCTN (-8.36 \u00b1 0.37 mV) or t-DCTN:HP?CD (-7.23 \u00b1 0.36 mV) in comparison with the \n\nunloaded microparticles (-12.68  \u00b1  0.56 mV) (Figure 2d). The decrease on the zeta potential \n\nin relation to unloaded microparticles can be due to a fraction of the drug adsorbed on the \n\nparticle surface that may influences the surface charge. In contrast, no changes were verified \n\nafter the incorporation of t-DCTN (-14.27 \u00b1 0.90 mV) or t-DCTN:HP?CD                  \n\n(-13.91 \u00b1 0.85 mV) in PLGA  microparticles (-14.03 \u00b1 0.80 mV),  confirming the higher \n\naffinity of t-DCTN with the PLGA and its incorporation in the core of the polymeric matrix. \n\nAs previously demonstrated, PLGA microparticles are negatively charged and this surface \n\ncharge is associated to carboxylic groups of this polyester (Bodmer et al., 1992; Garbayo et \n\nal., 2008; Manca et al., 2008).  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n74\n\n \n\nFigure 3. Diameter (a), span (b) and loading (c) of PLGA microparticles containing t-DCTN \n\n(white columns), t-DCTN:HP?CD inclusion complex (black columns) or  t-DCTN with               \n\nt-DCTN:HP?CD inclusion complex co-encapsulated (sparse gray columns). *Statistically \n\ndifferent (p<0.05): t-DCTN and t-DCTN:HP?CD at 1:10 drug:polymer ratio (I);    t-DCTN \n\nand  t-DCTN with  t-DCTN:HP?CD co-encapsulated at 1:5 drug:polymer ratio (II); t-DCTN \n\nat  1:10 and 1:5 drug:polymer ratios (III); t-DCTN:HP?CD at 1:10 drug:polymer ratio and      \n\nt-DCTN with  t-DCTN:HP?CD co-encapsulated at 1:5 drug:polymer ratio  (IV).   \n\n \n\nThe PLGA matrix provided higher drug loading, smaller particle size and narrow size \n\ndistribution. This fact suggests a higher affinity between the dug and polymer matrix \n\npromoting higher drug incorporation into PLGA-based microparticles.  \n\nBased on these findings, a study was performed to improve the drug loading by \n\nchanging the drug:polymer ratio from 1:10 to 1:5. Figure 3c shows that the drug loading \n\nchanged from 5.90 \u00b1 0.03 to 10.12 \u00b1 0.01% (w/w) for microparticles containing only              \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n75\n\nt-DCTN. However, there was an increase in the particle diameter (14.56 \u00b1 0.19 \u00b5m) and \n\npolidispersity (1.00) for microspheres at 1:10 drug:polymer ratio to 37.10 \u00b5m \u00b1 0.17 and span \n\n1.42 for microspheres at 1:5 drug:polymer ratio (Figure 3a and 3b). \n\nThe drug loading increased from 4.84 \u00b1 0.02% (w/w), containing only                  \n\nt-DCTN:HP?CD at 1:10 drug:polymer ratio, to 13.93 \u00b1 0.05% (w/w) containing                  \n\nt-DCTN:HP?CD and t-DCTN co-encapsulated at 1:5 drug:polymer ratio (Figure 3c). The \n\nparticle size and span values were changed from 7.11 \u00b1 0.11 \u00b5m and span 1.89 for                  \n\nt-DCTN:HP?CD to 9.59 \u00b1 0.11 \u00b5m and span 1.57 for co-encapsulated t-DCTN:HP?CD and    \n\nt-DCTN. \n\nThe presence of t-DCTN in the organic phase appears to have a great influence in the \n\nincrease of viscosity of the dispersed emulsion phase, because it was observed a higher \n\nparticle size for the systems containing only t-DCTN (37.10 \u00b5m) in comparison with                \n\nt-DCTN:HP?CD and t-DCTN co-encapsulated at 1:5 drug:polymer ratio (9.59 \u00b5m). It has \n\nbeen reported that the increase of the viscosity of the dispersed phase can increase the size of \n\nmicrospheres (Li et al., 2008). \n\n \n \n3.4 Morphological analysis of microparticles \n\nThe morphological characteristics of the PCL and PLGA microparticles containing           \n\nt-DCTN and t-DCTN:HP?CD inclusion complex are shown in SEM micrographs (Figure 4).  \n\nSEM microscopy revealed that t-DCTN-loaded microparticles prepared with PCL are \n\nspherical shaped with smooth surface (Figure 4a), while PLGA based-microparticles showed \n\nporous surface and inner structure (Figure 4c). These results are in disagreement with dense \n\nand non-porous microspheres obtained in our previous study (Morais et al., 2008). This fact \n\ncan be attributed to the modification of w/o/w parameters such as the increase of the external \n\naqueous phase (Mao et al., 2007) and increase of PEG amount into the inner aqueous phase. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n76\n\nAll these increased the osmotic gradient and the flux of water from w2 into the w1/polymer \n\nphase (Wischke and Schwendeman, 2008).  \n\n \n\nFigure 4. SEM micrographs of PCL and PLGA microparticles containing t-DCTN or                  \n\nt-DCTN:HP?CD inclusion complex: t-DCTN/PCL 1:10 drug:polymer ratio (5,000 x) (a);       \n\nt-DCTN:HP?CD/PCL 1:10 drug:polymer ratio (4,042 x) (b);  DCTN/PLGA 1:10 \n\ndrug:polymer ratio (5,000 x) (c); t-DCTN:HP?CD:PLGA 1:10 drug:polymer ratio (5,000 x) \n\n(d) and, t-DCTN with t-DCTN:HP?CD/PLGA co-encapsulated at 1:5 drug:polymer ratio \n\n(5,000 x) (e). \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n77\n\nThe encapsulation of t-DCTN:HP?CD inclusion complex in the microparticles did not \n\ncause significant change in their morphology independent on the polymer type device (Figure \n\n4b and 4d). The PLGA microparticles containing t-DCTN and t-DCTN:HP?CD                  \n\nco-encapsulated at 1:5 drug:polymer ratio exhibited morphological characteristics analogous \n\nto PLGA microparticles containing only t-DCTN:HP?CD at 1:10 drug:polymer ratio (Figure \n\n4e). This indicates that the presence of the inclusion complex in the internal aqueous phase \n\ncaused an alteration of solvent evaporation rate, reducing the porosity effect found in the \n\nincorporation of the drug alone (Yang et al., 2000; Wischke and Schwendeman, 2008).  \n\n \n\n3.5 Porosity analysis of microparticles \n\nThe integrated area under the curve (AUC) applied to incremental pore size distribution \n\n(PSD) of adsorption/desorption branches of isotherm was performed to characterize the \n\nporosity of the microspheres. Results showed that the increase of the specific surface area of \n\nmicroparticles (ABET) is correlated to an increase of porosity parameters (specific surface area \n\nand pore size distribution). This indicates that a higher specific surface area is associated to a \n\nhigher porosity of the microparticles (Table 5). \n\n \n\nTable 5. BET specific surface area and pore size distribution of the microparticles. \n\nAUC incremental PSD (10-3) Drug:polymer ABET (m2/g) \nAdsorption Desorption \n\nt-DCTN/PCL 2.874 61.539 31.239 \n\nt-DCTN/PLGA 5.166 77.694 34.799 \n\nt-DCTN:HP?CD/PCL 0.956 18.553 5.063 \n\nt-DCTN:HP?CD/PLGA 0.581 20.853 5.405 \n\nt-DCTN:HP?CD:t-DCTN/PLGA* 1.680 34.027 11.784 \n\nABET= specific surface area; PSD= pore size distributions; *1:5 drug/polymer ratio \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n78\n\nThe PLGA microparticles containing only t-DCTN at 1:10 drug:polymer ratio presented \n\nporosity parameter values (ABET=5.166  m2/g; AUCads=77.694 and AUCdes=34.799) greater \n\nthan PCL microparticles (ABET=2.874 m2/g; AUCads=61.539 and AUCdes=31.239) (Table 5). \n\nHowever, the incorporation of t-DCTN:HP?CD inclusion complex into microparticles \n\nproduced a significant decrease of porosity parameters independent of the polymeric matrix, \n\nPCL (ABET=0.956 m2/g; AUCads=18.553 and AUCdes=5.063) or PLGA (ABET=0.581 m2/g; \n\nAUCads=20.853 and AUCdes=5.405).  \n\nThe PLGA microspheres containing t-DCTN and t-DCTN:HP?CD co-encapsulated at 1:5 \n\ndrug:polymer ratio presented intermediate porosity parameter values (ABET=1.680 m2/g; \n\nAUCads=34.027 and AUCdes=11.784) compared to ones containing only t-DCTN. This fact \n\nemphasizes the stronger character of the influence of t-DCTN:HP?CD inclusion complex in \n\nthe porosity properties as also observed in the morphological analysis using SEM microscopy. \n\nThe higher porosity for the PLGA microparticles containing only t-DCTN can be \n\nattributed to the higher viscosity of the polymer solution and the smaller time required for \n\nPLGA solidification as compared to PCL (Mao et al., 2007). It had already reported that more \n\nrapid flux of solvent across the o/w interface stresses the precipitated polymer film and can \n\ncause an increase of the porosity of PLGA microparticles (Wischke and Schwendeman, \n\n2008). Besides, it suggests that the presence of PEG in the inner water phase might be \n\nfavorable to stablish strong interactions between PLGA/CH2Cl2 systems. Then, the higher \n\nporosity of the particles containing only t-DCTN can be reasonably attributed to PEG osmotic \n\nand porogen properties (\u00d6zdemir; Sahin, 1997; Courtois et al., 2006).  \n\nAs already demonstrated by the literature a high osmotic pressure in the internal aqueous \n\nphase of the double emulsion generates an influx of water toward the inner aqueous phase. \n\nThe occurrence of this process during particle hardening generally results in the formation of \n\na porous surface (Ungaro et al., 2006). This effect in porosity was less importance for \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n79\n\nmicrospheres containing t-DCTN:HP?CD because the presence of the inclusion complex \n\nmight have disadvantaged the interaction of PEG with polymeric matrices. \n\n \n\nFigure 5. Pore size distribution (PZD) of microspheres determined using the BHJ method \n\napplied to N2 adsorption isotherms: i) PCL microspheres: t-DCTN-loaded MP (white squares) \n\nand t-DCTN:HP?CD-loaded MP at 1:10 drug:polymer ratio (black squares); ii) PLGA \n\nmicrospheres: t-DCTN-loaded MP (white circles) and t-DCTN:HP?CD-loaded MP at 1:10 \n\ndrug:polymer ratio (black circles) and DCTN:HP?CD/DCTN-loaded MP at 1:5 drug:polymer \n\nratio (white/black circles). \n\n \n\nThe analysis of the N2 adsorption isotherm profiles using the BJH model showed that \n\nthe PCL and PLGA microspheres present from meso- (2 \u2013 50 nm) and macro-pore  (> 50 nm) \n\nranges according to the IUPAC classification  (Figure 5). The BJH curves (incremental pore \n\nvolume vs. pore size) showed higher pore volume at meso-pore range and a decrease in the \n\npopulation of mesopores smaller than ca. 50 nm for micropheres containing t-DCTN:HP?CD \n\ninclusion complex in both polymeric matrices. As previously reported for the specific surface \n\narea, the incorporation of t-DCTN:HP?CD inclusion complex into microspheres decreased \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n80\n\nthe pore volume. This decrease in pore volume of microspheres can be ascribed to the \n\nmodification of solvent removal rate and the longer time required for t-DCTN:HP?CD to \n\nsolidify as compared to t-DCTN (Mao et al., 2007).  \n\n \n\n3.6 Release kinectics of microparticles containing t-DCTN and t-DCTN:HP?CD inclusion \n\ncomplex  \n\nIn this paper, drug-loaded microparticles of different polymeric matrices were \n\nprepared to evaluate the influence of t-DCTN:HP?CD inclusion complex on the drug kinetics. \n\nThe release profiles of t-DCTN and t-DCTN:HP?CD from PCL and PLGA microparticles \n\nduring 6 days in phosphate buffer are illustrated in Figure 6. To understand which \n\nmechanisms are decisive for the control of the drug release from these systems, an analytical \n\nsolution of Fick\u2019s second law of diffusion was fitted to the experimental results.  \n\nThe symbols represent the data experimentally measured and the curves represent the \n\nfitting of mathematical modeling. The release during the first twelve hours with kinetics \n\nmodel is shown in more detail in the insert. The calculated kinetic parameters of           \n\nloaded-microparticles are summarized in Table 6. \n\nAs it can be seen in Figure 6a and 6b a good agreement between theorethical and \n\nexperimental data was obtained. This indicates that the simple diffusion mechanism is \n\ninvolved on the mass transport mechanism of the microparticulated systems. This fact is also \n\nconfirmed by the fitting of the t-DCTN release by square-root-of-time (t1/2) model (r ? 0.99). \n\nThe release rate (\u00b5g/mL) was calculated by the slope of the linear regression (Table 6). \n\nAll the microsphere formulations showed a biphasic drug release pattern characterized \n\nby an initial burst effect followed by a slower release step with different 2k  (exponencial \n\nmodel) and release rate (linear model) values. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n81\n\n \n\n \n\nFigure 6. In vitro release of t-DCTN from microparticles: PCL (a) and PLGA (b).                  \n\nt-DCTN-loaded microparticles (white squares); t-DCTN:HP?CD-loaded microparticles (black \n\nsquares) at 1:10 drug:polymer ratio and t-DCTN:HP?CD/DCTN-loaded microparticles at 1:5 \n\ndrug:polymer ratio (white/black squares). Each point represents the mean of three different \n\nexperiments \u00b1 S.D. Lines represent the non-linear fitting of Fickian diffusion model. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n82\n\nTable 6. Calculated release parameters from PCL and PLGA microparticles containing           \n\nt-DCTN and t-DCTN:HP?CD inclusion complex using exponential and linear models. \n\n \n\nExponential model \n\n)1(/ 21\ntk\n\nt ekMM\n?\n\n? ?=  \n\n \n\nLinear model \n\n(t1/2) \n\n \n\nDrug:polymer \n\n \n\n% Burst effect \n\n(1 h) \n\nk1 k2 Release rate \n\n(\u00b5g/h) \n\nt-DCTN/PCL 78.07 \u00b1 3.86 0.378 \u00b1 0.026 0.289 \u00b1 0.061 77.62 \u00b1 8.40 \n\nt-DCTN/PLGA 35.11 \u00b1 3.31 0.660 \u00b1 0.025 0.395 \u00b1 0.074 146.69 \u00b1 43.20 \n\nt-DCTN:HP?CD/PCL 76.10 \u00b1 5.37 0.280 \u00b1 0.025 0.105 \u00b1 0.020 39.80 \u00b1 11.66 \n\nt-DCTN:HP?CD/PLGA 17.27 \u00b1 2.03 0.857 \u00b1 0.012 0.107 \u00b1 0.007 67.88 \u00b1 10.19 \n\nt-DCTN:HP?CD:t-DCTN/ \n\nPLGA* \n\n7.45 \u00b1 0.53 0.978 \u00b1 0.006 0.079 \u00b1 0.009 52.79 \u00b1 10.37 \n\n*1:5 drug:polymer ratio. \n\n \n\nFor PCL microparticles, an elevated initial burst effect (> 60%) of drug released was \n\nfound (Table 6). This was followed with a sustained release stage during a period of about 8 h \n\nin the case of t-DCTN-loaded microparticles at 1:10 drug:polymer ratio ( 2k =0.289 and \n\nrelease rate=77.62 \u00b5g/h), in comparison with 10 h in the case of t-DCTN:HP?CD-loaded \n\nmicrospheres ( 2k =0.105 and release rate=39.80 \u00b5g/h). The drug release was fulfilled after \n\nonly 1 day for t-DCTN and after 3 days for t-DCTN:HP?CD.  \n\n           The burst effect was probably due to the release of the drug poorly entrapped or \n\nassociated to the surface or pores of the particles that diffuse from matrix faster (Klose et al., \n\n2008; Ho et al., 2008; Wang et al., 2009). This significant burst effect is consistent with the \n\nzeta potential for the drug-loaded PCL microparticles (Section 3.3), indicating the presence of \n\nt-DCTN at the surface of microparticles modifying their surface charge. The tendency of \n\nsurface localized-drugs may be associated to its lower affinity by the polymeric matrix  \n\n(Wang et al., 2009). The elevated burst effects and fast release profiles also suggest the lower \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n83\n\naffinity of t-DCTN by PCL systems, despite of a higher particle size and smaller porosity \n\n(Table 5, Section 3.4).          \n\n             In the case of PLGA matrix, the microparticles containing t-DCTN:HP?CD inclusion \n\ncomplex at 1:10 drug:polymer ratio and t-DCTN with t-DCTN:HP?CD inclusion complex   \n\nco-encapsulated at 1:5 drug:polymer ratio were evaluated on release kinetics. The PLGA \n\nmicroparticles containing only t-DCTN presented important burst effect and faster drug \n\nrelease due to the formation of a more porous structure in relation to the other systems as \n\ndemonstrated in SEM micrographs (Section 3.3) and porosity parameters (Table 5, Section \n\n3.4). This fact was also confirmed by a faster release ( 2k =0.395 and release rate=146.69 \u00b5g/h) \n\ncompared to the non-porous DCTN-loaded PLGA microparticles obtained on our previous \n\nstudy ( 2k =0.086 and release rate=90.56 \u00b5g/h) (Morais et al., 2008).  At present study, 60% of         \n\nt-DCTN content was released from microspheres within one day, while the same drug \n\npercentage was released within 3 days on previous work. Similarly, Yang et al. (2000) \n\nobserved that the porosity has an important effect on drug release characteristics and a large \n\nnumber of pores may greatly increase the rate of drug release. \n\n            The complexation of t-DCTN with cyclodextrin HP?CD influenced the initial release, \n\nsustained release stage and released total drug amount. The burst effect was drastically \n\nreduced in PLGA-based microparticles comparate to PCL systems, when t-DCTN:HP?CD \n\ninclusion complex was incorporated into microparticles (Table 6).  After the burst step, a \n\ngradual release stage was maintained during 26 h for only t-DCTN:HP?CD ( 2k =0.107 and \n\nrelease rate=67.88 \u00b5g/h), and during 58 h for t-DCTN:HP?CD/t-DCTN ( 2k =0.079 and \n\nrelease rate=52.79 \u00b5g/h), attaining a maximum drug release at 77.0 \u00b1 7.4% and 72.4 \u00b1 8.1% \n\nwithin about 4 days, respectively. The higher encapsulation efficiency from PLGA \n\nmicroparticles can be also contributed to reduce initial burst and slow down the release rate \n\n(Wang et al., 2009). \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n84\n\nThe t-DCTN:HP?CD controlled more efficiently the drug release comparate to           \n\nt-DCTN  in previous study that it had a sustained release during only 12 h (Morais et al., \n\n2008). Besides, the maximum drug release was increased slightly from almost 60% (Morais et \n\nal., 2008) to 77% as used the inclusion complex, probably due to the increased hydrophilicity \n\nof the polymer matrix in the presence of HP?CD (De Rosa et al., 2002; Trapani et al., 2003). \n\nIt had been reported that drug\u2013CD mixtures or their complexes when incorporated into \n\npolymeric matrices can improve hydration of the polymer matrix, promote its erosion      \n\n(Song et al., 1997; Trapani et al., 2003). \n\nThe diffusion is known to be a dominant mechanism in this type of controlled drug \n\ndelivery systems (Klose et al., 2008). Based on calculations of mathematical modeling, the \n\nconstants k2 (associated to apparent diffusion coefficients) of t-DCTN:HP?CD inclusion \n\ncomplex had smaller values in relation to that t-DCTN within of different polymeric matrices \n\n(Table 6). It indicates a smaller mobility of t-DCTN as associated to HP?CD within the \n\npolymeric network. This fact can be attributed to both the characteristics of prepared \n\nmicroparticles, as for instance the smaller porosity, as the inclusion complex-polymer \n\ninteractions that reduce effective diffusivity of parent drug as previously described       \n\n(Quaglia et al., 2003; Fernandes et al., 2007). It had been related that the drug solubility and \n\ndiffusivity can be modified when complexes of drugs with cyclodextrines are incorporated \n\ninto polymeric matrices, changing drug release profile from the polymeric device           \n\n(Bibby et al., 2000; Trapani et al, 2003). \n\nThe higher relative porosity associated to microparticles of higher size can justify the \n\nfact of relative drug release rates were been almost independent of the system size. Other \n\nfactor that has been associated to this is \u201cautocatalysis effect\u201d was found to compensate the \n\n\u201cincreased diffusion pathway length effect\u201d already reported to non-porous PLGA-based \n\nmicroparticles (Siepmann et al., 2005).  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n85\n\nSeveral authors have reported that the release kinetic is also dependent on different \n\ncharacteristics of the microparticles (e.g. type of polymer, surface morphology, \n\ninterconnected pores and channels) and the incorporation of additives (Poletto et al, 2007; \n\nGarbayo et al., 2008). For instance, the presence of pores in PLGA-based microparticles \n\nincreased the mobility of the involved diffusing species and altered the contributions of the \n\ninvolved physicochemical processes to the overall control of drug release (Klose et al., 2006). \n\nThe high internal porosity leads to much easier and deeper water penetration upon incubation \n\nand shortens the diffusion time and path of the loaded drug, leading to higher burst release.  \n\nOn the other hand, the co-encapsulation of t-DCTN and t-DCTN:HP?CD into     \n\nPLGA-based microparticles was crucial to reduce the release rate independent on porosity. \n\nThis indicates that in this case the formation of drug-cyclodextrin-polymer interactions was \n\nmost important. The interactions between polymer and drug will all potentially affect the \n\ndiffusion rates in the polymer matrix, and therefore, the drug release rate                  \n\n(Wischke and Schwendeman, 2008). A similar behavior could take place also to \n\ninsulin:HP?CD inclusion complex inside PLGA system (Quaglia et al., 2003). For all batches \n\nof the microparticles studied, the association of uncomplexed and complexed DCTN into the \n\nsame PLGA device provided the best release control for the tested conditions.  \n\nDrug release from a polymeric matrix is controlled by a variety of factors, such as the \n\nsolubility of the drug within the surrounding fluid, the size of the drug molecule and its \n\nmobility within the swollen polymeric network, and the dissolution rate of the polymer and \n\npolymer\u2013drug interactions. As observed from the release kinetics change in release properties \n\nwas observed with the polymeric matrix nature, the drug form (drug or drug:cyclodextrin \n\ninclusion complex), encapsulation manner (drug or drug:cyclodextrin inclusion complex \n\nalone or co-encapsulated), and with microparticles characteristics as porosity and loading \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n86\n\nunder in vitro conditions. Then, the drug release can be modulating varying these determining \n\nfactors to obtain the desired kinetic profile. \n\n \n\n3. Conclusions \n \n\nThe use of factorial design provided a new approach to study the influence of \n\nformulation parameters on size properties of unloaded PCL microspheres and to optimize \n\nthese controlled delivery systems to encapsulate t-DCTN and t-DCTN:HP?CD inclusion \n\ncomplex using the double emulsion/solvent evaporation method. Microparticle size and \n\npolidispersity (span) can thus be controlled by adapting the factors aqueous phase of simple \n\nemulsion and aqueous phase of multiple emulsion. Lower diameter and higher span values \n\nwere obtained with the increasing of the volume of the simple emulsion and decreasing of \n\nvolume of multiple emulsion. The t-DCTN was successfully encapsulated into PCL and \n\nPLGA microspheres with a higher encapsulation efficiency and drug loading at 1:10 \n\ndrug/polymer ratio. The t-DCTN:HP?CD inclusion complex decreased encapsulation \n\nefficiency, drug loading, particle size and porosity parameters (specific surface area and pore \n\nsize distribution) at 1:10 drug/polymer ratio in both polymeric matrices. The co-encapsulation \n\nof t-DCTN:HP?CD inclusion complex with t-DCTN at 1:5 drug/polymer ratio increased \n\nencapsulation efficiency and drug loading in PLGA microspheres maintaining small values of \n\nparticle size (&lt;10 \u00b5m) and span (&lt;2.00). The t-DCTN:HP?CD inclusion complex modified \n\nphysicochemical properties (encapsulation, size, zeta potential and porosity) and release \n\nproperties (burst step, sustained release stage and released total drug amount) from \n\nmicroparticles. The t-DCTN:HP?CD inclusion complex modify the difusibility and release \n\nrate (smaller values of k2 and release rate) in comparison with microparticles containing only \n\nt-DCTN. These results suggest a smaller affinity of t-DCTN by PCL matrix in relation to \n\nPLGA due its lower encapsulation, higher modification of the surface charge (zeta potential), \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n87\n\nhigher burst effect and faster release profiles independent on particle size and porosity \n\ncharacteristics. The co-encapsulation of t-DCTN:HP?CD with t-DCTN plays a significant \n\nrole in the characteristics of PLGA microparticles such as the encapsulation and release rate. \n\nFrom these findings novel oral formulations of PCL and PLGA microparticles containing       \n\nt-DCTN:HP?CD and/or t-DCTN were obtained to be applied in in vivo studies. \n\n \n\n \n\nAcknowledgments \n\n \n\nW.A.M. is grateful for a PhD scholarship from the Brazilian Council for Scientific and \n\nTechnological Development (CNPq) and the Pernambuco State Foundation for the \n\nAdvancement of Science (FACEPE). This research was supported by the CNPq               \n\n(Grant # 474071/2007-3).  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n88\n\nReferences  \n\n \n\nAbdelwahed,W.; Degobert, G.; Fessi, H.  Investigation of nanocapsules stabilization by \n\namorphous excipients during freeze-drying and storage. Eur. J. Pharm. Biopharm. v. 63     \n\np. 87\u201394, 2006.  \n\n \n\nAndr\u00e9-Abrant, A.; Taverdet, J.-L.; Jay, J. Microencapsulation par \u00e9vaporation de solvant. \n\nEur. Polym. J. v. 37, p. 955\u2013967, 2001. \n\n \n\nBalmayor, E.R.; Tuzlakoglu, K.; Azevedo, H.S.; Reis, R.L. Preparation and characterization \n\nof starch-poly-?-caprolactone microparticles incorporating bioactive agents for drug delivery \n\nand tissue engineering applications. Acta Biomaterialia v. 5, p. 1035\u20131045, 2009. \n\n \n\nBarrett, E. P.; Joyner, L. G.; Halenda, P. P.; J. The determination of pore volume and area \n\ndistributions in porous substances. I. Computations from Nitrogen Isotherms. Am. Chem. \n\nSoc. v.73, p. 373, 1951. \n\n \n\nBarros Neto, B.; Scarminio, I. S.; Bruns, R. E. Planejamento e Otimiza\u00e7\u00e3o de Experimentos. \n\nEditora Unicamp, 2\u00aa Edi\u00e7\u00e3o. Campinas, S\u00e3o Paulo, 1995. \n\n \n\nBibby, D.C.; Davies, N.M.; Tucker, I.G. Mechanisms by which cyclodextrins modify drug \n\nrelease from polymeric drug delivery systems. Int. J. Pharm. v. 197, p. 1\u201311, 2000. \n\n \n\nBodmer, D.; Kissel, T.; Traechslin, E. Factors influencing the release of peptides and proteins \n\nfrom biodegradable parenteral depot systems. J. Control. Release v. 21, p. 129\u2013138, 1992. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n89\n\nBrewster, M.E.; Loftsson, T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Del. \n\nRev. v. 59, p. 645-666, 2007. \n\n \n\nBrunauer, S.; Emmett, P.H.; Teller, E. Adsorption of gases in multimolecular layers. J. Am. \n\nChem. Soc. v. 2, p. 309\u2013319, 1938. \n\n \n\nCocero, M. J.; Mart\u00edn, A.; Mattea, F.; Varona, S. Encapsulation and co-precipitation processes \n\nwith supercritical fluids: Fundamentals and applications. J. Supercrit. Fluid. v. 47, p. 546\u2013\n\n555, 2009. \n\n \n\nCorr\u00eaa, D.H.A.; Melo, P.S.; De Carvallho, C.A.A.; De Azevedo, M.B.M.; Dur\u00e1n, N.; Haun, \n\nM. Dehydrocrotonin and its beta-cyclodextrin complex: Cytotoxicity in V79 fibroblasts and \n\nrat cultured hepatocytes. Eur. J. Pharmacol. v. 510, p. 17\u201324, 2005. \n\n \n\nCourtois, J.; Bystrom, E.; Irgum, K. Novel monolithic materials using poly(ethylene glycol) \n\nas porogen for protein separation. Polymer v. 47 p. 2603\u20132611, 2006.  \n\n \n\nDe Rosa, G.; Quaglia, F.; La Rotonda, M.I.; Appel, M.; Alphandary, H.; Fattal, E. \n\nPoly(lactide-co-glycolide) microparticles for the controlled release of \n\noligonucleotide/polyethylenimine complexes. J. Pharm. Sci. v. 91, p. 790\u2013799, 2002. \n\n \n\nDel Valle, E.M.M. Cyclodextrins and their uses: a review. Process Biochem. v. 39, p. 1033\u2013\n\n1046, 2004.  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n90\n\nDerakhshandeh, K.; Erfan, M.; Dadashzadeh, S. Encapsulation of 9-nitrocamptothecin, a \n\nnovel anticancer drug, in biodegradable nanoparticles: Factorial design, characterization and \n\nrelease kinetics. Eur. J.  Pharm. Biopharm. v. 66, p. 34\u201341, 2007.  \n\n \n\nDillen, K.; Vandervoort, J.; Van Den Mooter, G.; Verheyden, L.; Ludwig, A. Factorial design, \n\nphysicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int. J. \n\nPharm. v. 275, p. 171\u2013187, 2004. \n\n \n\nDuch\u00eane, D.; Wouessidjewe D.; Ponchel G. Cyclodextrins and carrier systems. J. Control. \n\nRelease v. 62, p. 263\u2013268, 1999. \n\n \n\nFarias, R.A.F.; Rao, V.S.N.; Viana, G.S.B.; Silveira, E.R.; Maciel, M.A.M.; Pinto, A.C. \n\nHypoglycemic effect of trans-dehydrocrotonin, a nor-clerodane diterpene from Croton \n\ncajucara. Planta Med. v. 66, p. 558\u2013560, 1997. \n\n \n\nFernandes, V.C.; Denadai, A.M.L.; Mill\u00e1n, R.D.S.; Alves, R.J.; Cunha J\u00fanior, A.S. \n\nCaracteriza\u00e7\u00e3o f\u00edsico-qu\u00edmica de complexos de insulina:dimetil-?-ciclodextrina e \n\ninsulina:hidroxipropil-?-ciclodextrina e avalia\u00e7\u00e3o da influ\u00eancia do tipo de complexo na \n\nprodu\u00e7\u00e3o de microesferas biodegrad\u00e1veis. Braz. J. Pharm. Sci. v. 43, n. 4, out./dez., 2007. \n\n \n\nFern\u00e1ndez-Carballido, A.; Pastoriz, P.; Barcia, E.; Montejo, C.; Negro, S. PLGA/PEG-\n\nderivative polymeric matrix for drug delivery system applications: Characterization and cell \n\nviability studies. Int. J. Pharm. v. 352, p. 50\u201357, 2008.  \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n91\n\nFreiberg, S.; Zhu, X. Polymer microparticles for controlled drug release. Int. J. Pharm. v. \n\n282 p. 1\u201318, 2004. \n\n \n\nGander, B.; Meinel, M.; Walter, E.; Merkle, H.P. Polymers an a platform for drug delivery: \n\nreviewing our current portfolio on poly (lactide-coglycolide) (PLGA) microparticles. Chimia \n\nv. 55, p. 212\u2013217, 2001.  \n\n \n\nGarbayo, E.; Ansorena, E.; Lanciego, J.L.; Aymerich, M.S.; Blanco-Prieto, M.J. Sustained \n\nrelease of bioactive glycosylated glial cell-line derived neurotrophic factor from \n\nbiodegradable polymeric microspheres. Eur. J. Pharm. Biopharm. v. 69, p. 844\u2013851, 2008.  \n\n \n\nGaumet, M.; Vargas, A.; Gurny, R.; Delie, F. Nanoparticles for drug delivery: The need for \n\nprecision in reporting particle size parameters. Eur. J. Pharm. Biopharm. v. 69,      p. 1\u20139, \n\n2007.  \n\n \n\nHo, M.L.; Fu, Y.C.; Wang, G.J.;  Chen, H.T.; Chang, J.K.; Tsai, T.H.; Wang, C.K. Controlled \n\nrelease carrier of BSA made by W/O/W emulsion method containing PLGA and \n\nhydroxyapatite. J. Control. Release v. 128, p. 142\u2013148, 2008. \n\n \n\nIshihara, T.; Kubota, T.; Choi, T.; Takahashi, M.; Ayano, E.; Kanazawa, H.; Higaki, M. \n\nPolymeric nanoparticles encapsulating betamethasone phosphate with different release \n\nprofiles and stealthiness. Int. J. Pharm.  v. 375, p. 148-154, 2009. \n\n \n\nJain, R.A. The manufacturing techniques of various drug loaded biodegradable poly(lacide-\n\nco-glycolide) (PLGA) devices. Biomaterials v. 21, p. 2475\u20132490, 2000. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n92\n\nJeyanthi, R.; Mehta, R.C.; Thanoo, B.C.; Deluca, P.P. Effect of processing parameters on the \n\nproperties of peptide-containing PLGA microparticles. J. Microencapsul. v. 14, p. 163\u2013174, \n\n1997. \n\n \n\nJiang, W.; Schwendeman, S.P. Stabilization and controlled release of bovine serum albumin \n\nencapsulated in poly(d, l-lactide) and poly(ethylene glycol) microparticle blends. Pharm. \n\nRes. v. 18, p. 878\u2013885, 2001. \n\n \n\nKlose, D.; Siepmann, F.; Elkharraz, K.; Krenzlin, S.; Siepmann, J. How porosity and size \n\naffect the drug release mechanisms from PLGA-based microparticles. Int. J. Pharm. v. 314, \n\np. 198\u2013206, 2006.  \n\n \n\nKlose, D.; Siepmann, F.; Elkharraz, K.; Siepmann, J. PLGA-based drug delivery systems: \n\nImportance of the type of drug and device geometry. Int. J. Pharm. v. 354, p. 95\u2013103, 2008. \n\n \n\nLapenda, T.L.S.; Morais, W.A.; Maciel, M.A.M.; Santos-Magalh\u00e3es, N.S. Validation of an \n\nUV spectrophotometric method for determining trans-dehydrocrotonin in inclusion \n\ncomplexes with hydroxypropyl-?-cyclodextrin. Spectrochim. Acta A, 2010. In preparation. \n\n \n\nLecaroz, C.; Gamazo, C.; Renedo, M.J.; Blanco-Prieto, M.J. Biodegradable micro- and \n\nnanoparticles as long-term delivery vehicles for gentamicin. J. Microencapsul. v. 23, p. 782\u2013\n\n792, 2006. \n\n \n\nLi, M.; Rouaud, O.; Poncelet, D. Microencapsulation by solvent evaporation: State of the art \n\nfor process engineering approaches. Int. J. Pharm.  v. 363, p. 26\u201339, 2008. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n93\n\nLoftsson, T.; Duch\u00eane, D. Cyclodextrins and their pharmaceutical applications. Int. J. \n\nPharm. v. 329, p. 1\u201311, 2007. \n\n \n\nLuciani, A.; Coccoli, V.; Orsi, S.; Ambrosio, L.; Netti, P. A. PCL microspheres based \n\nfunctional scaffolds by bottom-up approach with predefined microstructural properties and \n\nrelease profiles. Biomaterials v. 29, p. 4800\u20134807, 2008.  \n\n \n\nMaciel, M.A.M.; Pinto, A.C.; Arruda, A.C.; Pamplona, S.G.S.R.; Vanderlinde, F.A.; Lapa, \n\nA.J.; Echevarria, A.; Grynberg, N.F.; C\u00f3lus, I.M.S.; Farias, R.A.F.; Costa, A.M.L.; Rao, \n\nV.S.N. Ethnopharmacology, phytochesmistry and pharmacology: a successful combination in \n\nthe study of Croton cajucara. J. Ethnopharmacol. v. 70, p. 41-55, 2000. \n\n \n\nManca, M-L.; Mourtas, S.; Dracopoulos, V.; Fadda, A.M.; Antimisiaris, S.G. PLGA, chitosan \n\nor chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of \n\nparticle stability during nebulization. Colloid Surface B v. 62, p. 220\u2013231, 2008. \n\n \n\nMao, S.; Shi, Y.; Li, L.; Xu, J.; Schaper, A.; Kissel, T. Effects of process and formulation \n\nparameters on characteristics and internal morphology of poly(D,L-lactide-co-glycolide) \n\nmicroparticles formed by the solvent evaporation method. Eur. J. Pharm. Biopharm. v. 68, \n\np. 214\u2013223, 2008. \n\n \n\nMao, S.; Xu, J.; Cai, C.; Germershaus, O.; Schaper, A.; Kissel, T. Effect of WOW process \n\nparameters on morphology and burst release of FITC-dextran loaded PLGA microparticles. \n\nInt. J. Pharm. v. 334, p. 137\u2013148, 2007. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n94\n\nMart\u00ednez-Sancho, C.; Herrero-Vanrell, R.; Negro, S. Vitamin A palmitate and aciclovir \n\nbiodegradable microparticles for intraocular sustained release. Int. J. Pharm. v. 326, p. 100\u2013\n\n106, 2006. \n\n \n\nMorais, W. A.; Costa, M.; Paix\u00e3o, A.D.O.; Maciel, M.A.M; Santos-Magalh\u00e3es, N.S. \n\nEncapsulation and release characteristics of DCTN/PLGA microparticles. J. Microencapsul. \n\nv. 1, p. 1464\u20135246, 2008. \n\n \n\n\u00d6zdemir, N.; Sahin, J. Design of a controlled release osmotic pump system of ibuprofen. Int.  \n\nJ. Pharm. v. 158, p. 91-97, 1997.  \n\n \n\nQuaglia, F.; De Rosa, G.; Granata, E.; Ungaro, F.; Fattal, E.; La Rotonda, M.I. Feeding liquid, \n\nnon-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-\n\nglycolide) microparticles prepared by spray-drying. J. Control. Release v. 86, p. 267\u2013278, \n\n2003. \n\n \n\nRibeiro-Costa, R.M.; Cunha, M.R; Gongora-Rubio, M.R.; Michaluart-J\u00fanior, P.; R\u00e9, M.I. \n\nPreparation of protein-loaded-PLGA microparticles by an emulsion/solvent evaporation \n\nprocess employing LTCC micromixers. Powder Technol. v. 190, p. 107-111, 2008. \n\n \n\nSiepmann, J.; Elkharraz, K.; Siepmann, F.; Klose, D. How Autocatalysis Accelerates Drug \n\nRelease from PLGA-Based Microparticles: A Quantitative Treatment. Biomacromolecules v. \n\n6, p. 2312\u20132319, 2005. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n95\n\nSiepmann, J.; Siepmann, F. Mathematical modeling of drug delivery. Int.  J. Pharm. v. 364, \n\np. 328\u2013343, 2008. \n\n \n\nSilva, R.M.; Santos, F.A.; Rao, V.S.N.; Maciel, M.A.M.; Pinto, A.C. Blood glucose-and \n\ntriglyceride-lowering effect of trans-dehydrocrotonin, a diterpene from Croton cajucara Beth \n\nin rats. Diabetes Obes. Metab. v. 3, p. 452\u2013456, 2001. \n\n \n\nSong, C.X.; Labhasetwar, V.; Levy, R.J. Controlled release of U-86983 from double-layer \n\nbiodegradable matrices: effect of additives on release mechanism and kinetics. J. Control. \n\nRelease v. 45, p. 177\u2013192, 1997. \n\n \n\nTrapani, G.; Lopedota, A.; Boghetich, I.; Latrofa, A.; Franco, M.; Sanna, E.; Liso, G. \n\nEncapsulation and release of the hypnotic agent zolpidem from biodegradable polymer \n\nmicroparticles containing hydroxypropyl-?-cyclodextrin. Int. J. Pharm. v. 268, p. 47\u201357, \n\n2003.  \n\n \n\nTrichard, L.; Duch\u00eane, D.; Bochot, A. Cyclodextrins in dispersed systems. In: Dodziuk, H. \n\n(Ed.), Cyclodextrins and Their Complexes: Chemistry, Analytical Methods, Applications. \n\nWiley-VCH, Weinheim, p. 423\u2013449, 2006. \n\n \n\nUngaro, F.; De Rosa, G.; Miro, A.; Quaglia, F.; La Rotonda, M. I. Cyclodextrins in the \n\nproduction of large porous particles: Development of dry powders for the sustained release of \n\ninsulin to the lungs. Eur. J. Pharm. Sci. v. 28, p. 423\u2013432, 2006. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n96\n\nWan, L.S.C.; Heng, P.W.S.; Chan, L.W.. Drug encapsulation in alginate microparticles.by \n\nemulsification. J. Microencapsul. v. 9, p.309-316, 1992. \n\n \n\nWang, X.; Wang, Y.; Wei, K.; Zhao, N.; Zhang, S.; Chen, J. Drug distribution within poly(?-\n\ncaprolactone) microparticles and in vitro release. J. Mater. Process. Tech. v. 209, p. 348\u2013\n\n354, 2009. \n\n \n\nWischke, C.; Schwendeman, S.P. Principles of encapsulating hydrophobic drugs in \n\nPLA/PLGA microparticles. Int. J. Pharm. v. 364, p. 298\u2013327, 2008. \n\n \n\nYang, C.Y.; Tsay, S.Y.; Tsiang, R.C.C. An enhanced process for encapsulating aspirin in \n\nethylcellulose microcapsules by solvent evaporation in an O/W emulsion. J. Microencapsul. \n\nv. 17, p. 269\u2013277, 2000. \n\n \n\nYang, Y.-Y.; Chung, T.-S.; Ng, N. P. Morphology, drug distribution, and in vitro release \n\nprofiles of biodegradable polymeric microspheres containing protein fabricated by double-\n\nemulsion solvent extraction/evaporation method. Biomaterials v. 22, p. 231-241, 2001. \n\n \n\nZhang, H.; Lu, Y.; Zhang G.; Gao, S.; Sun, D.; Zhong, Y. Bupivacaine-loaded biodegradable \n\npoly(lactic-co-glycolic) acid microparticles I. Optimization of the drug incorporation into the \n\npolymer matrix and modelling of drug release. Int. J. Pharm. v. 351, p. 244\u2013249, 2008. \n\n \n\n \n\n \n\n \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n97\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\nCONCLUS\u00d5ES \n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n98\n\n4 CONCLUS\u00d5ES \n\n \n\n\u2022 A an\u00e1lise fatorial mostrou ser uma ferramenta eficiente no estudo da influ\u00eancia dos \n\npar\u00e2metros de formula\u00e7\u00e3o nas caracter\u00edsticas de tamanho de part\u00edcula (dv e span), \n\nsendo obtida uma formula\u00e7\u00e3o adequada para a encapsula\u00e7\u00e3o da t-DCTN e do \n\ncomplexo de inclus\u00e3o t-DCTN:HP?CD; \n\n\u2022 As microesferas preparadas por an\u00e1lise fatorial obtiveram tamanho m\u00e9dio de part\u00edcula \n\n(dv) e polidispers\u00e3o (span) bastante distintos, sendo os volumes das fases aquosas da \n\nemuls\u00e3o simples e m\u00faltipla os fatores determinantes na modifica\u00e7\u00e3o destas \n\npropriedades f\u00edsico-qu\u00edmicas; \n\n\u2022 A t-DCTN foi encapsulada com \u00eaxito nas microesferas de PCL e PLGA em diferentes \n\nraz\u00f5es f\u00e1rmaco:pol\u00edmero, com o aumento da quantidade de f\u00e1rmaco encapsulada com \n\no aumento da massa do f\u00e1rmaco,  com os melhores resultados obtidos na raz\u00e3o \n\nf\u00e1rmaco:pol\u00edmero 1:10 (PCL) e 1:5 (PLGA); \n\n\u2022 O complexo de inclus\u00e3o t-DCTN:HP?CD 1:1 (raz\u00e3o molar) foi encapsulado \n\nsatisfatoriamente nas microesferas das duas matrizes polim\u00e9ricas (PCL e PLGA) na \n\nraz\u00e3o f\u00e1rmaco:pol\u00edmero de 1:10; \n\n\u2022 A incorpora\u00e7\u00e3o do complexo de inclus\u00e3o t-DCTN:HP?CD nas matrizes polim\u00e9ricas de \n\nPCL e PLGA produziu microesferas homog\u00eaneas (span &lt;2,00), esf\u00e9ricas e de \n\nsuperf\u00edcie lisa, e ainda, com menores tamanho de part\u00edcula, percentual de f\u00e1rmaco \n\nencapsulado, potencial zeta e par\u00e2metros de porosidade (\u00e1rea de superf\u00edcie espec\u00edfica e \n\ndistribui\u00e7\u00e3o de tamanho de poro); \n\n\u2022 A modifica\u00e7\u00e3o da raz\u00e3o f\u00e1rmaco:pol\u00edmero de 1:10 para 1:5 aumentou \n\nconsideravelmente a quantidade de t-DCTN encapsulada na matriz de PLGA; \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n99\n\n\u2022 A coencapsula\u00e7\u00e3o do complexo de inclus\u00e3o t-DCTN:HP?CD, na fase aquosa interna, \n\ne  t-DCTN, na fase org\u00e2nica da emuls\u00e3o simples, na raz\u00e3o f\u00e1rmaco:pol\u00edmero 1:5        \n\n(t-DCTN:PLGA) aumentou a quantidade de f\u00e1rmaco encapsulada, mantendo o \n\ntamanho de part\u00edcula (9,59 \u00b1 0,11 \u00b5m) e a polidispers\u00e3o (span = 1,57) satisfat\u00f3rios \n\npara o transporte gastrointestinal, tornando-se vi\u00e1vel para uma futura aplica\u00e7\u00e3o \n\nfarmacol\u00f3gica pela via de administra\u00e7\u00e3o oral; \n\n\u2022 O uso do complexo de inclus\u00e3o t-DCTN:HP?CD, no que se refere \u00e0 cin\u00e9tica de \n\nlibera\u00e7\u00e3o in vitro, modificou o perfil de libera\u00e7\u00e3o com o aumento do percentual de \n\nf\u00e1rmaco liberado e um controle mais efetivo da velocidade de libera\u00e7\u00e3o (menores \n\nvalores de k2) associado ao maior car\u00e1ter hidrof\u00edlico das microesferas; \n\n\u2022 A coencapsula\u00e7\u00e3o de t-DCTN com t-DCTN:HP?CD reduziu o efeito burst (1,5%) e a \n\nvelocidade de libera\u00e7\u00e3o (k2= 0,079); \n\n\u2022 Os resultados sugerem uma menor afinidade da t-DCTN pela matriz polim\u00e9rica de \n\nPCL quando comparado ao PLGA, devido \u00e0 menor quantidade de f\u00e1rmaco \n\nencapsulada, maior modifica\u00e7\u00e3o no potencial zeta, um maior efeito burst e um perfil \n\nde libera\u00e7\u00e3o mais r\u00e1pido, independente do tamanho de part\u00edcula e porosidade; \n\n\u2022 O complexo de inclus\u00e3o t-DCTN:HP?CD modificou as propriedades f\u00edsico-qu\u00edmicas e \n\no perfil de libera\u00e7\u00e3o das microesferas de PCL e PLGA, quando comparadas aos \n\nsistemas contendo somente t-DCTN; \n\n\u2022 As microesferas contendo t-DCTN e/ou complexo de inclus\u00e3o t-DCTN:HP?CD \n\ndesenvolvidas neste estudo podem viabilizar uma formula\u00e7\u00e3o farmac\u00eautica inovadora \n\npara via oral com as matrizes polim\u00e9ricas biodegrad\u00e1veis de PCL e PLGA e, com isso, \n\npodendo ser avaliada a sua atividade hipoglicemiante e contribuir para o avan\u00e7o na \n\nterap\u00eautica do diabetes mellitus. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n100\n\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nPERSPECTIVAS \n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n101\n\n5 PERSPECTIVAS  \n\n \n\n Avaliar a citotoxicidade em hepat\u00f3citos de ratos e o efeito hipoglicemiante em ratos \n\ndiab\u00e9ticos das formula\u00e7\u00f5es de microesferas de PCL e PLGA contendo o complexo de \n\ninclus\u00e3o t-DCTN:HP?CD e comparar com o estudo pr\u00e9vio de t-DCTN/PLGA visando a \n\nadministra\u00e7\u00e3o oral. \n\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n102\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nREFER\u00caNCIAS BIBLIOGR\u00c1FICAS \n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n103\n\n6 REFER\u00caNCIAS BIBLIOGR\u00c1FICAS \n\n \nAGNER, A. R.; MACIEL, M. A. M.; PINTO, A. C.; C\u00d3LUS, I. M. S. Antigenotoxicity of \n\ntrans-dehydrocrotonin, a clerodane diterpene from Croton cajucara. Planta Med. v. 67, p. \n\n815-819, 2001.    \n\n \n\nAGNER, A. R.; MACIEL, M. A. M.; PINTO, A. C.; PAMPLONA, S. G. S. R.; C\u00d3LUS, I. \n\nM. S. Investigation of genotoxic activity of trans-dehydrocrotonin, a clerodane diterpene from \n\nCroton cajucara. Teratogen. Carcin. Mut. v. 19, p. 377-384, 1999. \n\n \n\nAHMED, A. R.; BODMEIER, R. Preparation of preformed porous PLGA microparticles and \n\nantisense oligonucleotides loading. Eur. J. Pharm. Biopharm. v. 71, p. 264\u2013270, 2009. \n\n \n\nAHMED, F.; PAKUNLU, R.I.; SRINIVAS, G.; BRANNAN, A.; BATES, F.; KLEIN, M.L.; \n\nMINKO, T.; DISCHER, D.E. Shrinkage of a rapidly growing tumor by drug-loaded \n\npolymersomes: pH-triggered release through copolymer degradation. Mol. Pharm. v. 3, p. \n\n340\u2013350, 2006. \n\n \n\nANAZETTI, M. C.; MELO, P. S.; DUR\u00c1N, N.; HAUN, M. Comparative cytotoxicity of \n\ndimethylamide-crotonin in the promyelocytic leukemia cell line (HL60) and human peripheral \n\nblood mononuclear cells. Toxicology v.188, p. 261-274, 2003. \n\n \n\nANAZETTI, M.C.; MELO, P.S.; DUR\u00c1N, N.; HAUN, M. Dehydrocrotonin and its \n\nderivative, dimethylamide-crotonin induce apoptosis with lipid peroxidation and activation of \n\ncaspases-2, -6 and -9 in human leukemic cells HL60. Toxicology v. 203, p. 123-137, 2004. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n104\n\nANDERSON, J. M.; SHIVE, M. S. Biodegradation and biocompatibility of PLA and PLGA \n\nmicrospheres. Adv. Drug Del. Rev. v. 28, p. 5\u201324, 1997. \n\n \n\nARNOLD, M. M.; GORMAN, E. M.; SCHIEBER, L. J.; MUNSON, E. J.; BERKLAND, C. \n\nNanoCipro encapsulation in monodisperse large porous PLGA microparticles. J. Control. \n\nRelease v. 121, p. 100\u2013109, 2007. \n\n \n\nBALMAYOR, E. R.; TUZLAKOGLU, K.; AZEVEDO, H. S.; REIS, R. L. Preparation and \n\ncharacterization of starch-poly-?-caprolactone microparticles incorporating bioactive agents \n\nfor drug delivery and tissue engineering applications. Acta Biomaterialia v. 5, p. 1035\u20131045, \n\n2009. \n\n \n\nBARAT, A.; CRANE, M.; RUSKIN, H. J. Quantitative multi-agent models for simulating \n\nprotein release from PLGA bioerodible nano- and microspheres. J. Pharmaceut. Biomed. v. \n\n48, p. 361\u2013368, 2008. \n\n \n\nBARCIA, E.;  HERRERO-VANRELL, R.; D\u00cdEZ, A.;  ALVAREZ-SANTIAGO, C.; L\u00d3PEZ, \n\nI.;  CALONGE, M. Downregulation of endotoxin-induced uveitis by intravitreal injection of \n\npolylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp. Eye Res. v. \n\n89, p. 238\u2013245, 2009. \n\n \n\nBARRETT, E. P.; JOYNER, L. G.; HALENDA, P. P. The Determination of Pore Volume \n\nand Area Distributions in Porous Substances. I. Computations from Nitrogen Isotherms. J. \n\nAm. Chem. Soc. v. 73, p. 373, 1951. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n105\n\nBERKLAND, C.; KIM, K. K.; PACK, D. W. Fabrication of PLG microspheres with precisely \n\ncontrolled and nanodisperse size distribuions. J. Control. Release v. 73, p. 59\u201374, 2001. \n\n \n\nBERKLAND, C.; KING, M.; COX, A.; KIM, K.; PACK, D. W. Precise control of PLG \n\nmicrosphere size provides enhanced control of drug release rate. J. Control. Release v. 82, p. \n\n137\u2013147, 2002. \n\n \n\nBERKLAND, C.; KIPPER, M. J.; NARASIMHAN, B.; KIM, K. K.; PACK, D. W. \n\nMicrosphere size, precipitation kinetics and drug distribution control drug release from \n\nbiodegradable polyanhydride microspheres. J. Control. Release v. 94, p. 129\u2013141, 2004. \n\n \n\nBIBBY, D. C.; DAVIES, N. M.; TUCKER, I. G. Mechanisms by which cyclodextrins modify \n\ndrug release from polymeric drug delivery systems. Int. J. Pharm. v. 197, p. 1\u201311, 2000. \n\n \n\nBIGHETTI, E. J. B.; SOUZA-BRITO, A. R. M.; DE FARIA, E. C.; OLIVEIRA, H. C. F. \n\nChronic treatment with bark infusion from Croton cajucara lowers plasma triglyceride levels \n\nin genetic hyperlipidemic mice. Can. J. Physiol. Pharmacol. v. 82, p. 387\u2013392, 2004. \n\n \n\nBILATI, U.; ALLEMANN, E.; DOELKER, E. Strategic approaches for overcoming peptide \n\nand protein instability within biodegradable nano- and microparticles, Eur. J. Pharm. \n\nBiopharm. v. 59, p. 375\u2013388, 2005.  \n\n \n\nBIRNBAUM, D. T.; KOSMALA, J. D.; HENTHORN, D. B.; BRANNON-PEPPAS, L. \n\nControlled release of ?-estradiol from PLAGA microparticles: the effect of organic phase \n\nsolvent on encapsulation and release. J. Control. Release v. 65, p. 375\u2013387, 2000. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n106\n\nBOZKIR, A.; SAKA, O. M. Formulation and investigation of 5-FU nanoparticles with \n\nfactorial design-based studies. Il Farmaco v. 60, p. 840\u2013846, 2005. \n\n \n\nBRANNON-PEPPAS, L. Recent advances on the use of biodegradable microparticles and \n\nnanoparticles in controlled drug delivery. Int. J. Pharm. v. 116, p. 1-9, 1995. \n\n \n\nBRANNON-PEPPAS, L.; BLANCHETTE, J. O. Nanoparticle and targeted systems for \n\ncancer therapy. Adv. Drug Del. Rev. v. 56, p. 1649-1659, 2004. \n\n \n\nBREWSTER, M. E.; LOFTSSON, T. Cyclodextrins as pharmaceutical solubilizers. Adv. \n\nDrug Del. Rev. v. 59, p. 645-666, 2007. \n\n \n\nBUDHIAN, A.; SIEGEL, S. J.; WINEY, K. I. Haloperidol-loaded PLGA nanoparticles: \n\nSystematic study of particle size and drug content. Int. J. Pharm. v. 336, p. 367\u2013375, 2007. \n\n \n\nCALABR\u00d2, M. L.; TOMMASINI, S.; DONATO, P.; RANERI, D.; STANCANELLI, R.; \n\nFICARRA, P.; FICARRA, R.; COSTA, C.; CATANIA, S.; RUSTICHELLI, C.; \n\nGAMBEERINI, G. Effects of a and ?-cyclodextrin complexation on the physico-quemical \n\nproperties and antioxidant activity of some 3-hydroxyflavones. J. Pharmaceut. Biomed. v. \n\n35, p. 365-377, 2004. \n\n \n\nCALVO, P.; VILA-JATO, J. L.; ALONSO, M. J. Evaluation of cationic polymer-coated \n\nnanocapsules as ocular drug carries. Int. J. Pharm. v. 153, p. 41-50, 1997. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n107\n\nCARVALHO, J. C. T.; SILVA, M. F. C.; MACIEL, M. A. M.; PINTO, A. C.; NUNES, D. S.; \n\nLIMA, R. M.; BASTOS, J. K.; SARTI, S. J. Investigation of anti-inflammatory and \n\nantinociceptive activities of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton \n\ncajucara. Part 1. Planta Med. v. 62, p. 402-404, 1996.  \n\n \n\nCHALLA, R.; AHUJA, A.; ALI J.; KHAR, R. K. Cyclodextrins in drug delivery: an updated \n\nreview. AAPS Pharm. Sci. Tech. v. 6, p. 329-357, 2005. \n\n \n\nCOCERO, M. J.; MART\u00cdN, A.; MATTEA, F.; VARONA, S. Encapsulation and co-\n\nprecipitation processes with supercritical fluids: Fundamentals and applications. J. Supercrit. \n\nFluid. v. 47, p. 546\u2013555, 2009. \n\n \n\nCONNORS, K. A. The Stability of Cyclodextrin Complexes in Solution. Chem. Rev. v. 97, \n\np. 1325-1358, 1997. \n\n \n\nCORR\u00caA, D. H. A.; MELO, P. S.; DE CARVALLHO, C. A. A.; DE AZEVEDO, M. B. M.; \n\nDUR\u00c1N, N.; HAUN, M. Dehydrocrotonin and its beta-cyclodextrin complex: Cytotoxicity in \n\nV79 fibroblasts and rat cultured hepatocytes. Eur. J. Pharmacol. v. 510, p. 17-24, 2005. \n\n \n\nCOSTA, M. P. Atividade Hipoglicemiante da trans-desidrocrotonina extra\u00eddo do Croton \n\ncajucara encapsulada em microesferas de copol\u00edmero de \u00e1cido l\u00e1ctico e glic\u00f3lico. 2005. \n\n80p. disserta\u00e7\u00e3o (Mestrado em Ci\u00eancias Farmac\u00eauticas) \u2013 Departamento de Ci\u00eancias \n\nFarmac\u00eauticas, Universidade Federal de Pernambuco (UFPE), Recife, 2005. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n108\n\nDAVIES, G-L.; BARRY, A.; GUN\u2019KO, Y. K. Preparation and size optimisation of silica \n\nnanoparticles using statistical analyses. Chem. Phys. Lett. v. 468, p. 239\u2013244, 2009. \n\n \n\nDAVIS, M. E.; BREWSTER, M. E. Cyclodextrin-Based Pharmaceutics: past, present and \n\nfuture. Nat. Rev. Drug Discov. v. 3, p. 1023-1035, 2004. \n\n \n\nDE ARA\u00daJO, M. V. G.; VIEIRA, E. K. B.; L\u00c1ZARO, G. S.; CONEGERO, L. S.; \n\nALMEIDA, L. E.; BARRETO, L. S.; DA COSTA JR, N. B.; GIMENEZ, I.F. \n\nSulfadiazine/hydroxypropyl-?-cyclodextrin host\u2013guest system: Characterization, phase-\n\nsolubility and molecular modeling. Bioorgan. Med. Chem. v. 16, p. 5788\u20135794, 2008. \n\n \n\nDE ROSA, G.; LAROBINA, D.; LA ROTONDA, M. I.; MUSTO, P.; QUAGLIA, F.; \n\nUNGARO, F. How cyclodextrin incorporation affects the properties of protein-loaded PLGA-\n\nbased microspheres: the case of insulin/hydroxypropyl-?-cyclodextrin system. J. Control. \n\nRelease v. 102, p. 71\u201383, 2005.  \n\n \n\nDEADMAN, C. M.; KELLAWAY, I. W.; YASIN, M.; DICKINSON, P. A.; MURDAN, S. \n\nAn investigation into the influence of drug lipophilicity on the in vivo absorption profiles \n\nfrom subcutaneous microspheres and in situ forming depots. J. Control. Release v. 122, p. \n\n79\u201385, 2007.  \n\n \n\nDERAKHSHANDEH, K.; ERFAN, M.; DADASHZADEH, S. Encapsulation of 9-\n\nnitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: Factorial design, \n\ncharacterization and release kinetics. Eur. J. Pharm. Biopharm. v. 66, p. 34\u201341, 2007. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n109\n\nDEVARAKONDA, B.; HILL, R. A.; LIEBENBERG, W.; BRITS, M.; VILLIERS, M. M. \n\nComparison of the aqueous solubilization of practically insoluble niclosamide by \n\npolyamidoamine (PAMAM) dendrimers and cyclodextrins. Int. J. Pharm. v. 304, p. 193\u2013\n\n209, 2005. \n\n \n\nDILLEN, K.; VANDERVOORT, J.; VAN DEN MOOTER, G.; VERHEYDEN, L.; \n\nLUDWIG, A. Factorial design, physicochemical characterisation and activity of \n\nciprofloxacin-PLGA nanoparticles. Int. J. Pharm. v. 275, p. 171\u2013187, 2004. \n\n \n\nDUCH\u00caNE, D.; WOUESSIDJEWE D.; PONCHEL G. Cyclodextrins and carrier systems.     \n\nJ. Control. Release v. 62, p. 263\u2013268, 1999. \n\n \n\nEMERICH, D. F.; THANOS, C. G. Nanotechnology and medicine. Expert Opin Biol Ther \n\nv. 3, p. 655 - 663. 2003.  \n\n \n\nFAISANT, N.; SIEPMANN, J.; BENOIT, J. P. PLGA-based microparticles: elucidation of \n\nmechanisms and a new, simple mathematical model quantifying drug release. Eur. J. Pharm. \n\nSci. v. 15, p. 355\u2013366, 2002.  \n\n \n\nFARAJI, A. H.; WIPF, P. Nanoparticles in cellular drug delivery. Bioorgan. Med. Chem.    \n\nv. 17, p. 2950\u20132962, 2009. \n\n \n\nFARIAS, R. A. F.; NETO, M. F. O.; VIANA, G. S. B.; RAO, V. S. N. Effects of Croton \n\ncajucara extract on serum lipids of rats fed a high fat diet. Phytother.Res. v. 10, p. 697-699, \n\n1996.  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n110\n\nFARIAS, R. A. F.; RAO, V. S. N.; VIANA, G. S. B.; SILVEIRA, E. R.; MACIEL, M. A. M.; \n\nPINTO, A. C. Hypoglycemic effect of trans-dehydrocrotonin, a nor-clerodane diterpene from \n\nCroton cajucara. Planta Med v. 66, p. 558-560, 1997. \n\n \n\nFENG, SI-SHEN; RUAN, G.; LI, QIU-TIAN. Fabrication and characterizations of a novel \n\ndrug delivery device liposomes-in-microsphere (LIM). Biomaterials v. 25, p. 5181-5189, \n\n2004. \n\n \n\nFERNANDES, V. C.; DENADAI, A. M. L.; MILL\u00c1N, R. D. S.; ALVES, R. J.; CUNHA \n\nJ\u00daNIOR, A. S. Caracteriza\u00e7\u00e3o f\u00edsico-qu\u00edmica de complexos de insulina:dimetil-?-\n\nciclodextrina e insulina:hidroxipropil-?-ciclodextrina e avalia\u00e7\u00e3o da influ\u00eancia do tipo de \n\ncomplexo na produ\u00e7\u00e3o de microesferas biodegrad\u00e1veis. Rev. Bras. Cienc. Farm. v. 43, p. \n\n543-553, 2007. \n\n \n\nFERN\u00c1NDEZ-CARBALLIDO, A.; PASTORIZA, P.; BARCIA, E.; MONTEJO, C.; \n\nNEGRO, S. PLGA/PEG-derivative polymeric matrix for drug delivery system applications: \n\nCharacterization and cell viability studies. Int. J. Pharm. v. 352, p. 50\u201357, 2008. \n\n \n\nFREIBERG, S.; ZHU, X. X. Polymer microspheres for Controlled drug release. Int. J. \n\nPharm., v. 282, p. 1-18, 2004.  \n\n \n\nFREIRE, A. C. G.; DE ASSIS, C. F.; FRICK, A. O.; MELO, P. S.; HAUN, M.; AOYAMA, \n\nH.; DURAN, N.; SAUER, M. M.; KALLAS, E. G; FERREIRA, C. V. Influence of protein \n\nphosphatase inhibitors on HL60 cells death induction by dehydrocrotonin. Leukemia Res.    \n\nv. 27, p. 823-829, 2003. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n111\n\nFREITAS, S.; MERKLE, H. P.; GANDER, B. Microencapsulation by solvent \n\nextraction/evaporation: reviewing the state of the art of microsphere preparation process \n\ntechnology. J. Control. Release v. 102, p. 313-332, 2005. \n\n \n\nGARBAYO, E.; ANSORENA, E.; LANCIEGO, J. L.; AYMERICH, M. S.; BLANCO-\n\nPRIETO, M. J. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic \n\nfactor from biodegradable polymeric microspheres. Eur. J. Pharm. Biopharm. v. 69, p. 844\u2013\n\n851, 2008. \n\n \n\nGASPARINI, G.; KOSVINTSEV, S. R.; STILLWELL, M. T.; HOLDICH, R. G. Preparation \n\nand characterization of PLGA particles for subcutaneous controlled drug release by \n\nmembrane emulsification. Colloid. Surface B v. 61, p. 199\u2013207, 2008.  \n\n \n\nGAUMET, M.; VARGAS, A.; GURNY, R.; DELIE, F. Nanoparticles for drug delivery: The \n\nneed for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. v. 69,      \n\np. 1\u20139, 2007.  \n\n \n\nGOHEL, M. C.; AMIN, A. F. Formulation optimization of controlled release diclofenac \n\nsodium microspheres using factorial design. J. Control. Release v. 51, p. 115\u2013122, 1998. \n\n \n\nGOULD, S.; SCOTT, R. C. 2-Hydroxypropyl-?-cyclodextrin (HP-?-CD): A toxicology \n\nreview. Food Chem. Toxicol. v. 43, p. 1451\u20131459, 2005. \n\n \n\nGRYNBERG, N. F.; ECHEVARRIA, A.; LIMA, J. E.; PAMPLONA, S. S. R.; PINTO, A. C.; \n\nMACIEL, M. A. M. Anti-tumor activity of two 19-nor-clerodane diterpenes,                  \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n112\n\ntrans-dehydrocrotonin and trans-crotonin, from Croton cajucara. Planta Med. v. 65, p. 687-\n\n689, 1999. \n\n \n\nHANS, M. L.; LOWMAN, A. M. Biodegradable nanoparticles for drug delivery and \n\ntargeting. Curr. Opin. Solid State Mater. Sci. v. 6, p. 319\u2013327, 2002. \n\n \n\nHERRERO-VANELL, R.; RAMIREZ, L.; FERNANDEZ-CARBALLIDO, A.; REFOLO, M. \n\nF. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. \n\nEncapsulation technique, in vitro release profiles, and sterilization process. Pharm. Res. v. \n\n17, p. 1323\u20131328, 2000. \n\n \n\nHIROTA, K.; HASEGAWA, T.; HINATA, H.; ITO, F.; INAGAWA, H.; KOCHI, C.; \n\nSOMA, G.-I.; MAKINO, K.; TERADA, H. Optimum conditions for efficient phagocytosis of \n\nrifampicin-loaded PLGA microspheres by alveolar macrophages. J. Control. Release v. 119, \n\np. 69\u201376, 2007. \n\n \n\nHIRUMA-LIMA, C. A.; SPADARI-BRATFISCH, R. C.; GRASSI-KASSISSE, D. M.; \n\nBRITO, A. R. M. Antiulceronic mechanisms of dehydrocrotonin, a diterpene lactone obtained \n\nfrom Croton cajucara. Planta Med. v. 65, p. 325-330, 1999. \n\n \n\nHO, M. L.; FU, Y. C.; WANG, G. J.; CHEN, H. T.; CHAN, J. K.; TSAI, T. H.; WANG, C. \n\nK. Controlled release carrier of BSA made by W/O/W emulsion method containing PLGA \n\nand hydroxyapatite. J. Control. Release v. 128, p.142\u2013148, 2008. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n113\n\nIGNATIUS, A. A.; CLEAS, L. E. In vitro biocompatibility of bioresorbable polymers: poly(l, \n\ndl-lactide) and poly(l-lactide-co-glycolide). Biomaterials v. 17, p. 831\u2013839, 1996. \n\n \n\nISHIHARA, T.; KUBOTA, T.; CHOI, T.; TAKAHASHI, M.; AYANO, E.; KANAZAWA, \n\nH.; HIGAKI, M. Polymeric nanoparticles encapsulating betamethasone phosphate with \n\ndifferent release profiles and stealthiness. Int. J. Pharm.  v. 375, p. 148-154, 2009. \n\n \n\nITO, F.; FUJIMORI, H.; HONNAMI, H.; KAWAKAMI, H.; KANAMURA, K.; MAKINO, \n\nK. Study of types and mixture ratio of organic solvent used to dissolve polymers for \n\npreparation of drug-containing PLGA microspheres. Eur. Polym. J. v. 45, p. 658\u2013667, 2009. \n\n \n\nITO, F.; FUJIMORI, H.; MAKINO, K. Factors affecting the loading efficiency of water-\n\nsoluble drugs in PLGA microspheres. Colloid. Surface B v. 61 p. 25\u201329, 2008. \n\n \n\nJAIN, R. A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-\n\nco-glycolide) (PLGA) devices. Biomaterials v. 21, p. 2475-2490, 2000. \n\n \n\nJANORIA, K. G.; MITRA, A. K. Effect of lactide/glycolide ratio on the in vitro release of \n\nganciclovir and its lipophilic prodrug (GCV-monobutyrate) from PLGA microspheres. Int. J. \n\nPharm. v. 338, p. 133\u2013141, 2007. \n\n \n\nKEMPEN, D. H. R.; LU, L.; HEFFERAN, T. E.; CREEMERS, L. B.; MARAN, A.; \n\nCLASSIC, K. L.; DHERT, W. J. A.; YASZEMSKI, M. J. Retention of in vitro and in vivo \n\nBMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials \n\nv. 29, p. 3245\u20133252, 2008. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n114\n\nKHATRI, K.; GOYAL, A. K.; GUPTA, P. N.; MISHRA, N.; MEHTA, A.; VYAS, S. P. \n\nSurface modified liposomes for nasal delivery of DNA vaccine. Vaccine v. 26, p. 2225 \u2013 \n\n2233, 2008. \n\n \n\nKLOSE, D.; LAPRAIS, M.; LEROUX, V.; SIEPMANN, F.; DEPREZ, B.; BORDET, R.; \n\nSIEPMANN, J. Fenofibrate-loaded PLGA microparticles: Effects on ischemic Stroke. Eur. J. \n\nPharm. Sci. v. 37, p. 43\u201352, 2009. \n\n \n\nKLOSE, D.; SIEPMANN, F.; ELKHARRAZ, K.; SIEPMANN, J. PLGA-based drug delivery \n\nsystems: Importance of the type of drug and device geometry. Int. J. Pharm. v. 354, p. 95\u2013\n\n103, 2008. \n\n \n\nKULKARNI, R. K.; MOORE, E. G.; HEGYELLI, A. F.; LEONARD, F. Biodegradable \n\npoly(lactic acid) polymers. J. Biomed. Mater. Res. v. 5, p. 169\u2013181, 1971. \n\n \n\nKUMAR, N.; RAVIKUMAR, M. N. V.; DOMB, A. J. Biodegradable block copolymers. \n\nAdv. Drug Deliver. Rev. v. 53, p. 23\u201344, 2001. \n\n \n\nLECAROZ, C.; AMAZO,C.; RENEDO,M. J.; BLANCO-PRIETO, M. J. Biodegradable \n\nmicro-and nanoparticles as long-term delivery vehicles for gentamicin. J. Microencapsul. v. \n\n23, p. 782\u2013792, 2006. \n\n \n\nLEE, C. C.; GILLIES, E. R.; FOX, M. E.; GUILLAUDEU, S. J.; FR\u00c9CHET, J. M.; DY, E. \n\nE.; SZOKA, F. C. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n115\n\nbearing C-26 colon carcinomas. Proc. Natl. Acad. Sci. U. S. A. v. 103, p. 16649\u201316654, \n\n2006. \n\n \n\nLEE, J.-S.; KIM, H. W.; CHUNG, D.; LEE, H. G. Catechin-loaded calcium pectinate \n\nmicroparticles reinforced with liposome and hydroxypropylmethylcellulose: Optimization and \n\nin vivo antioxidant activity. Food Hydrocolloids v. 23, p. 2226\u20132233, 2009.  \n\n \n\nLI, M.; ROUAUD, O.; PONCELET, D. Microencapsulation by solvent evaporation: state of \n\nthe art for process engineering approaches. Int. J. Pharm. v. 363, p. 26\u201339, 2008. \n\n \n\nLIMAYEN, I.; CHARCOSSET, C.; FESSI, H. Purification of nanoparticle suspensions by \n\nconcentration/diafiltration process. Sep. Purif. Technol. v. 38, p. 1-9, 2004. \n\n \n\nLINHART, W.; PETERS, F.; LEHMANN, W.; SCHILLING, A. F.; SCHWARZ, K.; \n\nAMLING, M.; RUEGER, J. M.; EPPLE, M. Biological and chemically optimized composites \n\nof carbonated apatite olyglycolide as bone substitution materials. J. Biomed. Mater. Res. v. \n\n54, p. 162\u2013171, 2001.  \n\n \n\nLIRA, M. C. B. Complexo de inclus\u00e3o \u00c1cido \u00dasnico: ?-Ciclodextrina; Prepara\u00e7\u00e3o, \n\nCaracteriza\u00e7\u00e3o e Nanoencapsula\u00e7\u00e3o em Lipossomas. 2007. 90 p. disserta\u00e7\u00e3o (Mestrado em \n\nCi\u00eancias Farmac\u00eauticas) - Departamento de Ci\u00eancias Farmac\u00eauticas, Universidade Federal de \n\nPernambuco (UFPE), Recife, 2007. \n\n \n\nLOFTSSON, T.; DUCH\u00caNE, D. Cyclodextrins and their pharmaceutical applications. Int. J. \n\nPharm. v. 329, p. 1\u201311, 2007. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n116\n\nLOFTSSON, T.; HREINSD\u00d3TTIR, D.; M\u00c1SSON, M. Evaluation of cyclodextrin \n\nsolubilization of drugs. Int. J. Pharm. v. 302, p. 18\u201328, 2005. \n\n \n\nLUCIANI, A.; COCCOLI, V.; ORSI, S.; AMBROSIO, L.; NETTI, P. A. PCL microspheres \n\nbased functional scaffolds by bottom-up approach with predefined microstructural properties \n\nand release profiles. Biomaterials v. 29, p. 4800\u20134807, 2008.  \n\n \n\nLUNA-COSTA, A. M.; SILA, J. C. R.; CAMPOS, A. R.; RAO, V. S. N.; MACIEL, M. A. M; \n\nPINTO, A. C. Antioestrogenic effect of trans-dehydrocrotonin, a nor-clerodane diterpene \n\nfrom Croton cajucara Benth in rats. Phytother. Res. v. 13, p. 689-691, 1999. \n\n \n\nMACIEL, M. A. M.; CORTEZ, J. K. P. C; GOMES, F. S. O g\u00eanero Croton e aspectos \n\nrelevantes de diterpenos clerodanos. Revista Fitos (ALANAC) v. 2, p. 54-73, 2006. \n\n \n\nMACIEL, M. A. M.; LEAL, R. S.; DANTAS, T. N. C.; VEIGA J\u00daNIOR, V. F. \n\nEspectrometria de Massas de Diterpenos do Tipo Clerodano Isolados de Croton cajucara \n\nBenth. Revista Fitos (ALANAC) v. 3, p. 37-45, 2007. \n\n \n\nMACIEL, M. A. M.; PINTO, A. C.; ARRUDA, A. C.; PAMPLONA, S. G. S. R.; \n\nVANDERLINDE, F. A.; LAPA, A. J.; ECHEVARRIA, A.; GRYNBERG, N. F.; C\u00d3LUS, I. \n\nM. S.; FARIAS, R. A. F.; COSTA, A. M. L.; RAO, V. S. N. Ethnopharmacology, \n\nphytochesmistry and pharmacology: a successful combination in the study of Croton \n\ncajucara. J. Ethnopharmacol. v. 70, p. 41-55, 2000. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n117\n\nMACIEL, M. A. M.; PINTO, A. C.; VEIGA JR., V. F.; MARTINS, J. R.; GRYNBERG, N. \n\nF.; ACHEVARRIA, A.; LAPA, A. J.; VANDERLINDE, F. A. Croton cajucara as an \n\nalternative to traditional medicine in a modern health system. Phytochem. Pharmacol. II \n\nSer. Recent Prog. Med. Plants v. 8, p. 459-475, 2002. \n\n \n\nMAGENHEIM, B.; BENITA, S. Nanoparticle characterization: a comprehensive \n\nphysicochemical approach. STP Pharma Sci. v. 1, p. 221-241, 1991. \n\n \n\nMANDAL, T. K.; BOSTANIAN, L. A.; GRAVES, R. A.; CHAPMAN, S. R.; IDODO, T. U. \n\nPorous biodegradable microparticles for delivery of pentamidine. Eur. J. Pharm. Biopharm. \n\nv. 52, p. 91-96, 2001. \n\n \n\nMAO, S.; SHI, Y.; LI, L.; XU, J.; SCHAPER, A.; KISSEL, T. Effects of process and \n\nformulation parameters on characteristics and internal morphology of poly(D,L-lactide-co-\n\nglycolide) microspheres formed by the solvent evaporation method. Eur. J. Pharm. \n\nBiopharm. v. 68, p. 214\u2013223, 2008. \n\n \n\nMARTIN DEL VALLE, E. M. Cyclodextrins and their uses: a review. Process Biochem. v. \n\n39, p. 1033\u20131046, 2004. \n\nMELO, P. S.; DURAN, N.; HAUN, M. Cytotoxicity of derivatives from dehydrocrotonin on \n\nV79 cells and Escherichia coli. Toxicology v. 159, p. 135-141, 2001. \n\nMELO, P. S.; DURAN, N.; HIRUMA-LIMA, C. A.; SOUZA-BRITO, A. R. M.; HAUN, M. \n\nComparison of the gastroprotective effect of a diterpene lactone isolated from Croton \n\ncajucara with its synthetic derivatives. J. Ethnopharmacol. v. 87, p. 169-174, 2003. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n118\n\nMELO, P. S.; JUSTO, G. Z.; DUR\u00c1N, N.; HAUN, M. Natural killer cell activity and anti-\n\ntumour effects of dehydrocrotonin and its synthetic derivatives. Eur. J. Pharmacol. v. 487, p. \n\n47-54, 2004. \n\n \n\nMOGI, T.; OHTAKE, N.; YOSHIDA, M.; CHIMURA, R.; KAMAGA, Y.; ANDO, S.; \n\nTSUKAMOTO, T.; NAKAJIMA, T.; UENODAN, H.; OTSUKA, M.; MATSUDA, Y.; \n\nOHSHIMA, H.; MAKINO, K. Sustained release of 17?-estradiol frompoly(lactide-co-\n\nglycolide) microspheres in vitro and in vivo. Colloids Surf. B v. 17, p. 153\u2013165, 2000. \n\n \n\nMORAIS, W. A.; COSTA, M.; PAIX\u00c3O, A. D. O.; MACIEL, M. A. M; SANTOS-\n\nMAGALH\u00c3ES, N. S. Encapsulation and release characteristics of DCTN/PLGA \n\nmicroparticles. J. Microencapsul. v. 1, p. 1464\u20135246, 2008. \n\n \n\nMOSQUEIRA, V. C. F.; LEGRAND, PHILIPPE; PINTO-ALPHANDARY, H.; PUISIEUX, \n\nF.; BARRATT, G. Poly (D,L-lactide) nanocapsules prepared by solvent displacement \nprocess: influence of composition on physico-chemical and structural properties. J. Pharm. \nSci. v.89, p. 614-626, 2000. \n \n\nMUNDARGI, R. C.; SRIRANGARAJAN, S.; AGNIHOTRI, S. A.; PATIL, S. A.; \n\nRAVINDRA, S.; SETTY, S. B.; AMINABHAVI, T. M. Development and evaluation of \n\nnovel biodegradable microspheres based on poly(D,L-lactide-co-glycolide) and poly(?-\n\ncaprolactone) for controlled delivery of doxycycline in the treatment of human periodontal \n\npocket: In vitro and in vivo studies. J. Control. Release v. 119, p. 59\u201368, 2007. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n119\n\nMURATA, N.; TAKASHIMA, Y.; TOYOSHIMA, K.; YAMAMOTO, M.; OKADA, H. \n\nAnti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. \n\nControl. Release v. 126, p. 246\u2013254, 2008. \n\n \n\nMUTHU, M. S.; RAWAT, M. K.; MISHRA, A.; SINGH, S. PLGA nanoparticle formulations \n\nof risperidone: preparation and neuropharmacological evaluation. Nanomedicine: \n\nNanotechnol. Biol. Med. v. 5, p. 323-333, 2009. \n\n \n\nNG, S.-M.; CHOI, J.-Y.; HAN, H.-S.; HUH, J.-S.; LIM, J. O. Novel microencapsulation of \n\npotential drugs with low molecular weight and high hydrophilicity: Hydrogen peroxide as a \n\ncandidate compound. Int. J. Pharm. v. 384, p. 120 \u2013 127, 2009.  \n\n \n\nOH, S. H.; LEE, J. Y.; GHIL, S. H.; LEE, S. S.; YUK, S. H.; LEE, J. H. PCL microparticle-\n\ndispersed PLGA solution as a potential injectable urethral bulking agent. Biomaterials v. 27, \n\np. 1936\u20131944, 2006. \n\n \n\nPETITTI, M.; VANNI, M.; BARRESI, A. A. Controlled release of drug encapsulated as a \n\nsolid core: Theoretical model and sensitivity analysis. Chem. Eng. Res. Des. v. 86, p. 1294\u2013\n\n1300, 2008. \n\n \n\nPOLETTO, F. S.; JAGER, E.; R\u00c9, M. I.; GUTERRES, S. S.; POHLMANN, A. R. Rate-\n\nmodulating PHBHV/PCL microparticles containing weak acid model drugs. Int. J. Pharm. v. \n\n345, p. 70\u201380, 2007.  \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n120\n\nRAVIVARAPU, H. B.; BURTON, K.; DELUCA, P. P. Polymer and microsphere blending to \n\nalter the release of a peptide from PLGA microspheres. Eur. J. Pharm. Biopharm. v. 50, p. \n\n263-270, 2000.  \n\n \n\nREVERCHON, E.; ADAMI, R.; CARDEA, S.; PORTA, G. D. Supercritical fluids processing \n\nof polymers for pharmaceutical and medical Applications. J. Supercritic. Fluids v. 47, p. \n\n484\u2013492, 2009. \n\n \n\nRIBEIRO-COSTA, R. M.; ALVES, A. J.; SANTOS, N. P.; NASCIMENTO, S. C.; \n\nGON\u00c7ALVES, E. C. P.; SILVA, N. H.; HONDA, N. K.; SANTOS - MAGALH\u00c3ES, N. S. In \n\nvitro and in vivo properties of usnic acid encapsulated into PLGA-microspheres. J. \n\nMicroencapsul. v. 21, p. 371-384, 2004. \n\n \n\nRIBEIRO-COSTA, R. M.; CUNHA, M. R; GONGORA-RUBIO, M. R.; MICHALUART-\n\nJ\u00daNIOR, P.; R\u00c9, M. I. Preparation of protein-loaded-PLGA microspheres by an \n\nemulsion/solvent evaporation process employing LTCC micromixers. Powder Technol. v. \n\n190, p. 107-111, 2008. \n\n \n\nRODR\u00cdGUEZ, J. A.; HAUN, M. Cytotoxicity of trans-dehydrocrotonin from Croton \n\ncajucara on V79 Cells and rat hepatocytes. Planta Med. v. 65, p. 522-526, 1999. \n\n \n\nRODR\u00cdGUEZ, J. A.; HIRUMA-LIMA, C. A.; SOUZA-BRITO, A. R. M. Antiulcer activity \n\nand subacute toxicity of trans-dehydrocrotonin from Croton cajucara. Hum. Exp. Toxicol.  \n\nv. 23, p. 455-461, 2004. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n121\n\nSAH, H.; LEE, B.-J. Development of new microencapsulation techniques useful for the \n\npreparation of PLGA microspheres. Macromol. Rapid Commun. v. 27, p. 1845\u20131851, 2006. \n\n \n\nSAHOO, S. K.; PARVEEN, S.; PANDA, J. J. The present and future of nanotechnology in \n\nhuman health care. Nanomedicine v. 3, p. 20\u201331, 2007.  \n\n \n\nSANT, S.; NADEAU, V.; HILDGEN, P. Effect of porosity on the release kinetics of \n\npropafenone-loaded PEG-g-PLA nanoparticles. J. Control. Release v. 107, p. 203\u2013214, \n\n2005.  \n\n \n\nSANTOS, N. P. S.; NASCIMENTO, S. C.; WANDERLEY, M. S. O.; PONTES - FILHO, N. \n\nT.; DA SILVA, J. F.; DE CASTRO, C. M. M. B.; PEREIRA, E. C.; DA SILVA,  N. H.; \n\nHONDA, N. K.; SANTOS - MAGALH\u00c3ES, N. S. Nanoencapsulation of usnic acid: An \n\nattempt to improve antitumour activity and reduce hepatotoxicity. Eur. J. Pharm. Biopharm. \n\nv. 64, p. 154-160, 2006. \n\n \n\nSANTOS-MAGALH\u00c3ES, N. S.; PONTES, A.; PEREIRA, V. M. W.; CAETANO, M. N. P. \n\nColloidal carriers for benzantine penicillin G: nanoemulsions and nanocapsules. Int. J. \n\nPharm. v. 208, p. 71-80, 2000. \n\n \n\nSANTOYO, S.; JAL\u00d3N, E. G.; YGARTUA, P.; RENEDO, M. J.; BLANCO-PR\u00cdETO, M. J. \n\nOptimization of topical cidofovir penetration using microparticles. Int. J. Pharm. v. 242,      \n\np. 107-113, 2002. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n122\n\nSCHAFFAZICK, S. R.; POHLMANN, A. R; MEZZALIRA, G.; GUTERRES, S. S. \n\nDevelopment of nanocapsule suspensions and nanocapsule spray-dried powders containing \n\nmelatonin. J. Braz. Chem. Soc. v.17, p. 562-569, 2006. \n\n \n\nSCHWINGEL, L.; FASOLO, D.; HOLZSCHUH, M.; LULA, I.; SINISTERRA, R.; \n\nKOESTER, L.; TEIXEIRA, H.; BASSANI, V. Association of 3-O-methylquercetin with ?-\n\ncyclodextrin: complex preparation, characterization and ex vivo skin permeation studies.        \n\nJ. Incl. Phenom. Macrocycl. Chem. v. 62, p. 149\u2013159, 2008. \n\n \n\nSHAH, K. A.; DATE, ABHIJIT A.; JOSHI, M. D.; PATRAVALE, V. B. Solid lipid \n\nnanoparticles (SLN) of tretinoin: Potential in topical delivery. Int. J. Pharm. v. 345,   p. 163-\n\n171, 2007. \n\n \n\nSIEPMANN, J.; ELKHARRAZ, K.; SIEPMANN, F.; KLOSE, D. How Autocatalysis \n\nAccelerates Drug Release from PLGA-Based Microparticles: A Quantitative Treatment. \n\nBiomacromolecules v. 6, p. 2312-2319, 2005. \n\n \n\nSILVA, R. M.; OLIVEIRA, F. A.; CUNHA, K. M. A.; MAIA, J. L.; MACIEL, M. A. M.; \n\nPINTO, A. C.; NASCIMENTO, N. R. F.; SANTOS, F. A.; RAO, V. S. N. Cardiovascular \n\neffects of trans-dehydrocrotonin, a diterpene from Croton cajucara in rats. Vascul. \n\nPharmacol. v. 43, p. 11-18, 2005. \n\n \n\nSILVA, R. M.; SANTOS, F. A.; RAO, V. S. N.; MACIEL, M. A. M.; PINTO, A. C. Blood \n\nglucose-and triglyceride-lowering effect of trans-dehydrocrotonin, a diterpene from Croton \n\ncajucara Beth in rats. Diabetes Obes. Metab. v. 3, p. 452-456, 2001a. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n123\n\nSILVA, R. M.; SANTOS, F. A.; RAO, V. S. N.; MACIEL, M. A. M.; PINTO, A. C. The \n\nlipid-lowering effect of trans-dehydrocrotonin, a clerodane diterpene from Croton cajucara \n\nBenth in mice fed on high-fat diet. J. Pharm. Pharmacol. v. 53, p. 535-539, 2001b. \n\n \n\nSILVA, R. M; SANTOS, F. A.; MACIEL, M. A. M; PINTO, A. C; RAO, V. S. N. Effect of \n\ntrans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental \n\nhypertriglyceridaemia and hypercholesterolaemia induced by triton WR1339 (tyloxapol) in \n\nmice. Planta Med. v. 67, p. 763-765, 2001c. \n\n \n\nSILVA-JUNIOR, A. A.; MATOS, J. R.; FORMARIZ, T. P.; ROSSANEZI, G.; SCARPA, M. \n\nV.; EGITO, E. S. T.; OLIVEIRA, A. G. Thermal behavior and stability of biodegradable \n\nspray-dried microparticles containing triamcinolone. Int. J. Pharm. v. 368, p. 45\u201355, 2009.  \n\n \n\nSINGH, M.; SHIRLEY, B.; BAJWA, K.; SAMARA, E.; HORA, M.; O`HAGAN, D. \n\nControlled release of recombinant insulin-like growth factor from a novel formulation of \n\npolylactide-co-glycolide microparticles. J.  Control. Release. v. 70, p. 21-28, 2001.  \n\n \n\nSINGH, R.; LILLARD JR, J. W. Nanoparticle-based targeted drug delivery. Exp. Mol. \n\nPathol. v. 86, p. 215-223, 2009. \n\n \n\nSONG, C. X.; LABHASETWAR, V.; LEVY, R. J. Controlled release of U-86983 from \n\ndouble-layer biodegradable matrices: effect of additives on release mechanism and kinetics.   \n\nJ. Control. Release v. 45, p. 177\u2013192, 1997. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n124\n\nSONG, L. X.; BAI, L.; XU, X. M.; HE, J.; PAN, S. Z. Inclusion complexation, encapsulation \n\ninteraction and inclusion number in cyclodextrin chemistry. Coordin. Chem. Rev. v. 253, p. \n\n1276\u20131284, 2009. \n\n \n\nSOPPIMATH, K. S.; AMINABHAVI, T. M.; KULKARNI, A. R.; RUDZINSKI, W. E. \n\nBiodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release v. 70, p. \n\n1-20, 2001. \n\n \n\nSOUZA-BRITO, A. R. M.; RODR\u00cdGUEZ, J. A.; HIRUMA-LIMA, C. A.; HAUN, M.; \n\nNUNES, D. S. Antiulcerogenic activity of trans-dehydrocrotonin from Croton cajucara. \n\nPlanta Med. v. 64, p. 126-129, 1998. \n\n \n\nSTAMATIALIS, D. F.; PAPENBURG, B. J.; GIRON\u00c9S, M.; SAIFUL, S.; BETTAHALLI, \n\nS. N. M.; SCHIMITMEIER, S.; WESSLING, M. Medical applications of membranes: Drug \n\ndelivery, artificial organs and tissue engineering. J. Membrane Sci. v. 308, p. 1-34, 2008. \n\n \n\nSUN, Y.; WANG, J. C.; ZHANG, X.; ZHANG, Z. J.; ZHENG, Y.; CHEN, D. W.; ZHANG, \n\nQ. Synchronic release of two hormonal contraceptives for about one month from the PLGA \n\nmicrospheres: In vitro and in vivo studies. J. Control. Release v. 129, p. 192\u2013199, 2008. \n\n \n\nTAYLOR, H. F. Vitamin preparations and methods of making same. US Patent 2, 183, 053 \n\n(12 December), 1938. \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n125\n\nTEIXEIRA, V. G.; COUTINHO, F. M. B.; GOMES, A. S. Principais M\u00e9todos de \n\nCaracteriza\u00e7\u00e3o da porosidade de resinas \u00e0 base de divinilbenzeno. Quim. Nova v. 24, p. 808-\n\n818, 2001. \n\n \n\nTORCHILIN, V. P. Recente advances with lipossomes as pharmaceutical carrier. Nat. Rev. \n\nDrug Discov. v.4, p.145-160, 2005. \n\n \n\nTRAPANI, G.; LOPEDOTA, A.; BOGHETICH, G.; LATROFA, A.; FRANCO, M.; \n\nSANNA, E.; LISO, G. Encapsulation and release of the hypnotic agent zolpidem from \n\nbiodegradable polymer microparticles containing hydroxypropyl-?-cyclodextrin. Int. J. \n\nPharm. v. 268, p. 47\u201357, 2003. \n\n \n\nTRICHARD, L.; DUCH\u00caNE, D.; BOCHOT, A. Cyclodextrins in dispersed systems. In: \n\nDodziuk, H. (Ed.), Cyclodextrins and Their Complexes: Chemistry, Analytical Methods, \n\nApplications. Wiley-VCH, Weinheim p. 423\u2013449, 2006. \n\n \n\nVASIR, J. K.; TAMBWEKAR, K.; GARG, S. Bioadhesive microspheres as a controlled drug \n\ndelivery system. Int. J. Pharm. v. 255, p. 13-32, 2003. \n\n \n\nVOISINE, J. M.; ZOLNIK, B. S.; BURGESS, DIANE J. In situ fiber optic method for long-\n\nterm in vitro release testing of microspheres. Int. J. Pharm. v. 356, p. 206\u2013211, 2008.  \n\n \n\nWANG, J.; WANG, B. M.; SCHWENDEMAN, S. P. Characterization of the initial burst \n\nrelease of a model peptide from poly(dl-lactide-co-glycolide) microspheres. J. Control. \n\nRelease v. 82, p. 289\u2013307, 2002. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n126\n\nWANG, X.; WANG, Y.; WEI, K.; ZHAO, N.; ZHANG, S.; CHEN, J. Drug distribution \n\nwithin poly(?-caprolactone) microspheres and in vitro release. J. Mater. Process. Tech. v. \n\n209, p. 348\u2013354, 2009. \n\n \n\nWHITAKER, M. J.; HAO, J.; DAVIES, O. R.; SERHATKULU, G.; STOLNIK-TRENKIC, \n\nS.; HOWDLE, S. M.; SHAKESHEFF, K. M. The production of protein-loaded microparticles \n\nby supercritical fluid enhanced mixing and spraying. J. Control. Release v. 101, 85\u201392, \n\n2005. \n\n \n\nWISCHKE, C.; SCHWENDEMAN, S. P. Principles of encapsulating hydrophobic drugs in \n\nPLA/PLGA microparticles. Int. J. Pharm. v. 364, p. 298\u2013327, 2008. \n\n \n\nXU, Q.; CZERNUSZKA, J. T. Controlled release of amoxicillin from hydroxyapatite-coated \n\npoly(lactic-co-glycolic acid) microspheres. J. Control. Release v. 127, p. 146\u2013153, 2008. \n\n \n\nYANG, L.; ALEXANDRIDIS, P. Physicochemical aspects of drug delivery and release from \n\npolymer-based colloids. Curr. Opin. Colloid Interf. Sci. v. 5, p. 132\u2013143, 2000. \n\n \n\nYUAN, H.; MIAO, J.; DU, Y.-Z.; YOU, J.; HU, F.-Q.; ZENG, S. Cellular uptake of solid \n\nlipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. \n\nPharm. v. 348, p. 137-145, 2007. \n\n \n\nZHANG, H.; LU, Y.; ZHANG, G.; GAO, S.; SUN, D.; ZHONG, Y. Bupivacaine-loaded \n\nbiodegradable poly(lactic-co-glycolic) acid microspheres. I. Optimization of the drug \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n127\n\nincorporation into the polymer matrix and modelling of drug release. Int. J. Pharm.  v. 351, \n\np. 244\u2013249, 2008.  \n\n \n\nZHAO, A.; RODGERS, V. G. J. Using TEM to couple transient protein distribution and \n\nrelease for PLGA microparticles for potential use as vaccine delivery vehicles. J. Control. \n\nRelease v. 113, p. 15\u201322, 2006. \n\n \n\nZINGONE, G.; RUBESSA, F. Preformulation study of the inclusion complex warfarin-?-\n\ncyclodextrin. Int. J. Pharm. v. 291, p. 3\u201310, 2005. \n\n \n\nZOLNIK, B. S.; BURGESS, D. J. Effect of acidic pH on PLGA microsphere degradation and \n\nrelease. J. Control.  Release v. 122, p. 338\u2013344, 2007.  \n\n \n\nZOLNIK, B. S.; LEARY, P. E.; BURGESS, D. J. Elevated temperature accelerated release \n\ntesting of PLGA microspheres. J. Control. Release v. 112, p. 293\u2013300, 2006. \n\n \n\nhttp://www.cas.org/. Acesso em 5 de fevereiro 2008. \n\n \n\nhttp://www.nanoparticles.org/links/Nanosphere.jpg. Acesso em 10 de setembro 2008. \n\n \n\nhttp://www.qmc.ufsc.br/qmcweb/exemplar15.html. Acesso em 20 de novembro 2008. \n\n \n\n \n\n \n\n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n128\n\nAANNEEXXOO  AA \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nAARRTTIIGGOO  II  \u2013\u2013  AAbbssttrraacctt    \n\nEEnnccaappssuullaattiioonn  aanndd  rreelleeaassee  cchhaarraacctteerriissttiiccss  ooff  \n\nDDCCTTNN//PPLLGGAA  mmiiccrroosspphheerreess    \n\nJJoouurrnnaall  ooff  MMiiccrrooeennccaappssuullaattiioonn,,  vv..  2266,,  nn\u00b0\u00b0  66,,                      \n\npp..  552299\u2013\u2013553344,,  22000088    \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n129\n\nEncapsulation and release characteristics of DCTN/PLGA microspheres \n\n \n \n\nWaldenice A. Morais1, Marcilia P. Costa1, Ana Durce O. Paix\u00e3o2, Maria Aparecida M. \n\nMaciel3 and Nereide S. Santos-Magalh\u00e3es1 \n\n \n\n1Universidade Federal de Pernambuco (UFPE), Laborat\u00f3rio de Imunopatologia Keizo-Asami \n\n(LIKA), Recife, PE, Brazil, 2Departamento de Farmacologia e Fisiologia, UFPE, Recife, PE, \n\nBrazil, 3Universidade Federal do Rio Grande do Norte (UFRN), Departamento de Qu\u00edmica, \n\nNatal, RN, Brazil. \n\n \n\n \n\nAbstract  \n\n \nIn the present study, poly (D,L-lactic-co-glycolic)-acid microspheres containing trans-\nDehydrocrotonin (DCTN) were prepared by the double emulsion method. The \nhypoglycemic activity of DCTN-loaded microspheres was monitored in normal \nglycemic mice after administration of a daily dose of DCTN (50 mg/kg body weight) \nfor 7 days. Spherical microspheres with 3.2\u00b10.1?m and 7.6\u00b10.7 ?m mean diameters \nsize were observed. The encapsulation efficiency of DCTN was 85.5\u00b13.9 %. The in \nvitro kinetic profile of DCTN from PLGA-microspheres was initially fast (burst effect \nof 19.4 % at 2 h), followed by a controlled release attaining a maximum drug released \nof 55.6 % within sixty hours. DCTN was able to reduce glucose levels (14.3%) of \nnormal glycemic animals and this effect was improved by its encapsulation into \nmicrospheres (26.8%). DCTN-loaded microspheres are thus offered as a potential \ndelivery system for the treatment of metabolic diseases characterized by hyperglycemia.  \n \n\n \n\n \n\nKeywords: trans-dehydrocrotonin, Croton cajucara, PLGA, microspheres, \n\nhypoglycemic activity. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n130\n\nAANNEEXXOO  BB \n \n \n \n \n\n  \n\n  \n\n  \n\n  \n\n  \n\n  \n\n  \n\nAARRTTIIGGOO  IIII  \u2013\u2013  AAbbssttrraacctt    \n\nVVaalliiddaattiioonn  ooff  UUVV  ssppeeccttrroopphhoottoommeettrriicc  mmeetthhoodd  \n\nffoorr  tthhee  ddeetteerrmmiinnaattiioonn  ooff  ddeehhyyddrrooccrroottoonniinn  aanndd  \n\naapppplliiccaattiioonn  iinn  iinncclluussiioonn  ccoommpplleexxeess  wwiitthh  \n\nhhyyddrrooxxyypprrooppyyll--??--ccyyccllooddeexxttrriinn  ((AA  sseerr  \n\nssuubbmmeettiiddoo))  \n \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n131\n\nValidation of UV spectrophotometric method for the determination of dehydrocrotonin \n\nand application in inclusion complexes with hydroxypropyl-?-cyclodextrin \n\n \n\nTaciana Lima Salviano Lapenda1,Waldenice de Alencar Morais1, Maria Aparecida Medeiros \nMaciel2, Nereide Stela Santos-Magalh\u00e3es1* \n\n \n \n \n\n1Universidade Federal de Pernambuco (UFPE), Laborat\u00f3rio de Imunopatologia Keizo-Asami \n\n(LIKA), Av. Prof. Moraes Rego, 1235 Cidade Universit\u00e1ria, Recife, PE, Brazil, 2Universidade \n\nFederal do Rio Grande do Norte (UFRN), Departamento de Qu\u00edmica, Natal, RN, Brazil. \n\n \n\nAbstract \n\n \n\nA simple and rapid spectrophotometric method was developed for determining trans-\ndehydrocrotonin (t-DCTN) in bulk and pharmaceutical formulations. The method was \nvalidated for various parameters according to ICH guidelines. The t-DCTN in acetonitrile \nexhibited maximum absorption peak (?max) at 234 nm. Beer\u2019s law correlating the absorbance \n(A) with t-DCTN concentration (C) was obeyed in the range of 1 \u2013 20 \u00b5g mL-1. The \nregression equation for the standard curve was A = -0.00147 + 0.04214C with good \ncorrelation coefficient (n = 6) ? 0.99987. The detection and quantitation limits were found to \nbe 0.16 and 0.48 \u00b5g mL-1, respectively.  The precision of the method was satisfactory with \nvalues of relative standard deviation less than 2% for all sample analyzed. The accuracy, \ndetermined from recovery studies, was between 99.62 and 100.02%. The method showed to \nhave specificity since HP-?-CD did not interfere in the analysis. The method was robust with \nchange of solvent manufacturer and temperature. Statistical analysis by analysis of variance \n(ANOVA) and Student's t-test and F-test were performed. The proposed method was \nsuccessfully applied to quantify the t-DCTN inclusion complexes with hydroxypropyl-?-\ncyclodextrin (HP-?-CD) obtained in solid state by freeze-drying. The complexed t-DCTN \ncontent was 99.78 \u00b1 0.71%. The method was practical and can be suitably to be used in the \nroutine analysis. \n \n \n \n \n \nKeywords: trans-Dehydrocrotonin; Hydroxypropyl-?-cyclodextrin; Inclusion complex; UV \n\nSpectrophotometry; Validation. \n\n\n\nMORAIS, W.A. Tese de doutorado (2010). Desenvolvimento e caracteriza\u00e7\u00e3o de microesferas contendo                     \n\ntrans-desidrocrotonina e complexo de inclus\u00e3o de trans-desidrocrotonina com 2-hidroxipropil-?-ciclodextrina. \n132\n\nAANNEEXXOO  CC \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nCCOONNCCUURRSSOO  PP\u00da\u00daBBLLIICCOO  \n\nAApprroovvaa\u00e7\u00e7\u00e3\u00e3oo  ppaarraa  oo  ccaarrggoo  ddee  PPrrooffeessssoorr  AAddjjuunnttoo  \n\nnnoo  DDeeppaarrttaammeennttoo  ddee  FFaarrmm\u00e1\u00e1cciiaa  nnaa  \u00e1\u00e1rreeaa  ddee  \n\nFFaarrmmaaccoott\u00e9\u00e9ccnniiccaa  nnaa  UUnniivveerrssiiddaaddee  FFeeddeerraall  ddoo  \n\nRRiioo  GGrraannddee  ddoo  NNoorrttee  \n\nDDOOUU,,  ssee\u00e7\u00e7\u00e3\u00e3oo  22,,  3311  ddee  ddeezzeemmbbrroo  ddee  22000099"}]}}}